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Editorial
A message as well as a note of acknow ledgement to our contributors,
subscribers and readers
A little while ago we examined the past and present state of our Journal. 
We were proud to note: Haematologia is a widely read international periodical. 
The articles appearing are of high standard and cover broad areas in haematology, 
immunology and blood transfusion. Just to attest this, the papers published in 
recent years included reviews of therapeutical trials, reports on diagnostic prob­
lems, advances in technology and laboratory tests as well as works dealing with 
many other complex research subjects. Typographically Haematologia is up to 
par with the best in the field.
At the same time, however, we had to concede that editing and printing 
problems have sometimes resulted in rather erratic appearances. Well, we are 
going to fundamentally change this now.
To compensate for preceding arrears of publishing, a slender volume is 
brought out for this year which will be sent free of charge to all subscribers. The 
first issue of Volume 17 will reach the subscribers not later than January 1984. 
This and the succeeding issues will contain the papers already accepted.
The Editors sincerely hope that acquiescing with our efforts, you will keep 
on contributing to the traditionally high standards as well as to the growing 
readership of our international Journal with your estimable works and comments.
Another change we wish to announce is that with Volume 15 Elsevier Bio­
medical discontinues its association with this journal and VNU SCIENCE PRESS 
BV will join AKADÉMIAI KIADÓ in the distribution of Haematologia.
It is also a pleasure to express my sincere thanks to the reviewers for their 
unfailing courtesy and invaluable advice and help throughout our collaboration.
Susan R. H ollán
Editor-in-Chief
Publishers' announcement
Please continue to send your 
manuscripts to the Editor-in-Chief 
Susan R. Hollán
National Institute of Haematology 
and Blood Transfusion 
Daróczi út 24 
H-1113 Budapest, Hungary
Subscriptions and inquiries should 
be sent to
VNU Science Press BV
P. O. Box 2073 
3500 GB Utrecht 
The Netherlands
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Perspectives in Hematology*
M. M. WlNTROBE
Department of Internal Medicine, The University of Utah, College of Medicine, 
50 N. Medical Drive, Salt Lake City, Utah 84132, USA
(Received 6 August 1982; accepted 21 January 1983)
Those of us who have chosen to concentrate our attention on the field of 
hematology have been very fortunate, indeed. Hematology has proved to be fasci­
nating and exciting. For me, the experience has been especially rewarding because 
my interest began just at the time that hematology was about to be transformed 
from a morphologic exercise to a wide-ranging discipline that has contributed 
enormously to many aspects of biologic science, as well as to the health of man.
The Mystique of the Blood
Our interest is not unique, of course. The blood has always fascinated man- 
kind. Blood caught the imagination of prehistoric man, as cave paintings in north­
ern Spain testify, and it continues to intrigue man today. It has fired the imagina­
tion of poets, and puzzled the philosophers; mystics have spun their tales about it 
and charlatans have used it to embroil their innocent victims. Fortunately, it has 
also been the subject of study by serious seekers of the truth.
The Bible states that ‘the life of the flesh is in the blood' and the Jews con­
sidered it to be the seat of the soul; consequently, the drinking of blood was pro­
hibited and the orthodox practice, based on Mosaic Law, of salting meat before its 
use as food, was designed to rid meat of blood. The Romans, on the other hand, 
had no such qualms; they drank the blood of fallen heroes so as to imbibe their 
strength and courage. Before them, the Egyptians employed blood baths for recupe­
ration and rejuvenation. And it was not only in ancient times that such extraordi­
nary properties were attributed to the blood. Even in the fifteenth century, and 
later, blood was recommended for lunacy, fits, palsy, melancholia and bad disposi­
tion. There is the apocryphal story that when Pope Innocent VIII was on his death­
bed in 1492, in a last desperate attempt to save his life, he received the blood of 
three youths, by draught, presumably. Shortly thereafter, he passed on, no doubt 
to Heaven; the three youths, likewise, one hopes. Nothing is known about the fate 
of the prescribing physician.
* Reprinted with the permission of the Editor from The Pharos, 46 (1983). Copyright 
by Alpha Omega Alpha Honor Medical Society.
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Needless to say, these views were held in the absence of any concept of the 
composition of blood, its functions or, until William Harvey’s discovery, even its 
circulation. The contrary view, namely that blood could be bad, also had its ardent 
proponents, as we know, for venisection was practised for many centuries and 
contributed to the death of many, many victims, including the first president of the 
United States, George Washington.
The Nature and Functions of the Blood
It is an interesting commentary on the way we often gain insight that allusion 
to what turned out to be one of the functions of the blood arose as the consequence 
of the lust for gold in the 16th century. It was Father Acosta, a Spanish priest who 
accompanied Pizarro on his incursions in the Peruvian Andes who suggested in 
1569 that the ‘elements of the air’ in those lofty heights might be so thin and delicate 
that it was not suitable for human breathing. He proposed that this might be re­
sponsible for the mountain sickness which presented so great a problem for Pizarro. 
More than another 200 years passed before oxygen was discovered. And even so, 
the relation of ‘thin air’ and oxygen to red corpuscles and hemoglobin was not ap­
preciated until after hemoglobin was discovered in 1851 by Funke, and until Hoppe- 
Seyler in 1865 showed that hemoglobin has the unique property of taking up and 
discharging oxygen. For untold years, the tiny globules that Leeuwenhoek described 
in the blood in 1674 were not regarded as being of any importance, even after Wil­
liam Hewson suggested that they surely played some important role since nature 
had provided them in such abundance.
Thus, for centuries knowledge grew at an infinitely slow pace. The micro- 
scopists of the 19th century had an extremely hard time attracting scientific interest 
and, for the most part, they were scorned by physicians. Goethe wrote in 1829 that, 
‘Microscope and telescope confuse in reality the pure human judgement.’ Madame 
de Pompadour and George III seemed to have been more interested in microscopy 
than the scientists of their time. The leukocytes also did not arouse much excite­
ment. Even after they were recognized, their role was long debated. Virchow only 
acknowledged their relationship to pus after holding a contrary view for many 
years. Unorthodox ideas find few advocates even today.
That knowledge for a long time grew so slowly is, perhaps, not as surprising 
as the fact that it grew at all. Roger Bacon, in the 13th century, described the use of 
single convex lenses and thus, in a sense, was the inventor of the simple microscope. 
However, he was imprisoned and his writings remained hidden. It was left for the 
Dutch spectacle maker to describe in the blood what man had never before seen or 
even dreamed of.
It is worth recognizing how often chance has played a role in scientific prog­
ress. Thus, it is largely because Antony van Leeuwenhoek had a friend who had 
some influence and also because the Secretary of the Royal Society of London was 
open-minded enough to publish the observations of a man without scientific ere-
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dentials that Leeuwenhoek’s observations were at least recorded for posterity. 
On the other hand, one wonders how much sooner understanding would have 
progressed if William Hewson had not died of an infection sustained during an 
autopsy at the age of 35. His contributions concerning coagulation of the blood 
and regarding lymphocytes and the lymphatic vessels were fundamental and very 
important. Then, again, the story seems to be well founded that Ehrlich might have 
been expelled from medical school because he was just ‘poking around’ and not 
attending the lectures of his professors. His brilliant career might have been inter­
rupted had it not been for the support of Professor Waldeyer. One wonders if 
George Minot would have carried out his liver therapy trials so successfully if he, 
as a diabetic, had not believed so strongly in the important role of food in blood 
formation. One could easily add to these examples of the role of chance in affecting 
the course of research. Biology is so extraordinarily complex that an unexpected 
observation, a happy accident, or a new interpretation of some seemingly unrelated 
finding can result in unforeseen applications and consequences of unpredicted and 
unpredictable implications.
Hematology in the 1920's
By the 1920’s hematology, with a few exceptions, had made no great ad­
vances. Of far-reaching importance had been the observation by Landsteiner at the 
turn of the century that the red cells of some individuals were clumped or aggluti­
nated by the sera of certain other persons. He showed that this was a phenomenon 
observable in the blood of normal individuals, not a manifestation of illness, as had 
been thought. As we know, this led to the discovery of the four major blood groups 
and made blood transfusion possible without the consequences that led in 1668 to 
the prohibition, by law, of the transfusion of blood. Blood incompatibility between 
species had been noted before but that not all bloods even of the same species were 
compatible and that this was a natural phenomenon occurring in normal individu­
als had not yet been recognized by the beginning of the present century.
Metchnikoff, a zoologist, had discovered phagocytosis and Paul Ehrlich, by 
means of his blood staining methods had stimulated great interest in blood mor­
phology. A number of the hematologic diseases we recognize today had by the 
1920’s been described but their pathogenesis was unknown. It is interesting to read 
the section on diseases of the blood in the first edition of Osier’s famous ‘Principles 
and Practice of Medicine’ published in 1892. A total of 24 pages was devoted to 
this subject in a textbook of 1079 pages. In contrast, 39 pages were devoted to 
typhoid fever and still more to tuberculosis. Elsewhere, almost a page was as­
signed to paroxysmal hemoglobinuria, but only the form of hemoglobinuria as­
sociated with Raynaud’s disease and exposure to cold was discussed, not the noc­
turnal form. Hemolysis was mentioned in relation to pernicious anemia and to 
‘toxic hemoglobinuria’. There was no entry, however, for acholuric jaundice. Poly­
cythemia vera and hereditary telangiectasia, diseases with which Osier’s name is
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now associated, were not mentioned. Even in his 10th edition, published in 1925, 
only 35 out of 1173 pages were devoted to the blood and blood disorders.
Another more modern book, the first edition of Cecil’s Textbook of Medicine, 
published in 1927, devoted only a total of 60 pages to diseases of the bloodforming 
organs, out of a total of 1500. In Volume II of J. Von Mering’s Lehrbuch der In­
neren Medizin, edited by L. Krehl and published in 1925, Naegeli discussed all 
Blutkrankheiten in 29 pages.
On the technical side, the situation was equally bleak. Methods for enumer­
ating red and white cells, developed in the latter half of the 19th century, were difficult 
to execute with any degree of accuracy and platelet counting amounted to scarcely 
more than an estimate. The measurement of hemoglobin could only be called crude, 
even if one ignored the Tallqvist scale —although one could not really ignore the 
Tallqvist because it was widely used! Hemoglobin was expressed in per cent, sup­
posedly as per cent of normal. To my surprise, however, when I began to develop 
an interest in hematology, the values that were then being quoted as representing 
normal were based on a few determinations made in the 19th century by the even 
cruder methods of that time. This is why I began to develop some data on which 
normal values could be based, as did a few others, especially E. E. Osgood. I was 
stimulated to initiate studies in normal male and female students, incidentally, 
because in 1927 the idea was prevalent in New Orleans, Louisiana, that there existed 
an ‘anaemia of the south’; that is, that normal blood levels in the southern United 
States were lower than in the North. This, incidentally, proved to be a figment of 
someone’s imagination.
Even though hemoglobin estimation was so crude and no allowance was 
made for the recognized difference in normal values for men as compared with 
women, per cent hemoglobin, divided by the percentage of the red cell count, 
taking 5.0 million RBC’s as 100 per cent normal, was used to determine the color 
index, a procedure introduced by Georges Hayem, the French ‘father of hematol­
ogy’. This index was widely used in Europe and in America, especially to help 
distinguish pernicious anemia from chlorosis and other ‘secondary’ anemias.
It is no wonder that the differential diagnosis of anemia was confused. Topro- 
vide a more accurate measurement of red cells than was then available, I devised 
a hematocrit which had a sealed bottom, required approximately 1 ml blood and 
could be easily calibrated, thereby to correct the deficiencies of the microhematocrit 
which was occasionally being used in the hope of improving hematologic method­
ology.
Measurement of the size of red cells was of great interest in the 1920’s. Cecil 
Price-Jones had clearly demonstrated the striking differences in the sizes of the red 
cells in pernicious anemia and in other anemias and the dreaded task of a student 
or house officer was the work and tedium involved in preparing a Price-Jones curve. 
The method was not only tedious but very time consuming. However, there was no 
gainsaying that Price-Jones made his point.
It was in this period that Russell Haden called attention to the Volume Index 
and introduced the Saturation Index, as complementary to the Color Index. These
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procedures troubled me, however, because they were based on the unjustified as­
sumption that a value for 100 per cent could be established for men and women 
and, it was also assumed, for children. Furthermore, 1 was impressed that thosewho 
used these terms did not really understand what they meant. For this reason, the 
thought came to me that one could devise a method of calculation that required 
no assumed normal values. The size and hemoglobin content of red cells could, 
moreover, be expressed in readily understandable terms. Thus, the calculations of 
MCV, MCH, and MCHC were introduced. Furthermore, on the basis of improved 
technical methods and such calculations, 1 then devised a classification of anemias 
which offered more than a means for separating pernicious anemia from a miscel­
lany of other forms of anemia.
The Beginning of the Modern Era
I am sure that everyone will agree that the modern era of hematology had its 
‘official’ inception with the publication of a paper entitled, ‘Treatment of Pernicious 
Anemia by a Special Diet,’ in the Journal of the American Medical Association, 87, 
470 (1926) by G. R. Minot and W. P. Murphy. This was a very significant turning 
point. It marked the introduction of the methods of experimental medicine in the 
field of hematology. The paper described a painstaking clinical study, supported 
by meticulous daily reticulocyte counts, in which test diets were given for periods 
of 10 days each and the results were observed daily. It might be pointed out, also, 
that without Ehrlich’s ‘useless’ study of reticulocytes and Minot’s finding that their 
increase heralded remission in pernicious anemia, the length of time required to 
clearly demonstrate the effect of liver in pernicious anemia would have been so long 
that the risk for the patients might have prohibited the experiments. Likewise, it 
would have been very difficult for Castle to show the effect of beef muscle, plain 
and then predigested, experiments that led to his famous intrinsic factor, extrinsic 
factor theory.
Minot’s and Castle’s series of experiments were convincing and had a pro­
found effect on hematology. One began to think about the various steps in erytnro- 
poiesis and to ask about mechanisms and substances essential for their production. 
To me, an intern in 1926, Minot’s report was inspiring. I realized how little was 
known or understood but, like many others, 1 was profoundly stimulated to begin 
to enquire.
As one looks back, it is surprising that progress at first was not very rapid. 
It is interesting to examine the first edition of my own book, Clinical Hematology, 
published in 1942. The words ‘stem cell’ and ‘tissue culture’ are only mentioned 
very briefly. Bone marrow puncture was just beginning to be utilized. Whether or 
not the red corpuscle possesses a membrane was uncertain. The efficiency of this 
structure as a carrier of oxygen was appreciated but its anerobic metabolism was 
suspected by only a few. As to the leukocytes, 1 stated that our concepts of their 
functions ‘are based largely on inference and are founded to a great extent on the
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variations which have been observed to occur in the blood and in the tissues in 
pathological conditions.’ This fact caused me to draw attention to the possibilities 
for error in this indirect method. The lymphocytes were stated to be still more 
mysterious than the polymorphonuclear cells and monocytes. Interestingly, on the 
basis of studies that Rich, Lewis and 1 conducted, we ventured to suggest that one 
function of the lymphocyte was concerned in some way with the body’s reaction 
to foreign protein.
Coagulation was a very simple process (don’t we wish it were so today!). 
Oncology, as we know it today, did not exist. ‘Mediterranean anemia’ was stated 
to be ‘rare, apparently, for less than 100 cases have been reported since Cooley’s 
paper appeared in 1925.’ It was stated that, although families have been said to be 
normal, . . . this claim has not been supported by evidence of thorough examina­
tions of such ‘normal adults.’ This fact troubled me and I pointed out that my own 
observations showed that both parents in two families with children having Medi­
terranean anemia had mild anemia and red cell abnormalities consistent with a ‘be­
nign’ form of Cooley’s anemia. This, as Neel has stated, was the final link between 
thalassemia and the conditions described by Angelini and by Caminopetros.
Progress was interrupted by World War II, but it is noteworthy that modern 
chemotherapy had its beginnings in the studies of the biological effects of nitrogen 
mustard that Goodman, Gilman, Dougherty and others (including myself) con­
ducted. It was also in connection with that war that Peter Medawar began inquiring 
why skin grafts used in the treatment of burns were rejected — investigations that we 
now know were so important in illuminating the functions of the lymphocyte. In a 
later war, incidentally, G6PD deficiency was discovered in the course of a search for 
more effective antimalaria] compounds.
The Present and the Future
All of these investigations, however, were but the prelude. It is in the last three 
decades that the greatest surge in knowledge and understanding has taken place. 
There has never before been a comparable growth of knowledge of living things 
and, among these phenomenal advances in the field of biology, hematology has 
held center stage. Consider only two examples. It was the investigations of the 
nature of the sickling phenomenon and, in particular, the observations by Sherman 
in my laboratory that deoxygenated sickle cells show birefringence in polarized 
light, that led Pauling and Itano to carry out the studies which resulted in the epochal 
report, ‘Sickle cell anemia, a molecular disease’, that initiated the molecular age 
in biology. And almost more astounding have been the results of the study of the 
lowly lymphocyte, the cell whose uniformly monotonous appearance hides its 
astonishing diversity. Who had ever dreamed that these morphologically anony­
mous cells have such diverse capabilities, possess so long a memory and have played 
so important a role in the process of evolution.
With all that has gone before, what can we say of the future? Where will cell
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culture, the study of cell surface markers, recombinant DNA, monoclonal anti­
bodies, gene splicing, bone marrow transplantation and a host of other advances 
carry us? Will monospecific antibodies make it possible to distinguish and to target 
malignant cells? With the better characterization of the leukemias that surface 
markers provide, will we be able more accurately to destroy the abnormal cells and 
leave the normal ones unharmed? As Peter Medawar has stated, an important 
objective of research is the detailed mapping of cell surfaces. When we learn the 
molecular basis of specificity we may learn why, in development, some cells go one 
way and others follow another route, why some stick together, others do not. 
In due course, we are likely to find a way to detect small métastasés and perhaps to 
deliver cytotoxic drugs to malignant cells. Tissue typing will be improved by the use 
of homogeneous antibodies and this should not only aid organ transplantation but 
it will further the study of the relationship of human leukocyte antigens (HLA) to 
the development of various diseases. There are good grounds to hope that one day 
we will be able to replace genes that are defective.
The visions and possibilities I have mentioned are based on realization of 
what we know today. It does not require much dreaming to conceive them and even 
to think of others.
But experience tells us that advances often have come from totally unexpected 
directions and in unforeseen ways. 1 find it very humbling when 1 try to imagine 
what I might have predicted even 35 years ago. Before we learned about the struc­
ture of hemoglobin, how many would have conceived the picture we have today of 
the abnormal hemoglobins and of thalassemia? Who would have guessed a little 
more than 30 years ago, before sickle cell anemia was found to be the consequence 
of an alteration in a single amino acid out of the 146 in the /i-globin chain of hemo­
globin, that we would find so many hemoglobin abnormalities. Or, even more 
recently than 30 years ago, who would have dreamed that there exist so many 
varieties of thalassemia, formed in so many different ways?
Shakespeare wrote:
Strange it is that our bloods 
of colour, weight, and heat, pour'd all together,
Would quite confound distinction, yet stand off 
In differences so mighty.
All's Well That Ends Well 
II, iii, 125 -  128
Little did he realize how wisely he was speaking.
A question I was asked when I was beginning my study of the blood and 
blood diseases was: Why does the blood remain ‘normal’ in healthy human 
beings? This, when we stop to reflect, is one of the most difficult questions of all. 
We are only now beginning to discover ways of investigating some of the regulatory 
mechanisms and the differences in the regulation of the growth and development 
of neoplastic cells as compared with normal cells. Hitherto, we have learned mainly 
by exploring the defects we have encountered, the so-called ‘experiments of nature.’
H aem ato log ia  16, 1983
12 М. М. Wintrobe: Perspectives in hematology
Now more direct approaches are being devised. And, incidentally, when we con­
template the extraordinary number and variety of defects that have been discovered, 
and consider those that could take place, one must marvel that we ever developed 
at all! But that is the essence of the evolutionary process.
There is good reason to expect that some day we will know how our compli­
cated and intricate biologic mechanism is regulated, corrected and faulty parts 
(cells?) destroyed. How soon this will come about and whether or not the answer 
will contain many surprises we can, each of us, speculate all we will. I suspect that 
few will dream imaginatively enough. And, no doubt, there also will be answers 
to questions we have not even thought to ask.
Dangers Ahead
Looking backwards, we have very good reasons to hope for a rosy future. 
But there are problems. In the field of biologic science we have been blessed with 
peace and trust in our fellow human beings. There has been more and more free 
exchange of ideas and support for research has increased, albeit in spurts and starts. 
Progress has been made because, as time has gone on, more and more ingenious 
minds have had an opportunity to pursue questions that have excited them. As these 
were answered, still more questions arose and, so, questions and answers have 
multiplied at a logarithmic rate.
Hitherto, and for some time now, medical science and hematology in particu­
lar, has attracted many young people. Success has bred success. As new discoveries 
were made, more and more young men and women were stimulated to try their 
talents. Will this continue? It seems to me that there are fewer now who want to 
dream and are willing to devote their lives to the search for greater understanding. 
Is there a general eating away of enthusiasm for research, even some pessimism 
regarding the future of civilization as a whole?
In certain respects we live in an irrational and even an insane world. Much 
more energy is spent every day on ways and means to destroy mankind than ways 
to benefit the human race. These means are becoming more and more widespread 
and one doesn't know when some madman will set a spark that will destroy all 
that we have learned. War is not a new experience for man, but now war can be 
totally devastating. We now are able to destroy all of mankind, not just thousands 
or a few million. Will sanity ever be restored? Will there be a return to idealism, 
general good will, a striving for the good of all mankind?
We cannot set these awesome thoughts aside but, nevertheless we must con­
tinue to give thought to less overwhelming considerations. One of these is the matter 
of free communication. An important element in the progress we have witnessed is 
the fact that communication has been open and ever more rapid. As a result, each 
investigator has stood on the shoulders of his predecessors and his contemporaries, 
adding rapidly thereby to our fund of knowledge. This has become the accepted 
practice and, by and large, credit has been given where it was due. But now a new
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aspect is entering biologic science. 1 refer to the potential exploitation of molecular 
biology. Discoveries relating to recombinant DNA and monoclonal antibodies 
have great potential for the manufacture of useful and profitable products. This is 
exciting and holds much promise. But we hear of scientists who have formed their 
own companies so as to profit financially from their discoveries and who, as a con­
sequence, have become multimillionaires overnight. We hear of famous universities 
doing the same or considering steps in this direction. One writer suggested that one 
such university whose motto includes the word, Veritas, should change it to Cupi- 
ditas.
The element of private gain, whether for the scientist or the university or a 
commercial institution, or for combinations of these, must by its nature stifle the 
free exchange of ideas. This is extremely disturbing because open communication 
is the bedrock of science. Hitherto, it has been mainly the developmental aspects of 
some scientific discoveries that have been in the domain of commercial ventures 
and the resulting inhibiting effect on free and open scientific research has been fairly 
limited. The new developments to which I refer bode ill. There is great danger.
One can understand the reasons for the desire of all parties to secure some of 
the profits that arise out of research. However, while the problem is not altogether 
new, now for the first time scientists and universities have something extremely 
valuable to sell and this comes at a time when funds for research support are be­
coming more scarce and research is becoming more costly. We must find a solu­
tion to this problem that is favorable to science. The scientist and the university 
must be beholden to no interest but the truth. If this ideal is shattered, our dreams 
for the future will be endangered. The goose has laid a golden egg, but will it be 
the last?
At the other end of the spectrum is the way in which medicine will be prac­
ticed. We are on the threshold of fundamental transformations in health practices 
as the result of the growth of knowledge and the technologic advances that have 
been made, such as innovative methods for securing data and computerized systems 
for integrating and interpreting them. These will have far-reaching social and eco­
nomic effects. Designed to improve our ability to help our patients, there is never­
theless a danger that the physician will be further and further removed from the 
patient and may, himself, lose the integrative skills that a well-trained physician 
develops. When our approach was mainly qualitative, we were forced to pay close 
attention to the patient. Now that we measure and measure, numbers rather than 
human qualities tend to dominate. It becomes easier to ignore the fact that each 
patient has his or her unique features. The need of our patients to communicate 
with the physician still is there and will never disappear. We must find ways to 
provide our patients with all the benefits of science but we must do this in a way 
that is not economically overwhelming. We must also continue to regard the con­
cerns, the fears and the worries of our patients with the same importance as their 
diseases and the fascinating problems that the latter present.
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Research on human leukemia antigens and immunity in leukemia has under­
gone considerable changes within the last few years. Until recently, most of the 
field was dominated by two of the concepts prevail ing overall in tumor immunology, 
that most tumor cells would be found to have tumor-associated antigens and that 
most tumors would have demonstrable immunogenicity, which could lead to host 
resistance against progressive disease. There were many efforts to identify leukemia- 
associated or specific antigens and indeed several were reported. There were also 
many studies on specific immune reactivity of leukemia patients against autologous 
leukemia cells. Upon more careful assessment of these data, however, considerable 
doubts about the documentation of the specificity were raised. The recent advent 
of monoclonal antibody technology raised new hopes for the identification of leu­
kemia-specific antigens. However, experience to date has indicated that this ap­
proach suffers from most of the same problems of specificity as the previous studies 
with antibodies in the sera of patients or with antisera produced in heterologous 
species.
Despite the overall disappointment in the usual failure to identify truly 
specific leukemia antigens, a quite intriguing and important pattern has emerged. 
It appears that almost all of the antigens detectable on leukemia cells are differen­
tiation antigens which are appropriate for the stage of development or differentia­
tion of the cells. Normal hematopoietic cells at the same stage of differentiation 
have been shown to share the same characteristics [1]. In each of the major types of 
leukemia and lymphoma, the marker information appears to fit well with this over­
all concept. One example of this relates to chronic myelogenous leukemia. 
Assessment of the distribution of the marker Philadelphia chromosome has indicat­
ed that the target cell is probably the pluripotential stem cell in the bone marrow, 
with potential for any of its derivatives to be affected by the leukemic process. 
This could provide a ready explanation why, in contrast to the usual myeloid 
differentiation in this condition, some cases of blast crisis show lymphoid markers 
rather than myeloid markers. This concept is of particular relevance to the contro­
versy over the classification of the K562 cell line derived from a patient with chronic 
myelogenous leukemia in blast crisis. Observations that these cells could be in­
duced to express markers oferythroid differentiation led many investigators to con-
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elude that this cell line was inappropriately classified and represented an erythroid 
leukemia. However, further characterization has revealed that this cell line also 
has the potential to express markers of myeloid and megakaryocytic differentiation 
[2]. In further support of this concept, Bonnard et al. [3] presented evidence for 
accessory functions of this cell line compatible with a macrophage or myeloid 
differentiation. It is also of note, in view of the widespread use of this cell line as 
the prototype target cell for studies of human natural killer (NK) activity, that P. 
Pattengale [personal communication] has found that fresh leukemia cells from 
patients with chronic myeologenous leukemia in blast crisis are also highly sus­
ceptible to attack by NK cells.
It has also been possible to assign most of the lymphocytic leukemias to a 
particulat phase of differentiation of normal lymphocytes. Although the common 
acute lymphocytic leukemia antigen was initially thought to be leukemia specific, 
it was later found to be expressed on a small subpopulation of normal bone marrow 
cells. It appears that this antigen is an indicator of a very early phase in B cell 
differentiation, prior to expression of cytoplasmic or surface immunoglobulins. 
At this Congress*, Jánossy and his colleagues [4] presented evidence for a normal 
equivalent cell for the usual form of chronic lymphocytic leukemia, which has B 
cell characteristics. In addition to expressing surface IgM, it paradoxically expresses 
the T1 antigen which has been mainly associated with T cells, and also has receptors 
for mouse erythrocytes. They have shown that its normal counterpart, which has 
the same characteristics, is clearly a peripheral B cell, being found in tonsils and 
reacting with two new monoclonal antibodies, RFA2 and 3, which appear specific 
for B cells in the periphery. It is of interest that the normal B cell with these charac­
teristics is quite rare, representing only about 5 per cent of normal B cells and local­
ized at the edges of germinal centers. Jánossy also summarized recent information 
of Diehl ei al. from the FRG regarding the normal cell counterpart of the Reed- 
Sternberg ceil of Hodgkin’s lymphoma. This group has developed a monoclonal 
antibody reactive against the Reed-Sternberg cell and has been able to show that 
there are small numbers of cells in normal lymph nodes, in clusters in the inner 
ring of the follicular mantle of lymph nodes, but which is entirely negative with T 
cells, interdigitating dendritic cells, macrophages, or any cells in the bone marrow 
or peripheral blood. It still remains to be determined what the cell lineage is of this 
type of cell. It was pointed out that the ability to accurately classify leukemias and 
lymphomas has therapeutic implications, since B cell lymphomas respond well 
to intensive chemotherapy. Further, by identifying antigens that are selectively 
associated with the particular leukemia or lymphoma, it may be quite useful to 
devise strategies for autologous bone marrow transplants, in which the bone mar­
row cells of the patient are pretreated with the appropriate antibodies to eliminate 
small numbers of leukemia cells, prior to infusion after intensive chemotherapy.
At this Congress,* there was considerable evidence of research activity on 
characteristics of T cell leukemias and lymphomas, particularly from Japan.
* Int. Congr. ISH-ISBT, Budapest 1982.
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In addition to a summary of these diseases by Watanabe in a symposium [5] there 
were several poster presentations. Nishioka et al. [6] reviewed a large series of 
lymphoid tumors in Japan and found that almost 80 per cent had T cell charac­
teristics. Other presentations also emphasized the predominance of T cell markers 
in these diseases, particularly with expression of the T4 antigen, which has been 
associated with a subpopulation of T cells with helper activity. However, some of 
the presentations emphasized the hazards of directly equating marker information 
with functional activity. Yamada [7] reported that some patients with this ‘helper’ 
phenotype in fact showed strong suppressor activity for B cell differentiation. 
Conversely, a case ofT cell chronic lymphocytic leukemia trom Taiwan was report­
ed by Chen et al. [8] to have the T8 phenotype but helper activity in vitro. One 
further interesting feature to some of the Japanese studies was the detection of 
antibodies in most of the patients that reacted with a T cell ieukemia-associated 
antigen by immunofluorescence. It appears that this antigen is related to the human 
T cell leukemia virus recently described by Gallo and also by some workers in 
Japan. It was of interest in the presentation by Ichimaru et al. [9] that the majority 
of spouses and siblings of leukemia patients were also found to have such anti­
bodies. Although such data are intriguing, they need to be interpreted cautiously, 
since no étiologie link has yet been made between this virus and T cell leukemia or 
lymphoma. It is also of note that in contrast to the high association of this virus 
with Japanese T cell tumors, the association is considerably less frequent among 
cases in the United States.
Another type of leukemia that was emphasized in several of the presentations 
was hairy cell leukemia. The lineage of the leukemia cells in this disease remains 
quite controversial, as evidenced by the heterogeneity of information presented 
at the Congress. Leukemia cells frequently show B cell characteristics, with mono­
clonal surface immunoglobulins and other B cell features. However, Reyes et al. 
[10] reported that hairy cell leukemias can display accessory function in T cell 
colony formation in agar, thus mimicking some features of macrophages. The cases 
described by this group initially had both monocytic and B cell markers but in 
culture the monocytic markers predominated. Najfeld et al. [11] reported on an 
interesting patient who had cells with features of T cells, B cells, and monocytes. 
The non-T leukemia cells were shown to be phagocytic and expressed monoclonal 
surface immunoglobulin, and reacted with several anti-hairy cell monoclonal 
antibodies. It will be of considerable interest to determine if this type of leukemia 
is derived from one normal cell type and if so, what its features and characteristics 
are.
A central practical issue, in addition to classification of leukemias and lym­
phomas, is the possible prognostic information provided by leukemia markers. 
For real clinical value, it would be important to demonstrate that a given marker 
would allow better prediction of survival or response to therapy than the currently 
available criteria. At this Congress* there were a few reports on the possible prog­
nostic value of some markers in leukemia and lymphoma. Kühnl et al. [12] reported 
on factor B levels in Hodgkin’s disease, showing a correlation with length of sur­
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vival. Some value of measurements of serum ß.2 microglobulin was suggested by 
Cajozzo [13] et al. as a marker for more aggressive or advanced lymphomas. 
However, it was not clear whether levels of this marker could discriminate within 
clinical stages of disease. Of considerable interest was the report by Welte et al. [14] 
that in childhood acute lymphocytic leukemia, low expression of terminal trans­
ferase (TdT) was associated with poor prognosis. Tóth et al. [15] evaluated five 
acute phase reactants in patients with Hodgkin’s disease and non-Hodgkin’s 
lymphoma. They found ceruloplasmin and haptoglobin to be particularly useful, 
with elevations in untreated patients with advanced disease. Patients with remain­
ing elevations or progressive rises in marker levels after therapy were found to have 
a poor prognosis. As a general caution about the use of circulating markers, 
Fertakis et al. [16] reported considerable diurnal fluctuations in levels of carcino- 
embryonic antigen and ß2 microglobulin in patients with leukemia and lymphoma, 
as well as in other diseases. They stressed the importance of repeated sampling, to 
assess more accurately the levels of markers.
In addition to leukemia markers, another important issue is immunity in 
leukemia. The shift in emphasis in this field was illustrated by the virtual absence 
of reports on specific T cell-mediated immunity against human leukemia. The only 
suggestion that the T cell compartment might be important in resistance against 
these diseases came from the symposium presentation by Freireich [17] showing 
that a general marker of T cell competence, lymphoproliférative responses to the 
mitogen phytohemagglutinin, had some value as a prognostic variable in acute 
myelogenous leukemia patients before therapy. Low responses were associated 
with poor prognosis.
Much of the immunologic emphasis at the meeting was devoted to NK cells, 
which have been shown in animal systems to have a significant role in resistance 
against tumor growth and particularly against metastasis. Of particular interest at 
the Congress* was the report by Oshimi et al., [18] who studied the susceptibility 
of leukemia and lymphoma cells to lysis by NK cells. Of 21 tumors studied, only 
three were susceptible to normal NK cells, but 11 became detectably susceptible 
when the effector cells were pretreated with interferon. Some types of tumor cells 
were particularly susceptible, especially well differentiated lymphocytic leukemia, 
Hodgkin’s lymphoma, and chronic myelogenous leukemia in blast crisis. In con­
trast, acute myelogenous leukemia cells were quite resistant. Particularly interesting 
was the observation that autologous lymphocytes from some patients could lyse 
the leukemia cells, but high doses (about 2500 units) on interferon were required 
for induction of detectable responses. Several groups reported depressed NK 
activity in patients with leukemia and lymphoma, and also in patients with other 
types of cancer. Yagita et al. [19] also found depressed NK activity in patients 
with aplastic anemia, which appeared to be due, at least in part, to adherent sup­
pressor cells. Some of this suppression appeared to be associated with T cell sup­
pressors for colony forming units. Of particular interest in relation to leukemia were 
the observations by Yoda et al. [20] that patients with paroxysmal nocturnal 
hemoglobinuria had depressed NK activity even after interferon pretreatment.
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He noted the frequent occurrence of leukemia in patients with this disease, suggest­
ing a possible pathophysiologic link between this tendency and the defective 
effector mechanism. In addition to attention to the associations between NK 
activity and disease, there were some reports on the nature of the specificity of 
recognition by NK cells. Benczúr et al. [21 ] reported a heterogeneity of specificities, 
with about sevendefined against autologous and allogeneicPHA-stimulated normal 
cells, in addition to expression on tumor cells. Some activity was depressed by 
antibodies to ß2 microglobulin, suggesting a role for the major histocompatibility 
complex. Szabó et al. [22] in a study of autologous cytotoxicity in chronic myelo­
genous leukemia reported that reactivity was inhibited by the gp70 of two onco­
genic viruses, gibbon ape leukemia virus and baboon endogenous virus. The 
meaning of this intriguing finding remains obscure, however.
It is worthwhile to briefly consider the therapeutic implications of these 
studies on leukemia antigens and immunity. Although manipulation of potential 
effector mechanisms might have therapeutic benefits, there is still little evidence 
to support this approach. In contrast, other approaches are of potential interest. 
In view of the apparent arrest of leukemia and lymphoma cells at a particular 
point in differentiation, Sachs [23] emphasized the possibility for stimulating these 
cells to further differentiation, which in some animal tumor systems resulted in a 
susbtantial decrease in growth. Also of considerable potential importance is the 
use of monoclonal antibodies directed against various markers on leukemia cells. 
A possible major limitation to this approach may be the induction of antigenic 
modulation by some of these antibodies, as was reported by Ritz et al. [24] in an 
attempt with a monoclonal antibody against the common acute lymphocytic 
leukemia antigen. However, some preliminary studies with antibodies to T cell 
antigens have shown promising results, with at least transient reductions in tumor 
burden [25]. Particularly intriguing has been the report of a case of B cell lympho­
ma which was treated by Miller et al. [26] with a monoclonal antibody against the 
immunoglobulin idiotype. The treatment had a dramatic antitumor effect. It will 
be of considerable interest to determine how consistently this approach will be 
successful. More generally, studies over the next year or two will undoubtedly 
provide more implications about the overall therapeutic value of this approach to 
the management of leukemia and lymphoma.
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Red Blood Cells
The blood container
The design of the blood container was the subject of a special symposium 
chaired by Cash [32]. Most of the closed plastic bag systems for blood collection 
and preparation of blood components are designed for storage and clinical use of 
the cellular components and plasma. Lane [33] emphasized the need of a container 
suited for the large-scale plasma fractionator, making it possible to preserve the 
excellence of fresh plasma and allowing a rational and hygienic procedure in the 
plasma fractionation plant. Experience with such a system has been reported.
Although closed systems have been proven to allow the greatest safety in 
blood component preparation and are recommended for such procedures by many 
national regulatory agencies, systems which are being opened, e.g. to remove 
plasma, are also in use. McClelland [35] reported that so-called pig-tail systems are 
sufficiently safe provided that the procedure is well controlled not to allow reflux 
[84]. Flexible plastic bags are superior to rigid containers, such as glass bottles, 
since by their use the separation process is easily done aseptically. As pointed out 
by Lovric [34] sedimentation can be done by gravity in developing countries where 
refrigerated centrifuges or freezers are scarce. If glass bottles are used in blood 
component production, high hygienic requirements should be applied, e.g. work 
in laminar flow hoods as reported by Strauss [72].
Sometimes it is desirable to enter a container, e.g. in order topool granulocyte 
or platelet preparations. Smit Sibinga [36] reviewed the sterile docking devices by 
which the connection between two containers is sterilized by heat before opening. 
The principle was reported in 1975 but so far only limited clinical experience is 
available. Apparently it is difficult to make the procedure sufficiently safe and cost- 
effective. A new design of a sterile connector was demonstrated at an exhibition 
by the Travenol Company.
So far most plastic bags used for storage and transfusion of blood components 
have been made from polyvinylchloride (PVC) using di-ethyl-hexyl-phthalate 
(DEHP) as plasticizer. The presence of microholes (‘pin-holes’) in the plastic film 
and other defects in the bags has been a matter of concern, putting emphasis on 
proper quality control in the manufacturing process. The fact that DEHP is extract­
ed from the wall of the bag into the plasma has been a matter of discussion for a 
decade. Still there is controversy if a contamination of blood products with DEHP
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is a real risk factor. Recent findings that very large doses of DEHP given orally 
to rats and mice increase the incidence of liver tumours have not, at least not yet, 
led to its abandonment in blood bags [1 ]. No doubt, however, that there is a desire 
to find materials without these potential disadvantages, but it has apparently been 
difficult to find other materials with equally good storage properties, at least for 
the red cells. The gas transport through the wall of the bag is of particular impor­
tance in the storage of platelets and will be dealt with below.
Reel cell preservation
The ACD and CPD solutions widely used for the collection and storage of 
blood were originally designed for whole blood. Addition of adenine or adenine + 
guanosine makes it possible to increase the maximum storage time. Such solutions 
have been used in Europe since the middle 1960s (for review see [2, 3]) but have 
not been allowed in other countries like the USA until more recently. The im­
portance of increasing the glucose content of the CPD anticoagulant was emphasiz­
ed by some authors [63, 64] as well as in the earlier literature [4].
A new trend is to use a separate suspension medium for the red cells, thus 
separating the function of anticoagulation from that of preservation. Systems such 
as the SAG and SAGM systems described by ourselves [82] and the Circle Pack 
System described by Lovric [34] have been used extensively in clinical practice 
with great success. The suspension media are basically a sodium chloride solution 
with adenine, glucose and mannitol (SAGM) or adenine, glucose, sodium citrate, 
citric acid and sodium phosphate (Circle Pack). The initial anticoagulants are 
normal CPD (SAG and SAGM systems) and CPD with double normal content 
of glucose (Circle Pack). A closed plastic bag system was used in both procedures. 
Optimally the system should include four bags by which the following fourproducts 
are obtained: 1. a platelet poor and white cell depleted red cell suspension (thus 
containing very little microaggregates), 2. a platelet concentrate, 3. a platelet poor 
plasma and 4. a buffy-coat preparation. Alternatively, such a system can be used 
to produce 1. a red cell suspension, 2. a buffy-coat preparation, a maximum yield 
of plasma which is further processed into 3. cryoprecipitate, and 4. ‘cryo-poor’ 
plasma. The buffy coat can be used for interferon production as it is done at a large 
scale in Finland [24], or as a source of granulocytes in granulocyte transfusion. 
A three bag system with pig-tail was described by Walker et al. [67]. This may 
reduce the cost of the system.
When a closed multiple bag system is used, the total content of the respective 
containers is transfused. This restricts the choice of additives to those which do not 
cause harmful effects in the recipient. Inosine is an example of an additive which, 
due to the formation of large amounts of the metabolite hypoxanthine, may raise 
the serum uric acid level in the recipient after transfusion of a few units, when used 
in amounts optimal for extended red cell storage. Thus, such a preservation solu­
tion is not suitable if the blood unit is expected to be used in massive transfusion
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without special treatment. By opening the system toxic additives or metabolites 
can be removed, e.g. by washing. This means that the unit is not available for 
immediate use and that the reconstitution procedure may be considered too time 
consuming in massive transfusions.
Several new resuspension media have been suggested in recent literature and 
at this Congress. The Adsol™ solution of the Travenol Company is very similar 
to the SAGM solution but contains about double as much glucose and 25 per cent 
more mannitol. It is at present under investigation in the USA. Addition of 
dihydroxyacetone to the SAGM solution improved the oxygen delivering capacity 
of the red cells as measured by the maintenance of 2,3-diphos.phoglycerate (DPG) 
[71]. Fabre, Leterrier, and Saint-Blancard showed that experimental resuspension 
solutions containing phosphate, adenine, glucose, guanosine, and sodium chloride 
in some respects were superior to other tested media including SAGM [61, 62, 70]. 
In order to reduce spontaneous storage haemolysis when all plasma had been re­
moved they added sorbitol. This apparently had a similar effect as mannitol. Sodium 
bicarbonate and ammonium bicarbonate had a favourable effect on the mainte­
nance of DPG as shown by Lukasiak et al. [65]. Beutler [5] in 1973 already showed 
that sodium bicarbonate is very effective in counteracting the acidification during 
storage and thereby causes maintenance of normal DPG. This is due to the fact 
that carbon dioxide which is formed through the action of red cell carbanhydrase, 
escapes from the bag through the plastic wall of the container. In practice, however, 
bicarbonate solutions cause difficulties because of their instability during sterili­
zation and storage. This is true also for some other substances which have been 
shown to influence favourably red cell storage, such as ascorbic acid [6] and phos- 
pho-enol-pyruvate [7]. As indicated above objections may also be raised when the 
preservative contains supernormal concentrations of a physiologic substance such 
as phosphate (20 times the physiologic concentration in some of the experimental 
preservatives). Obviously, clinical studies are necessary to prove the safety and 
clinical usefulness of the blood components preserved in several of these experi­
mental solutions.
Another trend in red cell preservation is that other tests are being used more 
frequently than the traditional biochemical studies in vitro and post-transfusion 
viability studies in vivo. Evaluation of the morphological changes from discocytes 
into echinocytes of different grades and echino-spherocytes was used by several 
research groups. Concerning morphology, CPD-A solution is superior to ACD
[61] , storage as a concentrate or suspension is superior to whole blood [8], and 
storage as a suspension in the PAGGS medium is superior to that in SAG [70].
The viscosity at constant haematocrit also changes during storage. Clearcut 
improvements were found when red cells were stored as red cell suspensions (e.g. 
in SAG) as compared to traditional storage as red cell concentrate or whole blood
[62] . Guanosine and phosphate in the suspension solution ensured further im­
provements. A more elaborate metabolic investigation than ATP alone is useful in 
order better to understand the effects of the manipulations. For instance, determi­
nation of NAD is useful when substances such as dihydroxyacetone are used [71 ].
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An in vitro model simulating in vivo post-transfusion conditions is also promising 
[69].
Purification o f red ceils
Removal of buffy coat as a means of improving the quality of the red cells, 
which are to be transfused, has been used for many years in some countries [9]. 
A platelet poor, buffy-coat poor and plasma poor red cell suspension was shown 
to reduce the incidence of transfusion reactions (febrile, urticarial) in elective 
surgery patients as compared to whole blood (0.14 per cent and 0.68 per cent, 
respectively) [82]. This means that even in this respect a red cell suspension which 
can be stored for 5 weeks is an improved product useful in the majority of patients. 
In some patients with leukocyte antibodies higher purity from leukocytes must 
be obtained in order to give a reaction-free transfusion. For practical reasons fil­
tration through cotton wool filters seems to be the method of choice, with an effec­
tiveness of 99 per cent [86], 97 per cent [68], or 92 per cent [85]. Clinical experience 
of 25 000 units of leukocyte poor blood was reported as very successful both with 
respect to reduction of febrile reactions and HL-A sensitization [68]. A combina­
tion of removal of buffy coat and cotton wool filtration can be expected to be 
advantageous since the former is effective in removing lymphocytes, and the latter 
is effective in removing granulocytes [10].
Clinical experience with stored red cell suspensions
Myllylä [66] showed that the post-transfusion survival in vivo of effectively 
plasma-depleted red cells suspended in SAGM medium was 79.2 per cent (range 
87.5-72.3) which was similar to our corresponding figures (83 per cent + 5.3 per 
cent) [82].
We have reported [82] on favourable clinical experience with plasma-poor 
red cell suspensions (SAGM-system), indicating that plasma or albumin solutions 
are normally not necessary at blood losses up to 50 per cent of the patient’s blood 
volume. This is in agreement with previous studies of Lundsgaard-Hansen [11]. 
The new haemotherapy programmes reduced the use of plasma/albumin by 75 per 
cent and the use of red cells by 25 per cent [82]. Thus, considerable volumes 
of plasma become available for other purposes, e.g. production of Factor VIII 
preparations.
Converting B cells to О cells
Goldstein [22] reviewed work to remove the blood group B antigenic deter­
minant by treatment with alpha-galactosidase. After treatment the red cells had 
97% 24 h post-transfusional survival in humans whose plasma contained anti-B. 
The half-time was also normal, 30 days. However, as the procedure includes
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several washing and incubation steps it is doubtful whether it will be cost-effective 
for more general use. In therapeutic use with certain rare blood types the procedure 
will probably find its first practical application.
Platelets
As early as 1975 Murphy and Gardner [12] showed that prolongation of 
storage at room temperature can be successfully applied by improving the gas 
transport through the wall of the container. This can be done by extending the size 
of the bag or using thinner or more gas-penetrable plastic materials.
A fundamental difference exists between red cells and platelets in that the 
latter contain mitochondria and can use oxidative phosphorylation for the pro­
duction of ATP. This way of energy supply to the cell is much more effective than 
the glycolytic pathway. If oxygen is consumed a switch to anaerobic metabolism 
occurs and the medium will be acidified rapidly due to the formation of lactic acid. 
This explains why there is sometimes a sudden drop in pH after one, two or more 
days of storage. A substantial reduction in viability occurs when the pH decreases 
below 6.0.
Oxygen consumption depends on the total number of platelets but also on 
the metabolic activity of the cells, as emphasized by Moroff et al. [74].
The diffusion of oxygen into the bag and of carbon dioxide out of the bag, 
the latter to reduce the content of carbonic acid, is thus important. The driving 
force is the difference in partial pressure between outside and inside. When oxygen 
is consumed by the platelets the p 0 2 is lowered which increases the flux into the 
bag if the conditions permit gas penetration. New plastic materials are available 
which allow improved gas transport: the PL-732 made of polyolefin material and 
manufactured by the Travenol Company and the CLX plastic made of PVC with 
a non-leachable plasticizer and manufactured by the Cutter Company. The useful­
ness of the latter material is shown in two reports [76, 78] indicating that room 
temperature storage of platelets may be extended upto 5-7 days in these plastic 
bags. Similar experience with the PL 732 plastic has been reported earlier [13, 14] 
and at this congress by Lamy et al. [77].
Other attempts to improve the storage of platelets were done by using 
different inhibitors of platelet aggregation of which Trapidil and PGEj were found 
the most effective [73]. The stable prostacyclin analogues, 7-oxo PGI3 and Chinoin 
M 1296 and M 1308 are also promising [88]. Kotelba-Witkowska et al. [75] used 
a drug, Craviten, which increased the activity of hexokinase and pyruvate kinase, 
prevented the fall of the ATP level, increased the cAMP level and inhibited sponta­
neous aggregation of the stored platelets.
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Granulocytes
In his review on granulocyte transfusions Huestis [26] said that the most 
commonly expressed consensus is that an adequate transfusion should include at 
least 1010 polymorphonuclear neutrophils. To achieve this dose, in most transfusions 
by centrifugal leukapheresis requires that the mean collection be at least 2 x Ю10 
PMN because of the unpredictable variability of cell yield from different donors. 
New antibiotics and an effective regimen to use them have made granulocyte 
transfusion unnecessary in a large number of patients with granulocytopenia and 
sepsis, following cytostatic treatment [79]. Although clinical effects even of smaller 
doses than those mentioned above were claimed by some groups [80] the overall 
impression is: More granulocytes should be given to fewer patients and more than 
once daily transfusions may be necessary in some cases.
A special indication may be neonatal neutropenia with depletion of mature 
marrow neutrophils in infected neonates who are at high risk of death from sepsis. 
In a recent prospective pilot study all of 7 such infants receiving granulocyte trans­
fusions survived, but 8 of 9 non-transfused patients died [15]. The poor prognosis 
in this study was correlated with a depletion of the marrow neutrophil storage pool 
cells, and not with peripheral neutropenia. The given dose of neutrophils was 
0.7 • 109/kg of the recipient’s body weight, range 0.2 to 1.0 ■ 10°.
No progress in the in vitro storage of granulocytes has been reported; it is 
still limited to 24 h, preferably at about 20 °C without agitation.
Transfusion in Transplantation
After the discovery by Opelz et al. [16] in 1973 that kidney transplant patients 
who had received transfusions showed a lower frequency of rejections than non- 
transfused patients, their observation has been confirmed by many studies. It is, 
however, unclear which components in the blood are responsible for the effect. 
It may now be concluded that red cells and plasma do not have this beneficial 
effect. In his review van Rood [25] showed that protection has been obtained using 
platelets in an experimental study in monkeys. This is of both theoretical and prac­
tical interest since the major histocompatibility antigens are less completely ex­
pressed on the surface of platelets than of lymphocytes. Further studies are needed 
to answer the question whether platelet transfusion regimens prior to kidney 
transplantation will be superior to the present widespread use of whole blood or 
red cells with or without partial removal of the buffy coat.
Another practical consequence of the higher immunogenicity of lymphocytes 
than of platelets was the finding that platelet concentrates depleted of contaminat­
ing lymphocytes gave much less refractoriness at repeated platelet transfusions 
than normal platelet concentrates which are usually at least to some extent 
contaminated with lymphocytes.
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Plasma Components for Therapeutic Use
New fractionation techniques
A new trend in plasma fractionation is the use for separation of plasma pro­
teins of other principles than the alcohol precipitation technique of Cohn. In his 
review on the subject Curling [23] concluded that the Cohn technique is best suited 
for large scale fractionation, e.g. in batches of 50001 plasma/week, while chromato­
graphic methods are useful up to 500 1/week. Affinity chromatography methods 
for the production of high yield and high purity albumin are available. The most 
important progress concerns, however, those plasma proteins which are partly 
denatured during the alcohol fractionation process. By the use of improved methods 
native preparations are obtained that can be applied intravenously without side 
effects.
Gamma globulin
Immunoglobulin G preparations obtained by Cohn fractionation are known 
to cause anaphylactoid reactions if used intravenously particularly at rapid infusion 
rates. This may be due to the presence of LgG aggregates or Pre-Kallikrein Activa­
tor (PKA) and the in vivo generation of vaso-active kinins. Nevertheless, successful 
intravenous administration of ordinary IgG preparations was observed by 
McClelland et al. [92] when given slowly (6 per cent complication frequency). 
The importance of proper testing of IgG preparations was emphasized by Nydegger 
[37] who showed that large variations exist between IgG preparations available 
on the market and intended for intravenous use (see also [17]). Some of them do 
not fulfil the requirement of being safe, potent and efficacious. The usefulness of an 
animal model in testing the preparations was shown by Bakker et al. [87]; short 
hypotension in the animals indicated PKA, while prolonged hypotension the 
presence of IgG aggregates.
Chromatographic IgG prepared by Suomela et al. [81 ] was native (less than 
1 percent non-monomeric IgG), of high purity, and contained potent antibodies 
to a wide spectrum of bacterial and viral antigens, as shown by Salonen and Suo­
mela [83]. All IgG subclasses were represented.
The clinical usefulness of intravenously administered IgG preparations in 
immunodeficient patients was shown by Cunningham-Rundles et al. [38]. Serum 
levels of 4-6 g/1 were obtained and the T x/2 was 2 weeks. Hospitalization and 
incidence of febrile reactions decreased considerably.
In addition to antibiotics intravenous IgG was given by von Murait and Sidi- 
ropoulos [39] to infants with neonatal septicaemia. The lethality was reduced 
from 26 per cent to 10 per cent and the incidence of recurrent infections decreased 
to one third.
Further experience was reported by Imbach [40] on his recent finding [18] 
that large doses of intravenous IgG normalized the platelet concentrations in pa-
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tients with idiopathic thrombocytopenic purpura (LTP). Excellent results were 
obtained in acute ITP in children, verified by others in the discussion. In chronic 
1TP most patients responded, some became refractory [41, 42]. The effect was 
better in children than in adults. The common dose was 0.4 g/kg/day for 5 days. 
The initial increment in platelet count was found by Bussei [42] to be predictive of 
the length of the response. Intravenous IgG was recommended as the method of 
choice in the initial treatment of ITP. The mechanism is not known but a competi­
tive, protective effect on the platelets or on the megakaryocytes seems possible.
Coagulation factor preparations
Britten [45] pointed out that haemophilia in contrast to many other congeni­
tal diseases, is evenly distributed all over the world with an approximative incidence 
of 50 cases per million inhabitants. The need of Factor V lllto  bring bleeding epi­
sodes under control was estimated at 4.5 • 109 IU/year. A rough estimate of the 
world’s present production indicated a total of 9 • IO8 IU which thus covered about 
20 per cent of the total need. Most of the produced Factor VIIL is, however, used in 
the USA and some of the European countries. In theworld there is awide spectrum, 
from no treatment at all to overtreatment and abuse. It was concluded that a yearly 
dose of 20 000 IU per haemophiliac, or 1 IU per inhabitant would be a realistic 
minimum goal of supply in any sufficiently well organized voluntary blood trans­
fusion service. For optimal treatment including prophylaxis at least 1.5-2 IU per 
inhabitant is probably needed [46].
The instability of Factor VIII causes difficulties obtaining high yields. Rock 
et al. [90] had made the important observation that the low molecular weight, 
carrier-freeform of Factor VIII:C is lost after 24h storage of CPDplasma, where­
as in heparin plasma or citrated recalcified plasma the small, carrier-free form 
of Factor VIII:C is stable. By collecting blood directly into heparin or by adding 
heparin plus calcium to citrated blood or plasma, the total of Factor VIII activity 
can be maintained. Smit Sibinga et al. [43] had obtained a 63 per cent mean yield 
and 20-30 IU/ml potency in a routine procedure for production of freeze-dried 
cryoprecipitate using double precipitation of heparin plasma, which was consider­
ably higher than in cryoprecipitate prepared by the traditional technique from 
CPD plasma of 44 per cent mean yield and 3-4 IU/ml potency. Also, the so-called 
thaw-siphon technique gave higher yields [91 ]. The high purity Factor VIII prepa­
rations produced at large scale industrial processes have certain advantages, 
particularly in home therapy and when very large quantities of Factor VIII have 
to be administered [44]. The yields are, however, low and the preparations do not 
contain the von Willebrand factor.
Two major problems in haemophilia treatment were discussed : the difficulties 
in the 15percentof haemophiliacs with inhibitors to Factor VIII, andthe occurrence 
of liver disease. By using non-activated and activated prothrombin complex con­
centrates, the bleeding episodes had been controlled in 50 per cent and 63 per cent 
respectively [47 ]. In a combined American-European study of mainly severe haemo -
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philiacs liver disease was investigated. Mild or trivial liver disease was found in 65 
per cent of the cases while 7 per cent had severe disease, 7 per cent had cirrhosis, 
another 10per cent were suspect of cirrhosis and 7 per cent had acute hepatitis [48].
Attempts to produce non-infective coagulation factor preparations have also 
been reported. The cold sterilization process using /1-propiolactone treatment 
with ultraviolet irradiation [49, 50] was found to reduce the virus titre about 10 
millionfold. Indication was obtained that non-A, non-B hepatitis viruses were also 
inactivated by these procedures and they were considered promising for practi­
cal use. Heat sterilization had also been applied with promising in vitro results [89].
Antithrombin III (AT)
AT is a potent protease inhibitor of activated Factors XII, XI, IX, X, and 
thrombin when occurring free in solution. Abildgaard [27] chaired a symposium 
on its biological action and clinical significance. Björk [28] reviewed the biochem­
istry of AT. After binding to a protease the molecule becomes modified and is 
cleared from the plasma with T 1/2 10 min. In the presence of heparin more AT is 
needed for inactivation of thrombin. The hereditary AT deficiencies were reviewed 
by Sas [29] and Nagy [30] who described different types of AT deficiency. Nagy 
surveyed the clinical aspects of the abnormality, and ten Cate [31] reviewed the 
diagnostic and therapeutic problems including the acquired deficiencies.
The hereditary form of AT deficiency seems to be particularly common in 
the Gipsy population of Hungary where the over-all incidence was found at 
1 :10 000 by Hungarian studies. The clinical manifestation is deep venous throm­
bosis which occurs preferentially in the lower extremities and is often accompanied 
with pulmonary embolism. The first manifestation may occur at the age of 10-16 
years. Urinary infections, pregnancy and injuries are precipitating factors. Heparin 
treatment in AT deficiency may have adverse effects. Hereditary AT deficiency 
patients with venous thrombosis should be put on a life-long antivitamin K 
regimen.
Acquired AT deficiency may be due to decreased synthesis (liver cirrhosis), 
increased loss (proteinuria) or increased consumption (DIC), not infrequently 
combined in the same patient. Acquired AT deficiency is also a frequent complica­
tion of postoperative Gram-negative infections, possibly caused by circulating 
endotoxins. Very low serum AT levels have a predictive value in the diagnos:s of 
septicaemia.
Concerning the indications for antithrombin concentrates there is general 
agreement about its value in hereditary deficiency complicated by thrombosis, or 
as a preventive measure at birth or operation. In acquired deficiency infusion of 
AT concentrate may normalize the consumption coagulopathy, and apparently 
be of clinical value. Abildgaard concluded that a common protocol should be 
elaborated for evaluating the results.
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Fibronectin
The biological and clinical significance of plasma fibronectin (FN) was dealt 
with in a symposium chaired by Lundsgaard-Hansen [51]. Clemmensen [52] 
reviewed the functional role of plasma FN. Like fibrinogen, FN occurs in soluble 
form in plasma and in insoluble form in connective tissue. Both proteins are con­
sidered to play an important role in tissue repair. In addition FN increases the 
solubility of fibrin monomers which appears to mitigate the sequels of disseminat­
ed intravascular coagulation (DIC). Consumption of plasma FN might thus 
aggravate organ damage in DIC.
Lundsgaard-Hansen [53] reviewed Saba’s concept [19] of plasma FN as a 
non-antibody, opsonic protein stimulating reticulo-endothelial function. Animal 
experiments suggest that a depletion of FN reduces the phagocyting capacity. 
The use of cryoprecipitate, which contains a concentrate of FN together with 
fibrinogen, Factor VIII and Factor XIII in intensive care patients has given anec- 
dotical evidence that substitution therapy may be important in patients with low 
levels of plasma FN.
Low levels of FN are often found in severe burns and renal insufficiency 
after surgical operations [54] and in those patients with malignant haematopoietic 
disease who are in poor condition [59]. After surgery a rebound occurs with super­
normal plasma levels [54].
Riibli et al. [55] investigated 98 patients treated in an intensive care unit. 
A number of serum proteins were severely decreased in patients with sepsis or 
DIC. The minimum FN value did not differ between survivors and non-survivors 
whereas this was the case for antithrombin III : lethality in patients with a minimum 
AT level <50 per cent of normal was 66 per cent, with >50 per cent 13 per cent, 
p < 0.005. All septic patients who died after more than two weeks in the intensive 
care unit had returned to the normal range of FN level prior to death. The study 
confirmed Saba’s concept of an association between low FN levels and life- 
threatening, septic and/or DIC-associated disease, but a causal relationship has 
to be proven.
Lundsgaard-Hansen concluded that the question is still open whether fibro­
nectin, recommended as an adjunct to established modes of intensive care, has any 
beneficial effects. Controlled trials are urgently needed.
Interferon
Nevanlinna [24] reviewed his institute's experience in the large scale produc­
tion of human interferon-alpha (IF) made from buffy coats. Both the yield of 
crude and purified interferon (PIF) had increased. Approximately 8 • 10® IU crude 
IF is produced per buffy coat and the final yield of PIF is around 60 per cent. 
Production of interferon-gamma from buffy coats has been started using Lens 
culinaris lectin as inducer. The yield per buffy coat has so far been poor, less 
than 1 • 10e IU. Clinical trials have been initiated.
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The production of IF from buffy coat cells is not an easy procedure, and in 
spite of large efforts many institutions have failed. The interest in leukocyte IF has 
decreased in recent years probably reflecting great expectations for the mass pro­
duction of bacterial IF.
Since, however, the human leukocyte IF products are a mixture of different 
IFs of which only some are being produced microbiologically in the near future, 
there may still be room for the human leukocyte derived products. In addition 
lymphokines other than interferon-gamma such as lnterleukin-2 (T cell growth 
. factor) may be of therapeutic interest. After all, human leukocytes is a by-product 
which can easily be collected in a well organized blood transfusion service.
Therapeutic Apheresis Procedures
Plasmapheresis to remove plasma and replace it with some other fluid nor­
mally including albumin and/or donor plasma, has increased tremendously in the 
last five years. In a workshop on the subject with Shumak as moderator and Rock 
and Gavrilov as chairmen, Wenz [57] showed that the number of therapeutic 
plasma exchanges (TPE) in the USA have increased from virtually none in 1977 
to an expected number of 80 000 in 1982. The extraordinary thing is that the 
indications are mainly based on theoretical considerations or anecdotical experi­
ence. Only few controlled trials have been performed and few indications have 
been scientifically established.
The dysglobulinaemic hyperviscosity syndrome where excessive quantities 
of monoclonal protein are removed, seems to be undisputed [20]. Shumak [56] 
concluded that in addition to cryoglobulinaemia, Factor VIII antibodies in hae­
mophilia and removal of A/B antibody before bone marrow transplantation may 
be clearcut indications. Other diseases in which promising results have been ob­
tained are thrombotic thrombocytopenic purpura (TTP) and idiopathic thrombocy­
topenic purpura (ITP) that have failed to respond to prednisone, and pregnancies 
at high risk of haemolytic disease of the newborn due to anti-D. Controlled multi­
centre trials in these diseases have been started in Canada. Another promising 
indication may be certain cases of aplastic anaemia. A successful case of temporary 
remission in pure red cell aplasia was also reported [60].
A number of neurological conditions with known or suspected plasma 
factors related to the disease have been the subject of treatment in 25 per cent of 
all TPE procedures in the USA [57]. The conclusion at the workshop was that 
TPE may be useful in selected cases and to a limited extent in myasthenia gravis, 
Guillain-Barré syndrome and Refsum’s disease, whereas for the moment there is 
no indication that the procedure is useful in amyotrophic lateral sclerosis. More 
knowledge has to be collected concerning the mechanism of action of the treat­
ment.
Urbaniak [58] gave a review on the use of TPE in renal diseases. Appropriate 
indication for the procedure should be considered to be due only when the patho-
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genesis is clearly related to a factor predominantly present in plasma. It is also 
important to prevent resynthesis of this factor. Some centres have experienced 
good but other centres poor results in Goodpasture’s disease. Urbaniak reported 
that in the experience of his institute none of 19 severe cases had benefited from 
the treatment while success had been encountered in mild forms of the disease. 
An obvious difficulty is to initiate treatment sufficiently early during the course 
of the disease. Immune complex nephritis is a reasonable indication, particularly 
when there is an exogenous agent. TPE has been used also in allograft rejection 
after kidney transplantation. In controlled studies the difference was not significant.
There are still many questions in TPE that have to be answered. One of the 
most important ones concerns the fluid for replacement. Because of the large 
requirement of albumin or plasma the procedure is very expensive. Practical and 
unexpensive methods to remove a causative factor more specifically by adsorption 
are awaited with great expectations. As an example it may be mentioned that pre­
liminary experience with protein-A Sepharose columns for perfusion of blood or 
plasma to remove IgG 1,2, and 4 is promising, e.g. in antihaemophilic factor treat­
ment [21 ]. Great interest is also shown in the possible removal of blocking factors 
in the treatment of malignancies.
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Current progress in fractionation concerns not only new fractions but also 
new techniques and known but considerably improved fractions. The improval 
of already existing fractions may have different meanings. For instance a higher 
degree of safety or a fraction with a considerably higher specific activity may be 
obtained. Both these features may, of course, be observed coincidentally in purer 
products.
Among these improved fractions we may mention factor VIII concentrates. 
The most important long-term side reactions associated with substitution therapy 
of haemophilia A concern the development of hepatitis [1], namely of the non-A, 
non-B type and the appearance of haemolytic anaemia [2] due to the presence of 
isoantibodies. Whereas hepatitis B transmission regressed due to better screening 
of the blood donors, non-A, non-B hepatitis became more frequent. The virus(es) 
responsible for this type of hepatitis can actually not be evidenced. Consequently, 
factor VIII concentrates should be submitted to a virus-inactivating treatment. 
Such a procedure has been in use formany years in the preparation of albumin solu­
tions by heating them to 60 °C in the presence of stabilizer during 10 h. Factor 
VIII proved to be a very labile protein as heavy losses were observed during 
fractionation steps performed under rather mild conditions. So it seemed impossi­
ble to submit factor VI11 preparations to such a rough treatment as heatingto60°C 
during several hours. Recently these difficulties have been overcome. It appeared 
that factor VIII could be protected from heat dénaturation by saccharose and 
glycine [3, 4]. The final product contains only trace amounts of fibrinogen as this 
undesirable contaminant precipitates during the preparation procedure. The highly 
purified material has a low protein concentration. It is therefore stabilized before 
freeze-drying by addition of albumin. It contains much less y globulins than the 
non-heated material, but still enough to carry some isoagglutinins. Whereas the 
product available at present is heated in the liquid state, other laboratories ob­
tained similar results by heating the freeze-dried material. Yet another way has been 
developed by inactivating the virus by UV irradiation in the presence of ß-pro- 
priolactone [5]. The efficiency of these treatments is currently checked in chim­
panzees. As already mentioned, heating or treatment by /f-propriolactone does 
not allow the removal of isoagglutinins. The best way for obtaining factor VIII
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concentrates devoid of anti-A, anti-B activities is obviously the use of isogroup 
plasma pools as starting material. This has been done by several producers [6].
In summary, factor VIII concentrates have been improved not only as far as 
the yield and specific activity are concerned, but also with respect to their safety. 
Unfortunately, the safest products are not those with the best yield, casting aside 
the availability of the starting material.
More severe quality criteria are now applied to serum albumin preparations. 
Hypotensive effects have been reported after infusion of plasma protein solutions 
containing roughly 90 per cent albumin. It soon became clear that the kallikrein- 
kinin system might be involved [7, 8]. Although bradykinin [9] was detected in 
some batches, laboratory findings revealed that the causative factor was usually 
not the end-product of the reaction cascade but the prekallikrein activator which 
is identical with a Hageman factor fragment (X llf) [7, 10, 11]. Therefore, tech­
niques have been developed to check for the absence of activator, (pre)-kallikrein 
and kinins [7, 12, 13]. Prekallikrein activator was rarely present in highly puri­
fied albumin solutions (>  95 per cent). In addition, oligo-and polymers present in 
concentrated albumin solutions have been presumed to be the causative agents of 
side reactions observed occasionally after albumin infusion. Careful analysis of 
25 different batches could not, however, reveal any correlation between the amount 
of di- and trimers in the albumin concentrate and the reported side reactions [14]. 
Though no objective relationship could be proven between albumin aggregates 
and the poor tolerance of these preparations, the manufacturers became aware 
of the eventual harmful effects of these polymers and tests were developed to quan­
tify the amount of di, tri and higher polymers. This is usually done by gel filtration 
[15] and/or polyacrylamide gradient electrophoresis. It seems, however, that there 
is no clear difference between oligomers and aggregated material [16]. The latter 
is eventually more harmful than are the tri- or tetramers. New definitions seem to 
be oriented towards a tolerance limit of 10 per cent of polymers.
Currently, attention has been drawn to the biological activity of albumin 
concerning the specific transport role in addition to its main role of maintaining 
the oncotic pressure in the vascular space. This activity may be checked by a bili­
rubin fixation test. In contrast to rather generalized ideas, conventional stabilizers 
influence only slightly the binding characteristics of albumin, whereas the heating 
process has an additional slight effect [14]. Hence, the bilirubin fixation capacity 
of albumin in the presence of a conventional stabilizer is well preserved. This fea­
ture is important for the paediatrician using this plasma derivative in jaundiced 
infants.
Much work has been done concerning the improval of i.v. y-globulin prepa­
rations. The relationship between poor clinical tolerance and the presence of 
aggregates in the y-globulin preparation inducing complement consumption has 
been known for a long time and several treatments had been developed to obtain 
well tolerated y-globulins. Among these methods we may mention enzymatic 
degradation, pepsin or plasmin being used for this purpose; chemical modification 
comprising reduction/alkylation, /1-propiolactone treatment and sulphonation
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[17-21]; mild acid (pH 4) treatment with small amounts of pepsin; polyethylene­
glycol treatment alone or in association with hydroxyethyl starch. Mild acid 
treatment is one of the oldest known methods [22] which has recently been consid­
erably improved. The product is now presented as a dry powder. Indeed, further 
aggregation may occur in preparations kept in the liquid form whereas such phe­
nomena are rare in conveniently dried material. During the freeze-drying process 
protection is obtained by addition of saccharose to the immuno-globulin solution. 
Very satisfying clinical results obtained with this product have been reported at a 
symposium held during this Congress [23]. New therapeutic trends with this 
preparation may also be mentioned as good effects were observed with high dose 
i.v. y-globulin in idiopathic thrombocytopenic purpura [24, 25] and autoimmune 
neutropenia [26].
Among the large variety of i.v. immunoglobulin preparations belonging to the 
group of modified IgG we may mention the recent improvement [19] of the original 
Japanese method to sulphitolyse globulins [27]. This modification is of particular 
interest as it seems reversible in vivo. Other initially promising methods such as 
precipitation of aggregated material by polyethylene glycol have been questioned 
in more recent publications [20]. The absence of anticomplementary activity 
(better expressed as complement consumption), was long the main criterion of the 
quality control of i.v. y-globulins. Only recently has it become clear that certain 
side effects of i.v. y-globulin preparations might be due to the presence of contact- 
activated factors with coagulant and vasoactive properties [28]. Certain small 
molecular weight fragments belonging to the group of kinins or anaphylatoxins 
[29] have also been found in y-globulin preparations. This brings us to the quality 
criteria which should be taken into account.
Intravenous immunoglobulin preparations should have their antigen binding 
capacity preserved (divalent binding function intact) [21 ], stimulate macrophage/ 
monocyte phagocytosis [17] and prove to be devoid of polymeric aggregates and 
antigen/antibody complexes by showing no or little activation of the classical 
complement pathway. They should reveal no or little inhibition of erythrocyte/anti- 
body rosette formation and little or no non-specific activation of neutrophils [17]. 
Animal models might be useful to detect short (due to PKA) or long lasting hy­
potension (due to IgG agregates).
New Techniques
Of the new methods we have to mention first the devices allowing the collec­
tion of plasma devoid of cellular components [30-33]. This is a very important 
feature for future fractionation development. Indeed, most of the plasma is frozen 
and thawed for the preparation of factor VIII concentrates. Leukocytes and plate­
lets will not withstand these operations and release their enzymes into the sur­
rounding fluid. Many plasma proteins are substrates of leukocyte proteases such as 
components of the clotting system comprising fibrinogen, factor II, VII, IX, X,
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Vili, XIII [34], protease inhibitors such as antithrombin III [35] and a2-antiplas- 
min [36], complement components C3 and C5 [37, 38] giving rise to chemotactic 
breakdown products, and also fibronectin [39]. Leukocyte proteases may thus 
interfere with the yield and quality of plasma fractions. Furthermore, one has also 
to take into account the pyrogens of leukocytic origin.
New trends have also been developed concerning the improval of freezing 
and thawing of plasma to obtain the cryoconcentrates whether as a direct product 
or as the starting material for intermediate or high purity factor VIII concentrates.
The most impressive new developments, however, concern the separation 
techniques based on the now widely used chromatographic procedures [40]. The 
initial method of Curling et al. [41] has been further developed. The results of the 
hrst plant using an industrial equipment supplied by Pharmacia for chromato­
graphic processing of albumin were presented by Viljoen et al. [42]. Several posters 
reported the recovery of albumin by combined anionic and cationic ion exchange 
chromatography [43-48]. These exchangers comprise different matrix material, 
Sephadex and Sepharose on the one hand and Trisacryl, for instance, on the other 
hand [49]. The choice of the matrix might well be of special importance as DEAE- 
cellulose, for instance, achieves activation of contact factors, whereas DEAE- 
Sephadex does not [50]. The supporting matrix may also influence the affinity of 
the proteins for a given adsorbent and thus influence the selectivity of the process 
[51].
The chromatographic methods have also been used for the purification of 
hyperimmune y-globulins [52] and y-globulin for i.v. use [53, 54]. In this latter 
process Aerocil, an inorganic adsorbent, is associated with DEAE-Sepharose and 
SP-Sepharose to give a product devoid of anti-complement activity. These results 
show that the new chromatographic procedures might overcome the difficulties 
encountered with the current production of ■y-globulins for i.v. use. If this is con­
firmed, there will be no more necessity for modifying the IgG by chemical treat­
ment, enzymatic digestion or mild acid treatment.
Some authors have shown that a final gel-filtration step might considerably 
improve the purified fractions, namely the quality of albumin [47].
The efficiency of affinity chromatography for the recovery of albumin from 
fraction IV usingCibacron blue 3GA-SepharoseCl-6B has been demonstrated [55].
It may further be mentioned that these techniques are sometimes associated 
with precipitation steps. Engineering applicable to this new type of fractionation is 
also in progress [56, 57] and the reference data concerning water consumption 
and the frigorifie, calorific and electric energies may already be obtained.
Among the new techniques used in the field of fractionation we may mention 
the new filtration techniques, namely the use of diafiltration where dialysis for the 
removal of salts and ethanol is associated with ultrafiltration to obtain the final 
concentration of the purified fraction [58]. As far as albumin is concerned the 
procedure seems superior to the usual freeze-drying process.
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New Fractions
In the recent past several new fractions have been developed. They may be 
subdivided in different groups, such as haemostatic components,protease inhibitors 
and an inactivator of biologically active peptides, immunoglobulin preparations, 
cholinesterase and fibronectin.
So-called activated prothrombin complex concentrates have been developed 
for the treatment of haemophiliacs with inhibitor. Such preparations are currently 
available. Whereas a certain number of clinical observations have already been 
published, the reaction mechanism of these fractions is still a matter of discussion. 
Likewise, the laboratory work is comparatively limited [59].
As there was much progress during the last years in the understanding of the 
molecular properties of factor VIII, there was also a growing interest in concen­
trates with v. Willebrand factor activity. Two trends may be distinguished. Whereas 
certain preparations of factor VIII :C have also v. Willebrand factor activity [60], 
concentrates obtained by the technique of Newman et al. [61 ] are nearly devoid of 
v. Willebrand factor. The high molecular weight material exhibiting v. Willebrand 
activity is removed by the first PEG-precipitation step. This precipitate is used as 
the starting material in another process which yields v. Willebrand factor concen­
trate [62]. This new fraction has the advantage of being derived from a by-product 
of factor VIII :C preparation which from the economical point of view is much 
more desirable. The different concentrates gave satisfying clinical results.
Prothrombin complex concentrates are now most frequently prepared by 
adsorption onto DEAE-Sephadex whereas the originally prepared fraction was 
obtained by adsorption onto Ca3(P 0 4)2 using EDTA plasma or fraction IVX as 
starting material. These earlier preparations contained more factor VII than 
the newer fractions because a pre-elution step needed for the removal of 
contaminating, undesirable proteins from DEAE-Sephadex elutes also most of 
factor VII. To overcome the problems arising from a relative lack of factor Vll 
in these fractions, special concentrates of factor VII were prepared and are cur­
rently available.
Concentrates of factor XIII have been known for several years. Similar frac­
tions are now produced by several plants and information concerning clinical 
indications and effects of this fraction is rapidly increasing. However, several years 
are usually needed before a new fraction can enter the therapeutic panel.
The same is the case with antithrombin III concentrates. Although they have 
been put at the disposal of clinicians several years ago, publications concerning its 
use, posology and clinical effects appeared only recently [63-67].
The high affinity of this antiprotease for heparin became the central pillar of 
almost all purification techniques based on affinity chromatography on im­
mobilized heparin. The purification of AT III is thus a brilliant example of the 
usefulness of affinity chromatography [68, 69]. Among the reported indications for 
the use of this fraction are congenital or acquired AT III deficiency in the presence 
of acute or moderate DIC, shock, post partum haemolytic syndrome, preeclampsia,
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periods of thrombogenic stress, acute liver failure and cerebral thrombosis [63-67, 
70,71].
Substitution therapy with antiproteases must take into account that the inhib­
itors usually react in a 1:1 molar proportion with enzymes, whereas the enzymes 
themselves, like the serine-proteases of the clotting system, may catalyse the turn­
over of several hundred molecules of their substrates. Furthermore, an inhibitor can 
usually combine with several different enzymes. Consequently, to account for a 
possible rapid consumption, the aim of substitution therapy with inhibitor con­
centrates such as AT III must be to bring the plasma concentration to at least 75 
per cent of normal. The injection of 1 unit AT III./kg causes a 1 per cent increase 
in the plasma concentration. An amount of 40 U/kg/day is recommended by several 
authors, one unit being the amount of activity found in 1 ml of plasma. Also, the 
efficiency of heparin therapy depends largely on the availability of AT III.
Another important antiprotease of human plasma is oq-antitrypsin (cqAT). 
Although this inhibitor inactivates manyproteolytic enzymes, its activity is specially 
important against the leukocyte proteases. In the view of Laurell [72] the major 
biological role of oqAT is self-protection from these enzymes and specially the 
macrophage elastase. Inherited aqAT deficiency is well known to be associated 
with certain cqAT variants (or Pi-types). The homozygotes PiZZ have only 
about 15 per cent of the amount of oqAT found in the most common PiMM 
type. It could be shown that this deficiency was related to the early development 
of emphysema. Patients with severe or partial oqAT deficiency suffering from 
repeated chest infections may benefit from oqAT substitution therapy.
The first clinical trial with cqAT has been published some months ago. 
A very impure preparation was used needing a large volume (1 1 per injection) to 
be handled but the 5 patients of the PiZZ-type improved considerably and the 
protease (elastase)-antiprotease imbalance was reversed within the alveolar struc­
tures [73]. It is to be hoped that these encouraging results will stimulate the devel­
opment of suitable techniques for the preparation of concentrates of cqAT. This 
protein is most concentrated in fraction IV and since it is very labile it requires a 
perfect control of technology.
Replacement therapy is also achieved with another antiprotease: the Cl- 
inactivator. Although attacks of hereditary angioedema have been preferentially 
treated in the past with fresh frozen plasma and considerable progress has been 
made in the prevention of these episodes by the use of androgens, replacement 
therapy is obtaining increasing attention. Several publications have reported very 
satisfying results [74, 75]. Although the exact mechanism of the oedema attack is 
still a matter of discussion it seems, nevertheless, that activation of Cl-esterase with 
the appearance of complement split products (possibly C2b) is the triggering factor. 
Cl-inactivator is the natural inhibitor of this enzyme but it inhibits also kallikrein 
and factor Xlla. This explains the good clinical results obtained by v. Starre et al. 
[76] in correcting the hypotensive effects o f‘stable plasma protein’ solution, a solu­
tion of approximately 90 per cent albumin apparently containing PK A. Control of 
(plasma) kallikrein activity by this inhibitor will be a helpful tool in kinin-related
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hypotension. This inhibitor has, however, no effect on formed kinins. The latter are 
inactivated by N-carboxypeptidase (or kininase I) which can be isolated from the 
preluates obtained during prothrombin complex preparation [77].
In conclusion, the kallikrein-kinin system can be controlled by inhibition of 
the proteolytic enzymes (factor XHa and kallikrein) and by inactivation of the 
already formed biologically active peptides. We may notice that anaphylatoxins are 
inactivated as well [78] underlining that concentrates of N-carboxypeptidase might 
be a valuable therapeutic enrichment for the treatment of endotoxin shock, severe 
septicaemia etc.
In the field of immunoglobulins there are also some new preparations. IgM 
has been isolated from fraction III which has previously been treated by ß-pro- 
piolactone [79]. IgM. preparations have a much higher antibody content against 
bacterial antigens than has IgG. Preparations containing a mixture of IgG and 
IgM, or IgG and IgA, or the mixture of all three (called IgGAM) have already been 
described [80-82] to give good therapeutical results.
Recently IgG preparations with an increased titre of IgG4 have been devel­
oped ; these preparations contain antibodies against several allergens.
Serum cholinesterase (ChE), another most interesting fraction, has been 
developed in recent years [83]. Whereas normal serum shows an activity of 3-8 
IU/ml, corresponding to a mean specific activity of 0.06 lU/mg protein, the 
purified product contains 300-320 IU/mg protein [84]. Vials of 5 ml containing 
an equivalent of 1000 ml of plasma are easily obtained. The enzyme concentrate 
may be useful in cases of prolonged apnoea after thoracic surgery or electroshock 
therapy with the use of muscular relaxants. In recent years the relationship between 
prolonged apnoea after injection of suxamethonium or related drugs and unusual 
pseudo-cholinesterase phenotypes of these patients has repeatedly been pointed 
out. As it would be fastidious to screen all patients submitted to thoracic surgery 
for their ChE phenotype, it would be preferable to have the enzyme concentrates 
available.
Another even more important indication for ChE therapy is the accidental 
poisoning of agricultural workers by parathion and related organosphosphates. 
ChE concentrates may be a helpful emergency treatment. However, the enzyme will 
be of no help if irreversible tissue damage has been produced.
The purification of transferrin (TF) from AT III supernatant was reported 
by Jakab et al. [85]. This protein is usually purified from fraction IV obtained 
during ethanol fractionation of plasma. In association with indium isotopes 
(u lIn and 113In) TF is currently used for the evaluation of the plasma volume 
[86- 88].
Haptoglobin (Hp), mostly concentrated in the same fraction IV, has been 
purified in different laboratories. The haptoglobin-haemoglobin complexes are 
taken up by the RES thus preventing renal losses of iron under physiological 
conditions. Renal damage after massive intravascular haemolysis results from a 
complex mechanism, but part of it is certainly due to Hb.
Hp concentrates gave positive clinical results in patients with massive intra-
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vascular haemolysis [89, 90] by avoiding the overload of the kidney by the liber­
ated Hb.
Another promising but clinically not yet investigated fraction is fibronectin. 
This protein, some years ago a biochemical curiosity called cold insoluble globulin 
by Mosesson who first described it [91 ], now encounters increasing interest. On the 
one hand, the biological activities of fibronectin have become known [92, 93]; on 
the other hand the deficiency states have also been defined. Fibronectin mediates 
the cell to cell adhesion and the cell to susbstrate anchoring; it regulates cell loco­
motion and mediates phagocytosis by tissue macrophages. As its deficiency was 
observed in severe infections, septicaemia, extensive surgery, burns and other trau­
ma, it is tentative to speculate that these patients would be improved by general 
or local (burns) treatment with fibronectin concentrates. Some beneficial results 
have already been reported with cryoconcentrate, a fraction containing fibronectin. 
Several isolation techniques are already known including affinity chromatography. 
A comparative study concerning the suitability of certain of these techniques for 
the preparation of therapeutic concentrates has been presented by Henon 
et al. [94].
Thus several different aspects of the recent trends in the field of plasma frac­
tionation may be noted. With increasing biological information new fractions are 
being developed and others, already existing, are being improved. Furthermore, 
considerable work has been done in the development of new technologies an­
nouncing a new era in the scope of fractionation.
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About 30 years ago at a Congress of the International Society of Blood 
Transfusion, I presented the first report of the transfusion of previously frozen 
erythrocytes [1]. This work, done in collaboration with P. L. Mollison, led us to 
believe that we would be able to preserve erythrocytes in large quantities for very 
long times and that with large reserves, there need never be a shortage. Preservation 
of erythrocytes in the frozen state has, in some places, contributed to the more 
efficient use of available blood, but the world-wide need for blood still far exceeds 
the supply [2]. Since it is likely that the demand will increase faster than the supply, 
the needs will have to be met by substances other than natural blood or its deriva­
tives.
Blood is a complex fluid with many components and multiple functions. The 
primary function of blood is to transport oxygen to the tissues and remove carbon 
dioxide. Several substitutes for blood plasma are available, but they cannot ade­
quately transport oxygen and carbon dioxide. The recent development of prepara­
tions which can transport oxygen and carbon dioxide provides the substitutes for 
the erythrocyte which, in combination with a simulated blood plasma, constitute 
a long-sought entity, ‘artificial blood’. An artificial blood, which is available in large 
amounts, which is not antigenic and is free of infectious agents, would be an ex­
tremely valuable therapeutic agent.
Table 1
Proposed artificial blood preparations
Biological Origin Synthetic
Solution of Hb Emulsion of perfluoro-
chemical (PFC)
Solution of modified Hb 
Solution of Hb encapsulated in
Oxygen chelator
liposomes or synthetic 
membranes
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The preparations which have been studied in recent years as possible substi­
tutes for the oxygen-transport function of the erythrocyte are listed in Table 1.
Oxygen Chelator
In this category are synthetic organic compounds which combine reversibly 
with oxygen in the same manner as hemoglobin. Some success has been achieved 
in the synthesis of compounds which resemble the hemoglobin molecule [3] but 
the conditions under which they combine with and release oxygen are still quite far 
from physiological. Although they may ultimately become useful biological oxygen 
transporters, they are at present still far from clinical usefulness.
Encapsulated Solution of Hb
When blood has been stored for too long in a blood bank, it is not usable 
because the erythrocyte membrane has lost its viability. The inner contents of the 
cell, the solution of hemoglobin, can still function as an oxygen transporter. There­
fore, it is quite logical to replace the old, non-viable membrane with a new one. 
Chang et al. [4] and Arakawa and Kondo [5], enclosed droplets of hemoglobin 
solution in microcapsules and suggested that they might function as substitutes for 
erythrocytes. However, it has not been shown that these microcapsules will be 
retained in the circulation for a significant period of time.
Liposomes containing a solution of Hb similar in composition to the contents 
of the erythrocytes were shown by Djordjevich and Miller [6] to load and unload 
oxygen in vitro much like the erythrocyte. After infusion in animals, these lipo­
somes persisted in the circulation for about one hour, but it was not shown that they 
delivered oxygen to the tissues. The major problem with liposome preparations 
is to prolong their retention and hence their function in the circulation. Another 
important problem is to prevent the oxidation of the enclosed hemoglobin to 
methemoglobin and hemichromes. Szebeni et al. [7] have presented results of 
their studies on the oxidation of Hb in liposomes.
Emulsion of Perfluorochemical (PFC)
Preparations of PFC can serve as transporters of oxygen because of their 
relatively high solubility for oxygen and other gases. The perfluorochemicals are 
non-polar liquids which are insoluble in water and do not dissolve salts, glucose or 
other components of plasma. Emulsions of PFC in a suitable aqueous medium 
(simulated plasma) have been used as ‘artificial blood’. The emulsified PFC contains 
about the same amount of oxygen as an equal volume of erythrocytes when equi­
librated with 100 per cent oxygen. However, unlike the Hb in erythrocytes, the
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Fig. 1. Oxygen content of packed human erythrocytes, perfluoro compounds (FC-80 and 
FC-47) and water at 37 °C as a function of oxygen tension. Although PFC carries about 
the same amount of О» as erythrocytes at p 0 2 =  760 torr, at p 0 2 =  100 torr (alveolar gas) 
PFC contains only about 15 per cent as much oxygen as an equal volume of erythrocytes
(from Ref. [37])
amount of oxygen contained in PFC is a linear function of the oxygen tension 
(p02) to which the PFC is exposed. Therefore, as shown in Figure 1, although the 
PFC carries about the same amount of oxygen as erythrocytes when exposed to 
100 per cent oxygen (p 0 2 = 760 torr), when equilibrated with air or alveolar gas 
(p02 = 100 torr) the PFC contains only 15-20 per cent as much oxygen as the 
same volume of erythrocytes. At present it seems unlikely that new PFC with much 
higher solubility for oxygen will become available. This means that when an emul­
sion of PFC is used as a substitute for blood, the recipient animal or man should 
inspire gas which has a considerably higher oxygen concentration than air.
The ability of an emulsion of PFC to deliver oxygen in adequate amounts to 
tissues was first demonstrated with an isolated, perfused rat brain preparation [8]. 
The emulsified PFC maintained the electrical and metabolic activities of this brain 
as well as erythrocytes did, but in the absence of an oxygen transporter, the electri­
cal activity rapidly disappeared.
The solubility of carbon dioxide in PFC is more than three times greater than 
that of oxygen. Therefore, the PFC can easily and adequately transport carbon 
dioxide under physiological conditions. This has been demonstrated with the iso­
lated, perfused rat brain preparation [8]. The mode of transport of carbon dioxide 
by PFC is different from that of the erythrocyte. The erythrocyte converts most of 
the carbon dioxide to bicarbonate which is then carried in the plasma; in PFC, 
little or no bicarbonate is formed and carbon dioxide remains physically dissolved. 
PFC may be useful experimentally in distinguishing between physiological effects 
of carbon dioxide, carbonic acid and hydrogen ions.
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Use of PFC Emulsions in Animals and Humans
The first demonstration that PFC could provide the major requirement for 
oxygen in whole animals was the finding [9] that frogs and mice previously infused 
with PFC emulsion survived much longer than untreated controls in concentrations 
of carbon monoxide which almost completely blocked the transport of oxygen by 
hemoglobin. Subsequently, Geyer [10] observed that rats survived after almost 
complete replacement of blood by PFC emulsion. Clark et al. [11] showed that 
PFC emulsion provided oxygen in the dog by finding that infusion of PFC emulsion 
caused an increase in the mixed venous oxygen tension.
The first infusion of PFC emulsion in humans was performed by Makowski 
et al. [12] in individuals who were legally dead as a result of severe brain trauma. 
They observed some changes in vital function after PFC infusion which returned 
to pre-infusion status after several hours. Subsequent studies in human volunteers 
[13] and in clinical cases [14-16] have indicated that the PFC emulsions are not 
acutely toxic, although some potentially unfavorable effects were observed. These 
studies have been done in all cases except that done by the group in China [14], 
with the PFC emulsion Fluosol-DA, manufactured by The Green Cross Corpora­
tion of Osaka, Japan. This preparation contains detergent (Pluronic F-68, BASF 
Wyandotte) as emulsifying agent. This detergent has been reported to have avariety 
of actions including effects on blood platelets, blood coagulation and blood viscosi­
ty [17]. Therefore, some effects observed after infusion of Fluosol-DA could be 
due to Pluronic F-68 instead of, or in addition to the delivery of oxygen by PFC.
Lipid-Coated PFC Emulsions
PFC have very unusual physical properties because of their extremely low 
intermolecular forces, which is due to the presence of the many fluorine atoms. 
One of the unusual properties is the extremely low surface tension of PFC. There­
fore, PFC will affect reactions or phenomena in which surface actions are involved. 
Although PFC are chemically inert, because of their surface activity, they do affect 
blood platelets and blood coagulation factors [18, 19]. Therefore, the use of PFC 
emulsions as artificial blood poses the potential hazards which may result from 
disorders of platelet function and blood coagulation.
In order to prevent the effects of the surface activity of PFC on platelets and 
blood coagulation, we attempted to cover the surface of PFC particles with a 
material which would mask this activity. We chose for this purpose a mixture of 
cholesterol and lecithin, in the proportion in which they constitute the major 
components of the erythrocyte membrane. PFC particles coated with this mixture 
of lipids did not affect aggregation of human blood platelets in vitro and did not 
cause thrombocytopenia when infused in animals [18]; non-lipid PFC emulsion 
did affect aggregation of platelets and did cause thrombocytopenia. Subsequently,
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we found that cholesterol was not necessary and that emulsions prepared with 
lecithin alone were just as satisfactory.
The emulsified PFC remains in the circulation for about 3 days after infusion 
[20]. We made the hypothesis that the lecithin-coated particles first lost the lecithin 
coating and were then removed from the circulation. If this were true, then slowing 
the removal of lecithin from the particles should prolong their retention in the 
circulation. We attempted to do this by maintaining a high concentration of lecithin 
in the blood by daily injection of lecithin. We have reported the results of this study 
at this Congress [21]. We found that 4 days after infusion of lecithin-coated PFC 
emulsion in rats, no PFC remained in the circulation. In rats so infused and then 
given daily injections of lecithin, 67 per cent of the PFC remained in the circulation 
after 4 days and complete removal of the PFC did not occur until about 14 days 
after infusion. Thus, it appears that the lipid-coated emulsion is safer because it 
does not affect blood platelets and blood coagulation, and that it is more efficacious 
because its retention in the circulation, and hence its function as transporter of 
oxygen, can be markedly prolonged.
Elimination of PFC
The principal avenue of exit of PFC from the body is via the lungs and to a 
minor extent via the skin. No measurable amounts are excreted in urine or feces. 
The PFC is removed from the bloodstream by the reticuloendothelial organs and 
accumulates mainly in liver and spleen. Many of the PFC are retained in liver and 
spleen for many months. Clark et al. [22] reported that perfluorotributylamine 
persisted in liver and spleen for years after a single infusion. After testing a large 
number of PFC, Clark et al. [23] found that perfluorodecalin was eliminated from 
liver and spleen relatively rapidly, in a matter of days. However, perfluorodecalin 
did not form a stable emulsion when treated in the same way as the perfluoro- 
amines. Naito and Yokoyama [24] reported the preparation of a relatively stable 
emulsion which contained a mixture of 70 per cent perfluorodecalin and 30 per cent 
perfluorotripropylamine. This preparation is the Fluosol-DA manufactured by 
The Green Cross Company of Osaka, Japan. This emulsion remains stable only ifit 
is stored in the frozen state and it must be used within one day after thawing. 
The perfluorotripropylamine contained in the preparation is not eliminated rapidly 
from the tissues, being retained in the spleen for many months. Heidebrandt et al. 
[25] have reported at this Congress their evaluation of four new PFC with respect 
to their retention in tissues and other criteria and concluded that none of them 
were more desirable than perfluorodecalin.
Solutions of Hemoglobin (Hb)
Since a solution of Hb (outside the erythrocyte) readily combines with oxy­
gen, it is an obvious candidate for use as a transporter of oxygen in vivo. Many 
early attempts were made to use cell-free solutions of Hb (i.e. hemolysates) as
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Table 2
Properties of Hb in plasma 
(in comparison with Hb inside erythrocyte)
1. Oxygen loading curve shifted to left:
2. Dissociates into dimers:
3. May be oxidized to metHb:
4. Cleared by reticuloendothelial system:
5. Cleared Hb catabolized in liver:
Oxygen affinity is increased; inadequate re­
lease of 0 2 to tissues
Dimers cross glomerulus and are excreted 
in urine
No reductase in plasma; metHb shifts 0 2 
loading curve of Hb to left and reduces 
release of 0 2 to tissues
Hb removed fairly rapidly from the circulat­
ing plasma
Iron accumulates; possible damage to liver
blood substitutes, but in all cases infusion of hemolysate in animals resulted in renal 
damage. Rabiner [26] demonstrated that stromal components of the erythrocyte 
were responsible for the renal damage and that infusion of large amounts of a stro­
ma-free hemoglobin solution in animals had no harmful effects and did provide 
some oxygen to the tissues.
Although solutions of purified Hb can be infused with no resulting harmful 
effects, the quantity of oxygen delivered is very small compared to Hb in erythro­
cytes. The changes in properties of Hb when released from the cell into plasma, 
and their consequences are listed inTable 2. In summary, the Hb in plasma does not 
adequately release oxygen, it dissociates into dimers which are excreted in the urine, 
it may be inactivated by oxidation and it is fairly rapidly cleared from the circula­
tion by the liver and catabolized with accumulation of iron in the liver.
Solutions of Modified Hemoglobins
An important advance came when Benesch et al. [27] modified Hb by attach­
ing pyridoxal phosphate to the Hb molecule. The resulting molecule has an affinity 
for oxygen which is much lower than that of unmodified Hb and thus will more 
readily release oxygen to the tissues. Greenburg etal. [28] demonstrated the im­
proved delivery of oxygen by this pyridoxalated Hb in experiments in hypotensive 
animals. However, this modified Hb dissociates into dimers and is excreted in the 
urine. The concentration of Hb in these solutions is limited by their colloid osmotic 
pressure to about 7 g/dl, which has an oncotic pressure approximately that of 
normal blood plasma. This concentration is only about 50 per cent of normal blood 
Hb concentration, and therefore after infusion of a large volume or total exchange 
transfusion, the recipient animal will be severely anemic.
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In order to prevent the dissociation of Hb and its subsequent excretion in 
urine, DeVenuto and Zegna [29], Moss [30], and Rozenberg [31 ] treated pyridoxal 
phosphate Hb with glutaraldehyde to form an intermolecular bridge cross-linking 
2 or more molecules. This ‘polymerized' Hb was found to be retained in the circula­
tion for significantly longer times than unmodified Hb. At this Congress, Bonhard 
[32] has reported the preparation of a similar polymerized pyridoxal phosphate-Hb 
which is relatively homogeneous and has an oxygen affinity close to that of Hb in 
the erythrocyte.
Another method of preventing dissociation of Hb was achieved by Benesch 
et al. [33] by the insertion of a covalently-bound bridge containing a phosphate 
group between the ß chains of Hb. This bridge and its phosphate group prevented 
dissociation and markedly reduced its affinity for oxygen. Sloviter et al. [34] found 
that after infusion in rats, none of this intramolecularly cross-linked Hb was excret­
ed in the urine, it was retained in the circulation considerably longer than unmodi­
fied Hb and it retained its low affinity for oxygen while in the blood stream. This 
confirms the notion that the Hb tetramer does not pass through the renal glomeru­
lus and that dissociation into dimers precedes excretion in the urine.
PFC Emulsions vs. Solutions of Hb
In Table 3 are listed the properties and functions of both PFC emulsions and 
Hb solutions which are important to evaluate the safety and efficacy of a substitute 
for blood (‘artificial blood’). For some of the items, further discussion is warrant­
ed :
1. At present, the supply of Hb solution comes mainly from outdated blood- 
bank blood, much of which is still being discarded. However, if Hb solutions 
become practical substitutes for blood, the demand for Hb may far exceed the 
supply available from outdated blood. Then, a unit of Hb solution will require 
the collection of somewhat more than one unit of blood. In contrast, PFC are 
commercial, organic chemicals and are available in unlimited amounts.
2. The possible acute toxic effects of the PFC emulsions would result from 
actions on constituents of blood, both formed elements (especially platelets) and 
plasma components (coagulation factors and complement). Although the serious 
damage to kidneys observed after infusion of crude hemolysates are not seen with 
purified Hb solutions, a transient impairment of renal function has been observed 
after infusion of purified Hb solution [35]. Further investigation of these effects 
is needed for both PFC emulsions and Hb solutions.
3. Both PFC emulsions and Hb solutions are cleared from the circulation by 
the reticuloendothelial system. Clearance of large quantities may cause blockade 
of the R-E system, with the resulting hazard of loss of resistance to infectious and 
other foreign agents. Also, repeated infusion of Hb solution would cause iron 
overload, so that Hb solutions are not likely to be suitable for treatment of chronic 
anemias such as thalassemias and sickle cell anemia.
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Table 3
Comparison of PFC emulsions and solutions of hemoglobin 
as substitutes for blood
PFC emulsion Hb solution
Supply 
Long storage 
Infectious agents 
Immunologic effect
Acute toxic effects, possible 
targets
Chronic toxic effects, 
possible targets
Respiratory gas required
Duration of action 
Oncotic pressure
Optical properties
Conditions of function
Unlimited
Possible
Absent
Not antigenic
Platelets
Blood coagulation Com­
plement
R-E system
Elevated oxygen concentra­
tion
Days
Iso-oncotic or variable
No color
No fluorescence
Not blocked by CO, 
oxidants or low 
temperature
Not unlimited
Possible
Absent
Probably not antigenic 
Kidney
R-E system 
Iron overload
Air
Hours
Limits concentration 
of Hb
Colored
Fluororescent
Inactivated by CO, 
oxidants and low 
temperature
4. Hb solutions have the important advantage that they can function ade­
quately in animals breathing air, whereas PFC emulsions will require that the animal 
breathe gas containing elevated concentrations (perhaps > 50 per cent) of oxygen 
in order to deliver enough oxygen to the tissues.
5. PFC emulsions have the advantage that they can be retained in the blood­
stream, and hence deliver oxygen, for considerably longer times than is presently 
possible with Hb solutions.
6. PFC emulsions are likely to be useful for treatment of carbon monoxide 
poisoning and during hypothermia. In these situations Hb solutions cannot deliver 
significant amounts of oxygen.
7. The absence of color or fluorescence in PFC emulsions permits some mea­
surements which cannot be made in the presence of Hb; e.g. the estimation of the 
redox status of the brain by fluorescence measurement was possible when PFC 
replaced blood [36].
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Bone Marrow Biopsy
C. Rozman
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(Received 15 November 1982; accepted 19 January 1983)
After introduction of the bone marrow aspiration technique, during many 
years the clinical haematologists have relied primarily on cytological examination 
of bone marrow smears. This was mainly due to technical difficulties in preparing 
tissue sections and to lack of knowledge in their correct interpretation.
During the last 15 years, however, a histological study of the bone marrow 
(BM) has been introduced in most haematological centres and a bulk of knowl­
edge has been achieved. Important contributions have been made by Burkhardt 
[1] in Germany, Duhamel [2] in France, Hernández Nieto [3] in Spain, Rywlin 
[4], Block [5] and Custer [6] in the United States and by many other authors. 
The indications of bone marrow biopsy have been greatly expanded.
One of the first and chief indications is the so-called ‘drytap’. This indica­
tion was very well expressed by Block [5] as follows: ‘An acellular marrow smear 
means that the marrow may be acellular, hypocellular, normocellular, hyper- 
cellular, fibrous, osteosclerotic, or replaced by abnormal tissue.’
In Table 1 the indications for BM biopsy are summarized. In the group 
of BM failure, the examination of marrow specimen can be useful not only in 
cases of aplasia, but also in myelodysplastic syndromes and in the study of BM 
grafting. The knowledge of chronic myeloproliferative disorders can be improved 
by BM biopsy. Among the lymphoproliférative syndromes, biopsy is mandatory 
for staging in lymphomas and for diagnosis in hairy cell leukaemia. In addition, 
a useful prognostic information can be drawn from BM biopsy in this disease 
and in chronic lymphocytic leukaemia. In some acute haemopathies such as 
acute promyelocytic leukaemia with ‘packed marrow’ or acute myelofibrosis, 
BM biopsy may be indispensable.
In the following paper Dr. Seewann from Austria will pinpoint the useful­
ness of BM biopsy in chronic granulocytic leukaemia. A further paper by 
Dr. Montserrat from our institution will discuss the prognostic value of BM 
biopsy in this condition. Recent studies suggest that from histological sections 
of BM, additional information can be obtained in monoclonal gammopathies. 
Finally, in an expanding group of miscellaneous disorders, BM biopsy can be 
useful or even essential.
Some years ago, Dr. Miale ingeniously commented: ‘The haematologist
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Table I
Indications for BM biopsy
B M  failure
Aplasia
Myelo-dysplastic syndrome 
BM transplantation
Chronic myeloproliferative disorders 
Chronic myeloid leukaemia 
Polycythaemia vera 
Myeloflbrosis/osteomyelosclerosis 
Idiopathic thrombocythaemia
Lymphoproliférative disorders 
Hodgkin’s disease 
Non-Hodgkin’s lymphomas 
Chronic lymphocytic leukaemia 
Hairy-cell leukaemia
Acute haemopathies
Acute leukaemia with packed marrow (i.e. AML-M3) 
Acute myelofibrosis (acute megakaryoblastic leukaemia) 
Monoclonal gammopathies
Multiple myeloma (focal)
Macroglobulinaemia
'Benign' monoclonal gammopathies
Miscellaneous
Malignant histiocytoses 
Metastatic cancer 
Thesaurismoses 
Granulomatous disorders 
Bone pathology 
Other
who doesn’t believe in tissue sections of bone marrow will be limited not only in 
his diagnostic success but also in his chances of going to heaven.’
I am sure that the number of haematologist addicts to the practice of BM 
biopsy will increase, and eventually, if Dr Miale was right, the heaven will be 
crowded by members of our specialty.
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The Value of Bone Marrow Biopsy 
in Chronic Myeloid Leukaemia
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Seventy-six patients with chronic myeloid leukaemia (CML) could be sub­
divided by core biopsy into chronic granulocytic leukaemia (CGL, n =  24) and 
chronic megakaryocytic granulocytic myelosis (CMGM, n =  52). By pure clinical 
definition 59 patients were grouped as classical CML and 17 showed a course which 
we termed atypical myelosis. The most reliable criteria for distinguishing between 
the classical and atypical forms were ALP-Index, peripheral leukocyte and platelet 
count and the estimated number of megakaryocytes in the bone marrow. The classical 
myeloses consisted of 40 per cent CGL and 60 per cent CMGM whereas the atypical 
consisted of CMGM only including all stages of fibrosis. Fibrosis was at the time of 
bone marrow biopsy found in 20 per cent of classical CML and in about 50 per cent 
of atypical myeloses. In classical CML Philadelphia chromosome could be detected 
in all the patients with CGL and in 50 per cent of those with myelofibrosis. Atypical 
myeloses did not exhibit Philadelphia chromosome. In 70 per cent of the cases it was 
possible to distinguish between CGL and CMGM by peripheral blood findings and 
bone marrow cytology.
Keywords: atypical myelosis, bone marrow biopsy, chronic granulocytic 
leukaemia, chronic megakaryocytic granulocytic myelosis, chronic myeloid leukaemia
❖
The clinical diagnosis of chronic myeloid leukaemia (CML) is suggested 
in an adult patient presenting with high granulocyte counts shifted to the left 
and splenomegaly. Other typical signs are a low or absent ALP index, a normal 
or sometimes elevated thrombocyte count [5, 11] and the Philadelphia chromo­
some. Bone marrow aspiration, although of little diagnostic value, is hyper- 
cellular with increased granulocytopoiesis and sometimes also marked mega- 
karyocytopoiesis with many thrombocyte clusters. In cases where a hypocellular 
bone marrow or a dry tap is found, myelofibrosis (MF) is suggested. MF of bone 
marrow as the consequence of CML has been found in 20-30 per cent of cases [4]. 
On the other hand MF was thought to be a separate entity called idiopathic 
myelofibrosis or agnogenic myeloid metaplasia (AMM) with its own natural 
history [10].
Signs and symptoms in CML and AMM are sometimes overlapping, and 
one must suspect at least some relationship between these two disorders.
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Termination of polycythaemia vera (PV) in an AMM like syndrome occurs 
in 15-20 per cent of patients [8] and marrow fibrosis may be present in CML. 
Whether one should distinguish between AMM, atypical CML and idiopathic 
thrombocythaemia or consider these syndromes as variants of AMM is debat­
able [11].
The term atypical myelosis has been used for Philadelphia chromosome 
negative CML with usually less good prognosis and an atypical course of disease. 
The absence of Philadelphia chromosome did not exclude a long survival in a few 
patients although the survival in Philadelphia chromosome negative patients was 
shorter than that of Philadelphia chromosome positive patients [1].
On the basis of clinical parameters we were able to divide CML into two 
variants, a classical form and one which we termed atypical myelosis, based on 
the following criteria [7]:
longer prediagnostic period 
higher average age 
larger spleen size
lower leukocyte count (<  30 x 10a/l)
slight shift to the left
higher thrombocyte count (>  500 x 10°/1)
elevated ALP-Index
higher number of dacryocytes
lower cellularity in aspired bone marrow
elevated number of magakaryocytes
increased number of thrombocyte clusters in the bone marrow.
None of these findings by itself proved to be typical of atypical myelosis, 
but taken together a classification was possible and deviating values facilitated 
the decision.
Karyogenetic investigations were not done routinely but all the patients 
with atypical myelosis were Philadelphia chromosome negative.
Similar differences between typical and atypical myelosis have been found 
by Canellos et al. [1] except the platelet counts which tended to be lower in 
their study.
Histology of bone marrow allows to subdivide CML into two discernible 
subtypes [3], i.e. chronic granulocytic leukaemia (CGL) and chronic mega- 
karyocytic granulocytic myelosis (CMGM). The histological features of CGL 
are a neoplastic proliferation of granulocytopoiesis with sometimes a slight re­
active increase of megakaryocytes. In contrast, CMGM shows a neoplastic pro­
liferation of two cell lineages, i.e. granulocytopoiesis with uninterrupted matura­
tion starting in the peritrabecular areas and extending continuously towards the 
venous sinusoids and a neoplastic proliferation of megakaryocytes with atypical 
cytology (bizarre, oversized cells with hyperlobulated nuclei) and an abnormal 
site of growth (expansion towards the osseous trabecules). Erythropoiesis may 
be prominent but does not disclose any abnormal proliferation of erythroblasts. 
CMGM initially exhibits no fibres. In the later course an increase in the
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amount of fibres in the bone marrow of CMGM patients leads to three other 
stages [2]:
Stage I: CMGM without any fibres
Stage II: early MF (scattered augmentation of reticulin fibres)
Stage III: MF (overt increase of reticulin and collagen fibres) and
Stage IV: myelosclerosis (partial obliteration of marrow spaces by apposi­
tion of newly formed bone).
Abnormal and polymorphous megakaryocytopoiesis is a prominent feature 
of all stages. Erythropoiesis and granulocytopoiesis are increasingly replaced in 
the later course of the disease.
Materials and Methods
Bone marrow biopsies were performed in 76 patients with CML. The 
procedure was usually done at the time of diagnosis but some 10 patients entered 
the study later on. We used the method described by Jamshidi and Swaim. Bone 
cylinders were fixed in Schaffer’s solution and embedded in methyl acrylate. 
Semithin sectioning was done without décalcification by the Institute of Pathol­
ogy, Medical School Hannover, FRG. The histological diagnosis of CGL and 
CMGM with the different stages of fibrosis were correlated with the two clinical 
courses, i.e. classical and atypical CML.
Mean age of the 76 patients with CML was 54 and a half years. There were 
43 males and 33 females. The histologic classification revealed 24 cases with CGL 
and 52 cases with CMGM at different stages of fibrosis ( I  18, II 14, III 15, IV 5). 
By pure clinical definition 59 patients were grouped into the classical form of 
CML and 17 into the atypical variety. The classical CML were histologically 
inhomogeneous and consisted of 24 (40 per cent) CGL and 35 (60 per cent) 
CMGM of the following stages : I 12, II 11,111 11,IV 1. All the atypical myeloses 
belonged to the histologic subtype of CMGM; 6 cases were in stage 1, 3 in stage 
II, 4 in stage III and 4 in stage IV.
The 5 most frequent symptoms were fatigue in 75 per cent, weight loss in 
50 per cent, upper abdominal discomfort in 24 per cent, fever in 18 per cent and 
night sweating in 13 per cent of the patients. The two clinical variants did not 
show considerable differences in these figures.
Mean enlargement of the spleen below the costal margin was 4.2 cm in 
CGL, 3.8 cm in CMGM stage I/II and 7.8 cm in MF/MS. In a comparison be­
tween classical versus atypical myeloses the differences were 5.1 : 6.5 cm.
The haematological data showed clear differences between atypical CML 
and the CGL subtype of classical myelosis. The three most reliable criteria in 
distinguishing the two clinical variants were leukocyte count, platelet count and 
the ALP-index (Table 1). The lowest mean leukocyte counts and highest ALP- 
indices as well as the highest mean thrombocyte counts were found in atypical 
CML. Erythroblasts did not appear to be of diagnostic value whereas tear drop 
shaped erythrocytes predominated in atypical CML.
H aem ato log ia 16, 1983
70 H. L. Seewann: Bone marrow biopsy in CML
Table 1
Haematological data in CML (mean values)
n =  76 total
59
Classical CM L
CM GM
35
CGL
24
Atypical
CML
17
Lx 109/1 1 0 7 6 2 1 72 16
ALP Index 7 2 1 0 4 2 6 1 48
Thx 1 0 9/1 
% Patients with
3 7 3 4 5 3 2 5 6 6 8 8
L >  3 0  X 1 0 9/1 6 6 5 4 83 6
Th >  5 0 0  X 109/1 10 17 0 41
Erythroblasts 51 5 4 4 6 5 9
Dacryocytes 4 7 65 21 7 2
The surprisingly high ALP-index in the whole group of classical CML 
could be explained by the fact that in this group more patients had entered the 
study later and some of them showed signs of beginning accelerated phase. The 
ALP-index in this group therefore might not reflect the ALP-index characteristic 
of the pure chronic phase.
Cellularity of bone marrow aspirates was diminished or absent in 47 per 
cent of atypical myeloses and in 25 per cent of classical myeloses but in no case 
of CGL. Megakaryopoiesis was found to be increased in 93 per cent of atypical 
myeloses, in 54 per cent of classical myeloses and only in 17 per cent of CGL. 
Thrombocyte clusters predominated with 79 vs. 8 per cent in atypical myeloses 
as compared to CGL.
In 32 of 76 patients it was possible to perform karyogenetic investigations. 
There were 13 cases of CGL, all of them showed Philadelphia chromosome. 
In 7 of the 15 CMGM-I-I11 of the clinical group classical myelosis (46 per cent) 
was the Philadelphia chromosome detected. In this group 6 MF were included; 
three of them showed the Philadelphia chromosome while 4 cases of atypical 
myelosis were Philadelphia chromosome negative.
The prediagnostic period was 22.9 months in our patients with atypical 
myelosis vs. 5.6 months in the classical group, whereas no striking differences 
were found between CGL and CMGM in the classical myeloses.
Conclusion
We have tried to find out whether the histologic subtypes of CML, i.e. CGL 
and CMGM could be correlated to different clinical courses. The clinical group 
of atypical myelosis was histologically homogeneous (all cases were CMGM) 
whereas the classical myeloses consisted of 40 per cent CGL and 60 per cent 
CMGM. The diagnosis of CMGM or CGL was possible in about 70 per cent
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of the cases on the basis of clinical methods, i.e. bone marrow and peripheral 
blood morphology.
AMM is defined by the trias splenomegaly, extramedullary haematopoiesis 
and fibrosis or sclerosis of the bone marrow. Thus it was not possible to compare 
AMM with our group of atypical myelosis since half of these patients did not 
show fibrosis at the time of bone marrow biopsy.
Courses of CML are found to be very different, with survival times ranging 
from less than one year to more than ten years with a mean of 44 months [6, 9]. 
These differences might not depend only on the Philadelphia chromosome defect 
but also on histological variants.
Thus, bone marrow biopsy in CML revealed that CGL was never accom­
panied with thrombocythaemia at any time of the disease and neither were bleed­
ing and thrombotic complications ever seen. We have not found transition of 
CGL into fibrosis, therefore we have to expect a blast crisis to terminate the 
disease. CMGM on the other hand may result either in blast crisis or fibrosis. 
Sometimes both conditions, blast crisis and fibrosis, coincide in terminating 
CMGM. In CMGM we sometimes observed very high thrombocyte counts 
(1000-5000 X 109/]) associated with bleeding complications.
The last stage of CMGM may show a histological architecture indistinguish­
able from that of AMM. Serial histological investigations in the course of CMGM 
might show a transition into AMM. The clinical course of atypical myelosis 
resembles AMM, so it was concluded that AMM was a variant of CML. With 
regard to therapy, we are not able to anticipate basis therapeutic consequences 
by a clinical or histological subdivision of CML, but in advanced stages of CMGM 
or cases of atypical myelosis we are rather reserved in initiating aggressive cyto­
toxic drug treatment.
We are greatly indebted to Professor A. Georgii, director of the Institute of Pathology, 
Medical School Hannover and coworkers for the histologic investigation of our bone marrow 
specimens.
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Bone Marrow Biopsy in Chronic Lymphocytic 
Leukaemia: A Study of 208 Cases
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In 208 cases of chronic lymphocytic leukaemia (CLL) in which a bone marrow 
biopsy has been performed, the correlation between histopathological bone marrow 
patterns (interstitial, nodular, mixed and diffuse) and both Rai’s clinical stages and 
the recent International Workshop on CLL proposal (A, B, C stages) has been ana­
lyzed. In general, a fairly good correlation has been found between the bone marrow 
patterns and both Rai’s and A, B, C systems. As far as the correlation between the 
bone marrow patterns and the tumoral load (lymphadenopathy, organomegalies, 
lymphocytosis, anaemia and thrombocytopenia) is concerned, the correlation was 
also fairly good.
Bone marrow pattern is an important prognostic factor in CLL and it is sug­
gested to use a combined clinical and pathological (bone marrow biopsy) staging 
ín CLL.
Keywords: bone marrow biopsy, clinical staging, chronic lymphocytic leukaemia
Introduction
In 1977, Hernández-Nieto et al. [1] described four different types of bone 
marrow involvement in patients with chronic lymphocytic leukaemia (CLL): inter­
stitial, nodular, rrixed (interstitial and nodular) and diffuse, assuming that in CLL 
the bone marrow infiltration could start with either interstitial or nodular patterns 
and then evolve to mixed and diffuse ones. In addition, a significant correlation 
between these patterns and CLL clinical stages according to Rai et al. [2] was found 
[1,3]. Thereafter, other authors have been able to recognize the same types of bone 
marrow involvement as well as their correlation with Rai’s clinical stages [4, 5]. 
On the other hand, Rozman et al. [6] in 1981 demonstrated that in CLL bone mar­
row biopsy has a clear prognostic significance, the patients with either interstitial 
or nodular infiltration patterns have a longer survival than those with mixed or 
diffuse ones.
In order to explore the prognostic significance of bone marrow biopsy in CLL 
and its anatomoclinical correlations, in 1981 a Spanish Cooperative Group started 
a study on a prospective and a retrospective basis. This report is an interim analysis 
of 208 patients included in the study up to January 1982.
* Spanish Cooperative Group for CLL Study.
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CLL: Diagnostic Criteria
The diagnostic criteria of CLL were those usually recommended [7]: (i) more 
than 15X 10°/1 lymphocytes in peripheral blood; (ii) bone marrow infiltration by 
lymphocytes of 50 per cent or more; (iii) less than 10 per cent atypical lymphocytes 
in either the peripheral blood or the bone marrow. Some cases of otherwise typical 
CLL with less than 15 x 109/1 lymphocytes in peripheral blood were also included. 
Lymphosarcoma cell leukaemia [8, 9], prolymphocytic leukaemia [10] and leukae- 
mic reticuloendotheliosis [11] were excluded.
Bone Marrow Biopsy
On the basis of preliminary studies four different histological patterns have 
been analyzed. These patterns were as follows.
Interstitial. Some degree of replacement of normal haemopoietic tissue by 
mature lymphocytes but with preservation of fat cells and bone marrow structure.
Nodular. Nodules made up of mature lymphocytes appear. These nodules are 
greater than normal lymphoid follicles and lack clear centres. There is no interstitial 
infiltration. Fat cells are preserved.
Mixed. A combination of the interstitial and the nodular pattern.
Diffuse. Diffuse lymphoid infiltration with massive replacement of normal 
haemopoietic tissue as well as fat cells.
The bone marrow biopsies were reviewed independently by two observers 
without any information of the clinical stage of the patients. When diagnostic 
discrepancies were found, the two observers reviewed together the biopsy until a 
final diagnosis was arrived at.
Staging Systems
According to Rai et al. [2] Stage 0 is defined by lymphocytosis only. Stage 
I is lymphocytosis with lymphadenopathy. Stage II is lymphocytosis with enlarged 
spleen or liver or both. Lymph nodes may or may not be enlarged. Stage III is 
defined by anaemia (Hb < 11 g/dl or haematocrit <33 percent). Lymph nodes, 
liver, or spleen may or may not be enlarged. Stage IV is established in the presence 
of thrombocytopenia (platelets <  100 x 10n/liter). Anaemia or organomegaly may 
or may not be present.
International Workshop on CLL [12]. In this staging system, besides anaemia 
(Hb < 10 g/dl) and thrombocytopenia (platelets <  100 x 109/liter), special atten­
tion is focussed on the clinical enlargement of spleen, liver, and lymph nodes in the 
cervical, axillary, and inguinal regions (irrespectively of the lymphadenopathy being 
unilateral or bilateral), constituting five separate ‘lymphoid’ areas of involvement. 
Three stages are considered: Stage A: no anaemia or thrombocytopenia with less
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than three areas of lymphoid enlargement. Stage B: No anaemia or thrombocyto­
penia with three or more involved areas. Clinical stage C : Anaemia or thrombocy­
topenia regardless of the number of areas of lymphoid enlargement.
Results
The frequency of different bone marrow types, sex distribution and age of 208 
cases so far studied are shown in Table 1. The bone marrow type most frequently 
seen was the diffuse (36 per cent), followed by interstitial (32 per cent), mixed (23 
per cent) and nodular (9 per cent). No differences either in sex or age distribution 
were found among the different bone marrow types.
In Tables 2 and 3 the correlation between Rai’s and the International CLL 
Workshop stages and bone marrow types is shown. Гп Rai’s classification, stages 
0 and I (low risk stages) were considered a sole group as well as stages III and IV 
(high risk stages). Both in Rai’s stages and in the A, B and C system, in the less 
advanced stages (either A or 0 +1) low (nodular, interstitial) infiltration patterns
Table 1
Frequency of different bone marrow patterns, sex and age distribution
N г M D
Number (%) 19 (9) 66 (32) 47 (23) 76 (36)
M/F 13/6 42/24 34/13 43/33
Age (years, mean +  SD) 62+ 10 64+10 64+8 62+11
N =  nodular; 1 =  interstitial; M =  mixed; D =  diffuse
Table 2
Correlation between Rai’s :staging system and bone marrow patterns
R ai’s staging system N I M D
Stages 0 +  Г 
N (%) 15 (18) 43 (51) 23 (27) 4 (4)
Stage 11
N (%) 3 (5) 18 (30) 16 (27) 23 (38)
Stages 111 +  IV
N (%) 1 (2) 5 (8) 8 (13) 49 (77)
=  nodular; 1 =  interstitial; M =  mixed; D =  diffuse
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Table 3
Correlation between International CLL Workshop staging system and 
bone marrow patterns
W o rk sh o p  staging system N Í M D
Stage A 
N (%) 1 4  (7 4 ) 4 3 (6 5 ) 2 4 (5 1 ) 7  (9 )
Stage B 
N (%) 4  (2 1 ) 1 9 ( 2 9 ) 16 (3 4 ) 2 5  ( 3 3 )
Stage C 
N (%) 1 (5 ) 4 (6 ) 7 (1 5 ) 4 4  (5 8 )
N =  nodular; T =  interstitial; M =  mixed; D =  diffuse
predominate, whereas in the high risk stages (either C or III +  IV) the heavy (dif­
fuse) infiltration type was found. Mixed infiltration type was distributed among the 
different clinical stages without a clear predominance in any of them. The correla­
tion between bone marrow patterns and clinical stages was not absolute.
In Table 4 the correlation between bone marrow type and different clinical 
and analytical datais presented. Anaemia and thrombocytopenia were predom­
inantly found in the diffuse type and, in a similar way, lymphocytosis above 
5 0 x l0 9/l was more common in this particular bone marrow pattern. On the
Table 4
Correlation between bone marrow patterns and some clinical and analytical data
(n
N
-  19) (n
i
=  66)
M
(n =  47) (n
D
=  76)
Generalized
lymphadenopathy 5 (26) 28 (42) 21 (45) 56 (74)
Splenomegaly 3 (16) 17 (26) 19 (40) 64 (84)
Hepatomegaly 3 (16) 18 (27) 21 (45) 51 (67)
Lymphocytes 
(X  109/1) 28+27 40+33 39 +  35 112+112
Lymphocytes 
(>50x 109/1) 3 (16) 14 (21) 14 (30) 46 (60)
Haemoglobin 
« 1 1  g/dl) 1 (5) 5 (7) 6 (13) 46 (60)
Platelets
(ClOOx 1109/I) 0 (0) 2 (3) 5 (11) 23 (30)
N =  nodular; I =  intermediate; M =  mixed; D =  diffuse
All results are expressed as number (%) of cases presenting a feature or as mean
( +  SD)
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contrary, anaemia and thrombocytopenia were infrequent in the low infiltration 
types (nodular, interstitial). As a rule, the more advanced the bone marrow 
infiltration the more often were the lymph nodes, spleen and liver enlarged.
In respect to the survival probability of patients with CLL according to the 
sole basis of their bone marrow biopsy pattern, no significant differences were 
found in the О/E ratio of interstitial type (1.02) as compared to the nodular one 
(0.93). Therefore, these two patterns were analyzed as a sole group. In Table 5,
Table 5
Statistical analysis (log-rank test) of survival
Observed/
to tal Expected
Observed/
expected X 2
Interstitial +  nodular 13/85 29.24 0.44 9.02
Mixed 9/47 15.17 0.59 2.51
Diffuse 42/76 19.59 2.14 25.65
y2 heterogeneity =  37.18 p <  0.001 
X 2  for trend =  31.55 p <  0.001
statistical analysis of the three groups (interstitial/nodular, mixed and diffuse) is 
presented. The estimated median survival probability was greater than 70 months 
for the interstitial, nodular and mixed groups (non-diffuse patterns) and of 20 
months for the diffuse bone marrow type.
Discussion
The prognostic significance of bone marrow histology in CLL has been the 
subject of several reports. Gray et al. [13] in a study of 115 patients, including cases 
of lymphosarcoma cell leukaemia, showed that cases with diffuse bone marrow in­
filtration had a poor prognosis as compared with cases with nodular or mixed 
(nodular and diffuse) patterns. Although the bone marrow patterns in CLL have 
usually been described just as nodular (or focal) and diffuse, some authors have 
distinguished other types of bone marrow involvement in CLL. Thus, Rywlin [14] 
recognized (i) an interstitial pattern in which the marrow architecture is preserved 
and lymphocytic infiltrates are found among the haemopoietic cells in between the 
fat spaces; (ii) a nodular pattern in which there are nodular lymphocytic infiltrates 
replacing the haematopoietic cell areas as well as fat cells, (iii) a diffuse pattern in 
which there is a total effacement of marrow architecture and substitution by lym­
phocytes of normal haemopoietic and fat cells. In addition, there is a mixed pattern
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formed by the combination of nodular and diffuse infiltration types. Although in 
some cases of otherwise diffuse bone marrow involvement, nodular or confluent 
structures can be seen among the lymphocytic infiltrations, this particular type of 
mixed pattern (nodular 4- diffuse) would better be classified as diffuse, since in 
these cases a great tumoral load is usually present with (lymphadenopathy, orga­
nomegalies, lymphocytosis, anaemia and thrombocytopenia). It is important to note 
that the mixed type described by Rywlin [14] and also recognized by Gray et al. 
[13], is not the same mixed type that we use in our study (nodular + interstitial).
Recently, Bartl et al. [15] assessing the bone marrow structure in patients 
with CLL have described two major types of bone marrow involvement: (i) diffuse 
(non-nodular patterns) which could be subclassified in interstitial and packed mar­
row types, and (ii) nodular patterns. In this work a certain degree of correlation has 
also been found between the bone marrow pattern and the clinical stages. It is not 
clear from the description of these authors whether the interstitial type described 
by them is the same interstitial type recognized by Hernândez-Nieto et al. [1], as 
the interstitial type described by the latter authors probably represents a lower lym­
phocytic infiltration than that encountered by Bartl et al. [15] in their so-called dif­
fuse (interstitial) type.
The prognostic significance of bone marrow biopsy has been demonstrated 
clearly by Rozman et al. [6]. Thus, patients with interstitial and nodular bone mar­
row involvement had a longer survival than those with mixed and diffuse ones. 
Since the overall follow-up of the present series is still rather short, no definitive 
conclusions can be drawn in respect to the eventual differences in the survival 
probability among patients with interstitial, nodular and mixed bone marrow pat­
terns. The different prognosis of patients with non-diffuse patterns in comparison 
to those with diffuse bone marrow involvement is clear.
In the present interim analysis we have explored the anatomoclinical correla­
tions of bone marrow patterns in CLL. It has been concluded that the different bone 
marrow patterns in CLL seem to reflect variable amounts of lymphocytic infiltra­
tion along the course of the disease. Therefore, the suggestion seems to be appro­
priate that in CLL the histological bone marrow patterns could follow the sequence 
of progression from interstitial and nodular types to the mixed and diffuse ones [6]. 
Furthermore, in sequential bone marrow biopsies performed in patients with CLL 
a parallelism exists between the clinical stages and the different bone marrow types. 
In cases where the clinical stage progresses it is usual that the bone marrow shows 
a switch to a more heavy infiltration pattern. Conversely, successful treatment of 
advanced cases of CLL may be accompanied by a regression of bone marrow lym­
phocytic infiltration or even by a normal biopsy (unpublished observation). Car­
bone et al. [16] and Charron et al. [17] considering just nodular and diffuse bone 
marrow patterns have done similar observations.
In this study a certain degree of correlation between the histological types of 
bone marrow infiltration and the different clinical staging systems in CLL as well 
as with the tumoral load has been found. On the other hand, it is clear that in CLL 
the bone marrow patterns have a prognostic significance. Since the correlation
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between bone marrow pattern and clinical stage is far to be absolute, it is possible 
that different subsets of patients, with different prognosis, could be distinguished 
in the future on the basis of a combined clinical and ‘pathological’ (bone marrow 
patterns) staging system [14]. The Spanish Cooperative Group for CLL Study is 
now testing this possibility on a prospective basis.
*
We are indebted to M. R. Bruguès (Postgraduate School of Haematology ‘Farreras 
Valenti’, University of Barcelona), for help in the analysis of bone marrow biopsies and to 
Ms. Angelines Aguado and Ms. Begona Ramirez for their secretarial work.
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Introduction
Chromosome analysis at diagnosis can be used to distinguish poor risk pa­
tients from good or better risk patients in both types of acute leukaemia.
With the possibility of bone marrow transplantation in first remission for 
acute lymphoblastic leukaemia patients, the identification of those who respond 
badly to current chemotherapeutic regimes is crucial.
Conversely in acute non-lymphocytic patients the fact that there is an im­
portant group of long term survivors with conventional therapy makes their iden­
tification equally challenging.
First, it will be discussed how chromosomes relate to survival in acute lym­
phoblastic leukaemia and then consider how this has been demonstrated for acute 
non-lymphoblastic leukaemia.
Acute Lymphoblastic Leukaemia
The relationship between chromosome findings and prognosis in ALL has 
been demonstrated in two ways. First, by means of a chromosomal classification 
based on the chromosome numbers in the cells of the leukaemic tissue at diagnosis 
[1-4]. Second, by the identification of chromosomal subgroups, some of which 
have a particularly poor prognosis [3, 5]. The effect of chromosomal classification 
is different in children and adults and I shall first describe how chromosomes may 
be used as prognostic indicators in children.
ALL in Children
A relationship between chromosome findings and survival in children was 
first demonstrated by Secker-Walker et al. in 1978 [1 ]. We showed at that time that 
it was important to distinguish patients with different kinds of chromosome abnor­
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malities, as well as those with normal chromosomes. Differential prognosis between 
groups of patients was apparent when the patients were divided into the following 
categories. Normal — no detectable abnormalities; hyperdiploid — more than 46 
chromosomes (the group which did best); pseudodiploid — 46 chromosomes with 
structural rearrangements (the group which did worst); hypodiploid — less than 
46 chromosomes.
Since that time the value of chromosomal classification has been confirmed 
and the findings extended in other surveys [2-4]. The prognostic effect of chromo­
somal classification has moreover been shown to be independent of other factors 
known to influence survival. The findings of our second survey of 93 children with 
a maximum follow up of 9 years are demonstrated in Figure 1 ; they confirmed our 
earlier observation that hyperdiploid groups do better and pseudodiploid groups 
do worse than those with normal chromosomes. Survival was best in this survey 
for the 6 hypodiploid patients, none of whom have died; it is difficult to assess the
Fig. 1. Survival according to chromosomal category in 93 children with ALL [4]
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importance of this in such a small group. When patients with normal chromosomes 
are compared with those with abnormal chromosomes no difference in survival is 
found. From Figure 1 it is clear that when the hypo-, hyper- and pseudodiploid 
groups are combined the opposite effects of the different types of abnormality 
cancel each other.
A similar classification was used for the 157 children presented at the Work­
shop at Lund in 1980 [3]. The hyperdiploid patients were divided into two groups, 
one with 47-50 chromosomes and another with 51-60 chromosomes. Survival was 
best for the group with more than 50 chromosomes. Those with 47-50 chromo­
somes did better than those with normal chromosomes and pseudodiploid patients 
had the worse prognosis.
In three surveys pseudodiploidy has been identified as a poor prognostic indi­
cator. As to the distribution of poor and standard risk children, we know that
Fig. 2. Remission duration of 93 children with ALL and leukocyte counts below 20x 109/1 [4]
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pseudodiploidy is associated with male sex [3, 4], high white blood counts above 
20 X 109/1 [4] or 50 X 10°/l [3] and with children aged under 2 or over 11 years [4]. 
Hyperdiploidy, conversely, is associated with female sex, low white blood count 
and an age between 2 and 11 years [4]. The unequal distribution of patients by age 
groups between chromosomal categories was statistically significant in our series 
(p < 0.01). In both surveys patients with a mediastinal mass at diagnosis and those 
with T cell surface markers were found only in the normal or pseudodiploid cate­
gories.
The log-rank analysis was reapplied in our study with adjustment for the ef­
fects of the unequal distribution of patients according to sex, age and white blood 
count. The differences between chromosomal categories remained statistically sig­
nificant for the duration of the first remission (p < 0.04) and for survival (p < 0.006).
Fig. 3. Duration of remission of 93 children with ALL and leukocyte counts
above 20x 103/1 [4]
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Figure 2 shows the cumulative proportion of patients surviving by chromosomal 
category, with low white counts where the hyperdiploids did well and the pseudo­
diploids badly. Figure 3 shows those with high white counts; here no patient with 
pseudodiploidy and more than 20 x 109/l white cells was alive after 2 JA years.-.
ALL in Adults
The value of chromosome classification in adults was demonstrated for the 
first time at the Lund Workshop [3]; 173 patients were considered, and the patients 
were classified in a number of different ways.
First of all, unlike in children, a comparison of chromosomally normal and 
abnormal cases was important. The median survival in different chromosomal 
groups was estimated from life table analysis. Patients with all normal chromo­
somes had a median survival of 31 months. The presence of an abnormal clone in 
all or only some of the analyzed cells was a poor prognostic feature with a mean 
survival of 9 months in each case. This finding was partly a reflection of the statisti­
cally significant association between the presence of an abnormal clone with a num­
ber of adverse prognostic features (Table 1). AA and AN patients were older and 
had higher white counts at diagnosis than the NN and NCI groups. Significantly 
more patients in the normal groups, i.e. 89 per cent achieved complete remission 
against 55 per cent in the abnormal groups.
When the patients were divided according to modal number it was found 
that by classifying them simply as normal or abnormal, one small abnormal cate­
gory with a good prognosis was missed. Patients with more than 50 chromosomes 
actually did better than the normal category with a projected survival of more than 
50 per cent o f ‘hyperdiploid 51-60’ patients alive at 2 /2 years after diagnosis as 
compared with 30 per cent of patients in the normal category. Patients with lower 
numbers in the hyperdiploid range, unlike the children in this group, had an even
Table 1
Association of chromosomal groups with good or bad prognostic features (adults)
NN N N  NCI AN AA p
Number of patients 21 32 76 44
Median age, years 24 27 34 35 =  0.02
Median WBCx 109/1 13 14 21 26 =  0.05
% Complete remission 95 84 55 54 <  0.001
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poorer prognosis than those in the pseudodiploid group. So once again the chromo­
some number was important as a prognostic indicator, but here the only group 
doing better than that with all normal chromosomes was the group with more than 
50 chromosomes.
Five chromosomal sub-groups in ALL characterized by a particular chromo­
somal translocation or arm deletion have been identified and their survival relative 
to each other and to those with other chromosome findings was calculated at the 
Workshop at Lund. Each of these has been found in both adults and children and 
the effect on prognosis of the particular abnormality appeared to be similar regard­
less of the age group. The survival relative to each other and to normal cases is 
shown for adults in Figure 4 and for children in Figure 5.
The Ph' +ve ALLs, those with a t(8 ; 14) the Burkett-like translocation and 
those with t(4 ; 11 ) were found in both children and adults. In adults an additional 
group was that with other 14q+ translocations. All had a worse prognosis than 
the remaining pseudodiploid patients, and than those classified as normal. In chil­
dren a fifth group with 6q—, on the other hand, had a good prognosis with a projected 
survival of nearly 70 per cent at three years.
The incidence of Ph' +  ve ALL is higher in adults than in children, 17 per cent 
compared with 5.7 per cent at the Workshop. Marker studies were all non-T non-B 
on the cases tested but recently one T-cell ALL with a Ph' has been reported [6].
The t(8 ; 14) and half the 14q + cases were B-cell ALL of FAB type L3. As de­
scribed by Berger et al. [7] they form a distinct sub-group of ALL with a very poor
Fig. 4. Survival according to chromosomal subgroups in ALL in adults [3]
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Fig. 5. Survival according to chromosomal subgroups in children with ALL [3]
prognosis. At the Workshop the incidence was 3.8 per cent in children and 5.8 per 
cent in adults for t(8 ; 14), and for I4q + it was 7 percent for adults and 2 per cent for 
children. t4 ; 11 first described by van den Berge [8 ] was found in about 5 per cent of 
both children and adults. Most of the children were under 2 years but it occurred 
in two older children and in 5 adults under the age of 40. All but one patient had 
very high initial blood counts, and all but one of the cases tested were non-B non-T. 
The remaining case was a T-cell ALL. In ALL then chromosome analysis has iden­
tified good and poor risk groups in both children and adults.
Acute Non-lymphocytic Leukaemia
The importance of chromosome findings in ANLL was first described by 
Sakurai and Sandberg in 1973 [9] who noted a longer survival of patients with all 
or some normal chromosomes as compared to those with all abnormal chromo­
somes. These findings have since been confirmed by Nilsson et al. [10], Golomb 
étal. [11] and Lawler et al. [12]. In a recent report by Hagemeijer et al. [13], no dif­
ference in survival was, however, seen between the chromosome groups NN and 
AN + AA. Findings at the First International Workshop on Chromosomes [14] 
suggested that there was a difference in survival between patients with different 
proportions of normal and abnormal cells, but only in AML FAB types Mt and M2.
What was perhaps more interesting was] the confirmation at the Workshop of 
chromosomally abnormal sub-groups with different prognoses. These are shown
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in Table 2 with their distribution among the FAB groupings and the relationship 
of such sub-groups to the attainment of remission and their median survival. 
Of particular interest is the 8/21 translocation now believed to be associated 
exclusively with AML M2, monosomy 7 in AML and the 15/17 translocation found 
only in APL M,.
Table 2
Karyotype findings in 139 chromosomally abnormal cases of ANLL
Ab- Percent abnorm al cases
Other**normal
cases +  8 — 7 t ( 8 q - ; 2 1 q + ) t(15q; 17q — ) 22q —
AML Mj-M.. 85 20 18 11 _ 2.35 48.23
APL M3 11 — — — 81.81 — 18.18
AMMOL M4 29 6.9 13.79 3.44 — 3.44 72.41
AMOL M5 2 1* — — — — 1*
EL Mfi 5 1* 1* — — — 3*
Undifferentiated 7 1* — — — 2* 4*
Total 139 22 20 11 9 5 72
CR°„ 27 32 13 50 33 20 30
Median survival, 
months — 6.5 4.0 6.0 1.0 4.0 5.0
The 8/21 translocation examined at the 2nd International Workshop [15] was 
described by Rowley in 1973 [16]. The findings in Table 3 are taken from the 2nd 
International Workshop in 1979; 46 cases with 8/21 translocation were presented 
each of which was FAB type M2. The points to notice here are as follows: the 
median survival of patients with the translocation, either alone or with other ab­
normalities, was longer than the 8 months median survival for AML with 
normal chromosomes shown at the First International Workshop; the very adverse 
effect on survival of the accompanying loss of a sex chromosome. Unfortunately, 
the follow-up was not very long but we do know that 11 out of the 46 patients 
were alive 2 years after diagnosis. Better complete remission rates and longer 
median survival for 6 t(8; 21) patients compared with 17 normal, and 6 patients 
with other chromosome abnormalities were reported by Takeuchi et ai. [17]. 
With a maximum follow-up of 18 months there was, however, no significant 
difference in survival between the t(8; 21) and normal categories. Clearly further 
follow up of these cases and more studies are needed to find whether t8; 21 is 
associated with really long-term survival.
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Cytogenetics Cases Median age' years CR %
Median
AN
survival,
AA
months 
AN +  AA
Alive at
1
years
2
t only female 10 52 80 21.5 9.5 1 6 3
male 7 52 71 26 6.5 1 4 2
t — X female 9 40 56 11 2 1 2 0
t — Y male 7 37 71 7 3.5 1 2 2
t +  other 13 31 85 18 14 15.5 9 4
Total 46 45 74 - - 1 1.5 23 11
Ref. [15]
Monosomy 7 in adult ANLL was examined by Borgstrom et al. [18] follow­
ing the 2nd Workshop. Eighteen patients with monosomy 7 were compared with 
18 chromosomally normal patients with ANLL in terms of factors which adversely 
affect prognosis. A very poor remission rate and survival at 18 months of the - 7 pa­
tients was seen. This could be explained by an increase in fever at diagnosis and 
afterwards, increased number of infections, and the low granulocyte count. The 
defective chemotaxis shown by Ruutu et al. [19] to be associated with monosomy 
7 may influence the response to infections of these patients.
Acute promyelocytic leukaemia, a rare disease (5 per cent of all acute leukae­
mias), has a very high early mortality. There is, however, a small but important 
group of long term survivors in this kind of leukaemia as described by Bernard et al. 
in 1973 [20]. Of the 80 cases with APL examined at the 2nd International Work­
shop, half were chromosomally normal, t( 15 ; 17) was found in 41 per cent and the 
other 9 per cent had other chromosome abnormalities (Table 4). Important are the 
considerably lower median age of the patients with 115 ; 17 alone, coupled with con­
siderably lower complete remission rate and poorer survival, than that in the other 
groups. The percentage of patients alive at 1 year was greatest in the normal 
category. In a recent report of 5 APL patients by Fraser et al. [21 ] the only fairly 
long term survivor, at 314 years follow-up, had a normal karyotype at diagnosis. 
Again in APL more studies and longer follow-up are needed to determine the 
significance of the karyotype in long term survival, but this seems to be associated 
with a normal karyotype at diagnosis.
Summary and Conclusions
Chromosome findings at diagnosis can help to distinguish groups of patients 
with different prognoses. In ANLL there is a small group of patients who achieve 
longterm remissions on conventional therapy. In acute myeloid leukaemia these
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Table 4
t(15q+; 17q—) in APL M3 (80 cases)
Cytogenetics Cases Median age, 
years CR %
Median
survival,
months
Alive at 
1 year, %
Normal 40 43 45 4.0 28
t(15q+; 1 7q —) 23 25 26 1.0 j
t(l5 q + ; 17q—) + 10 41 30 1.5 18* Others 7 37 28 5.0 1
* 4 =  +  8, 2 =  — 7, 1 =  ring marker [15]
patients are to be found mainly among those with normal chromosomes at diagnosis. 
In FAB type M>, however, patients with the best remission rates are those with 8 ;21 
translocation, providing this is not accompanied by the loss of a sex chromosome. 
Whether significant numbers of long term survivors will be found among those 
with t8;21 remains to be seen.
Monosomy 7 carries a poor prognosis.
In acute promyelocytic leukaemia long term survivors may be found among 
those with normal chromosomes, while those with 115 ; 17 do badly.
In ALL, chromosome investigations have identified groups of patients who 
do badly on current chemotherapeutic regimes and should perhaps be considered 
for transplantation during the first remission.
Adults with pseudodiploidy (which includes the Ph'+ves, t8 ; 14s, 14q+s and 
t4;Ils) and hyperdiploidy with less than 50 chromosomes have poor complete re­
mission rates and their projected survival at 20 months is poor. Even those with 
normal chromosomes do not do too well. In children chromosomal groups with 
low percentage survival at 8 years are those classified as pseudodiploid, regardless 
of the white blood count, and those with normal chromosomes and white counts 
above 20 x 10°/l. They are candidates for bone marrow transplantation in the first 
remission.
Conversely, children with more than 46 chromosomes had a 78 per cent pro­
jected survival at 5 years. Among the cases presented at Lund those with a 6q — did 
well and those with more than 50 chromosomes had a projected survival of more 
than 90 per cent at three years. In these patients conventional therapy appears to be 
capable of completely eradicating the leukaemic clone. Bone marrow transplanta­
tion at the present state of the art would have nothing to offer.
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Tn polyagglutination or persistent mixed field polyagglutination is a rare ac­
quired erythrocytic state which has been associated with haematologic abnormalities 
including four reported cases of acute leukaemia. Recent information has proven that 
the abnormality is clonal and the haematologic findings suggest a mutation of a 
somatic stem cell. The red cell membrane defect results from a deficiency of B-3-D 
galactosyltransférase. Tn polyagglutination has been described in patients presenting 
with acute leukaemia and has preceded acute leukaemia. The Tn syndrome has 
similarities to other forms of preleukaemic syndromes including paroxysmal nocturnal 
haemoglobinuria. Patients with Tn should be carefully monitored, although there is 
little justification for any specific therapy at the present time.
Keywords: acute leukaemia, clonal abnormality, preleukaemia, Tn poly­
agglutination
Introduction
Tn polyagglutination or persistent mixed field polyagglutination is a rare 
acquired erythrocytic state which has been associated with haemolytic anemia, 
leukopenia, thrombocytopenia, and acute leukaemia [1, 2].
At the time of this review, four cases of acute leukaemia associated with the 
Tn red cell state have been reported [2-5]. This paper will review the serology, 
clonal haematopoietic stem cell origin, biochemical nature, and clinical cases rel­
evant to Tn and leukaemia.
Serology
The red cell abnormalities are well known to immunohaematologists and 
can be demonstrated by the findings of previously reported patient F. G. [2] (Table 
1). The patient’s red cells were found to react with anti-A, anti-B, and anti-A,B. 
Agglutination showed a mixed field appearance. The patient’s serum reacted with 
A cells and B cells but did not react with reagent О cells nor the patient’s own cells. 
The patient’s saliva contained H substance but no A or B. It was concluded that the 
patient’s type was О and mixed field polyagglutination had caused the ABO dis-
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Table 1
Blood grouping results, F.G.
Red cells Anti-A + + (Mixed field)
Anti-B ± (Mixed field)
Anti-A, B + + (Mixed field)
Serum A cells + + + +
B cells + + + +
О cells 0
Auto 0
Saliva Secretor of H, not A or B
crepancy. To determine if T or Tn activation was the cause of the polyagglutina- 
tion, the patient’s red cells were tested with a lectin panel. The cells reacted strongly 
with Dolichos biflorus, Salvia horminum, and Salvia sclarea but failed to react with 
Arachis hypogaea. As shown in Table 2, the red cells demonstrated the classic pat­
tern of Tn and could be distinguished from other forms of polyagglutination [6].
Table 2
Lectin identification of polyagglutinable red cells
Red cells
Lectin
Arachis
hypogaea
Dolichos
biflorus
Salvia
sclarea
Salvia
horm inum
T-activated + 0 0 0
Tn-activated 0 + + +
Cad-polyagglutination 0 + 0 +
Group О 0 0 0 0
Group A 0 + 0 0
Patient F. G. 0 + + +
Further confirmatory tests showed that the red cells failed to react with serum 
from another case of Tn and that the patient’s serum lacked anti-Tn. When the 
patient’s red cells were treated with papain, the Tn activity was eliminated. The pa­
tient’s red cells were aggregated only weakly by polybrene but were agglutinated 
strongly by soy bean lectin. The sialic acid level (measured by Dr. Ed Steane) was 
low, 11.1 p.g/10'J RBC (normal 13-17 p.g) [7]. Beck and co-workers studied this 
patient’s buffy coat and were able to demonstrate greater absorption of lectin activ­
ity than by controls, suggesting Tn polyagglutination of buffy coat elements [8].
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Development and Biochemistry of Tn
The characteristic features of Tn polyagglutination are thought to result from 
a mutation of a somatic stem cell since this polyagglutination phenomenon is 
known to be acquired. A mutation of the pluripotent haematopoietic stem cell 
occurring at different stages of haematopoietic development may explain the varia­
bility in erythrocyte, platelet, or leukocyte polyagglutinability. Recent work by 
Vainchenker et al. gives strong evidence of the clonal origin of Tn cells [9]. These 
investigators used cell culture studies to demonstrate that red cells, granulocytes, 
and platelets which express Tn are derived from a Tn positive clone which under­
goes clonal expansion at an unknown stage of development. It was found that the 
percentage of red cells and platelets in the peripheral blood typing as Tn positive 
was similar to the percentage of colonies whose cells were uniformly positive for Tn.
The nature of the red cell membrane defect in Tn polyagglutination is now 
also better understood. Cartron et al. have shown that Tn red cells have a selective 
deficiency of an enzyme, B-3-D galactosyltransférase, which normally transfers 
galactose to the Tn structure to then produce T substance [10]. This blockage of 
galactose transfer due to the deficiency of T transferase results in persistent ex­
posure of Tn antigen with N-acetyl-D-galactosamine as a terminal structure. These 
facts may also explain the А-like properties of Tn red cells and the lack of M and N 
antigens on Tn red cells.
Tn and the Leukemic State
A review of 19 published cases of Tn polyagglutination in 1979 included 3 
cases associated with myeloid leukaemia [4]. Bird was the first to call attention to 
this occurrence [3]. A 63 year old male presented with leukemia and the classic 
features of Tn polyagglutination. Although the paper’s title gives the diagnosis of 
acute myelocytic leukemia (AML), the discussion considers the likelihood that this 
patient did not have AML. The lymphadenopathy, the inability to aspirate bone 
marrow, the low leukocyte alkaline phosphatase score, and the elevated vitamin Br2 
level favored the diagnosis of Philadelphia-chromosome-negative chronic myelo­
genous leukemia (CML). The patient was given cytotoxic chemotherapy and the 
Tn activation disappeared in 5 months.
Around the time of Bird’s report, our patient F. G., previously known to have 
had Tn polyagglutination for at least 2 years, developed acute myelomonocytic 
leukaemia [2]. This case was similar to Bird’s case with the disappearance of the 
Tn activity with cytotoxic chemotherapy, giving further support to the description 
of Tn polyagglutination as persistent, not permanent. There were several differences 
from Bird’s case which expanded the picture of Tn and leukemia. First, our pa­
tient’s Tn state preceded his leukemia. The leukemic transformation occurred in 
a patient with pre-existing pancytopenia and hypercellular marrow, a constellation 
of hematologic findings which commonly precede acute myeloid leukemia and are
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called pre-leukemia [11]. The similarities between the pre-leukemic syndrome and 
Tn polyagglutination suggested a relationship or that perhaps Tn polyaggiutination 
was a specific form of pre-leukemia. The features of what is now called the Tn syn­
drome are also suggestive of the features of another hematologic disorder, parox­
ysmal nocturnal hemoglobinuria or PNH [12]. Both disorders are marked by red 
cell membrane defects resulting from proposed hematopoietic cell mutations, both 
disorders appear to be clonal, and both feature hemolytic anemia, various cyto- 
penias, and increased likelihood of developing acute leukemia (Table 3).
Table 3
Hematologic syndromes
Features Tn Preleukemia PNH
Acquired nature + + +
Anemia + + +
Hemolysis + — +
RBC membrane defects + — +
Granulocytopenia + + +
Thrombocytopenia + + +
Leukemic potential + + +
Another important difference in these two cases is morphologic. F. G.’s mor­
phology appeared to be acute myelomonocytic leukemia although his leukemic cells 
had unusual morphologic features of vacuoles. The problems encountered by Bird 
in making a firm morphologic diagnosis between AML and CML have already 
been discussed.
A third case occurring in a 71 year old black male was reported by Baldwin 
et al. [4]. The patient had had a refractory anemia for two years before presenting 
with acute myelomonocytic leukemia. His Tn status was identified when leukemia 
was diagnosed but no immunohematologic investigations had been performed 
previously. He died before chemotherapy could be instituted.
These three published cases led Dr. Jiji in Baltimore to update his oral pre­
sentation at the 1973 American Association of Blood Banks meeting of a patient 
with pancytopenia and ringed sideroblasts in the marrow along with Tn polyaggiu­
tination [5, 13]. The patient was treated with anabolic drugs and pyridoxine with 
correction of the pancytopenia and almost complete elimination of the clone with 
Tn polyaggiutination. A year later, the patient relapsed with acute myeloid leuke­
mia at which time the Tn polyaggiutination returned. The patient died in 1975 at 
home of bleeding from thrombocytopenia. There are most likely other unpublished 
cases of Tn and leukemia. A registry of cases of leukemia associated with Tn poly­
aggiutination would be helpful to identify the incidence of this association.
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Conclusions
I have reviewed the serologic identification, the biochemical nature, the clonal 
hematopoietic stem cell origin, and the 4 (or perhaps more) cases of Tn polyagglu­
tination and leukemia. The following conclusions appear to be warranted.
First, among the hematologic abnormalities associated with Tn polyaggluti­
nation, we should include hematologic malignancies. We should be careful to avoid 
limiting this association to cases with acute myelomonocytic leukemia, in view of 
the difficulties in firmly classifying Bird’s case. Perhaps a retrospective morphologic 
review of these cases by blinded observers could resolve whether this association 
was limited to AMML or must be broadened.
Second, cytotoxic treatment of several patients with Tn and leukemia has 
shown that the Tn clone can be ablated, justifying the classification of Tn as persis­
tent but not permanent.
Third, most authors conclude these discussions by stating that any patient or 
donor with the Tn syndrome merits careful hematologic monitoring. Included in 
these hematologic observations should be chromosome studies, since certain chro­
mosomal abnormalities are associated with a propensity to develop leukemia [14]. 
This simplistic conclusion to monitor these patients avoids the real question of 
what to do with these patients or donors. It could be suggested that a patient with 
Tn and hematologic findings compatible with a pre-leukemic status could be given 
cytotoxic therapy. Several pieces of evidence would contradict this suggestion. 
In 3 of the 4 patients reported, Tn was successfully ablated but leukemia recurred 
or persisted, once with Tn and twice without a recurrence of Tn. Thus, removal or 
disappearance of the Tn clone does not mean hematologic cure. Many of the Tn 
patients have not developed leukemia. Finally, early treatment of pre-leukemia 
patients has been generally disappointing. The definitive answer of a controlled 
clinical trial is obviously impossible because of the rarity of these patients. How­
ever, the weight of current evidence suggests that cytotoxic chemotherapy would 
not be indicated.
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If blood donor selection were an efficacious means of preventing posttrans- 
fusion hepatitis B, three conditions should be fulfilled: 1. the incidence of the disease 
should decrease immediately after the exclusion of blood donations that contain pre­
sumed infectivity markers; 2. the incidence of the disease should likewise decrease 
when donor blood is completely replaced by autologous blood; 3. retesting of donors 
implicated in cases of posttransfusion hepatitis B should regularly detect one or more 
anti-HBc positive individuals per case.
Since none of these conditions turned out to be fulfilled when tried in the 
FRG, it remains an open question whether the transfusion-transmitted part of post­
transfusion hepatitis B is significant enough to justify laborious donor screening 
procedures.
Key words: posttransfusion hepatitis, screening for infectivity, transfusion- 
transmitted hepatitis.
What is the Origin of Posttransfusion Hepatitis?
According to a widely accepted theory, the occurrence of hepatitis in a 
blood recipient within a certain period after transfusion indicates that at least one 
of the transfused blood units contained hepatitis agents. This theory was derived 
from the observation that in blood recipients the incidence of hepatitis is generally 
higher than in patients without transfusions [1 ]. However, the elevated hepatitis 
risk of blood recipients, if analysed in detail, turns out to be an overgeneralization.
In the FRG, a significant statistical association between transfusion and 
hepatitis could only be established in patients who beside receiving blood trans­
fusions had concomitant surgery [2-4] and in recipients of pooled plasma prod­
ucts [5]. The peculiar problem of pooled plasma products shall not be discussed 
in this paper.
In recipients with concomitant surgery, two possible pathways of hepatitis 
agents have to be taken into consideration, namely the administration of blood 
containing HY and the parenteral exposure to an environment containing HV. 
The theory of transfusion-transmitted hepatitis stimulated the search for serologic 
markers which make the infectivity of a donor detectable. In the case of post­
transfusion hepatitis B (PTH-B), the hepatitis-Bs-antigen (HBsAg) is regarded 
as such a marker of infectivity.
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What has been Achieved by HBsAg Donor Screening?
If a significant amount of PTH-B had in fact been really transfusion-trans­
mitted, and if HBsAg were indeed a specific infectivity marker and not a mere 
marker of past HB infection, the elimination of all blood units exhibiting this 
marker ought to have significantly reduced the incidence of PTH-B.
This appears to have happened when third generation HBsAg donor screen­
ing procedures were introduced in the USA. The elimination of Ag positive 
units was followed by a dramatic reduction of PTH-B [6].
If this reduction of PTH-B following the elimination of all HBsAg positive 
blood donations were reproducible anywhere, it would give strong empirical 
support to the assumption that HBsAg testing of blood donors is a useful tool for 
preventing PTH-B.
Table 1 shows that this reduction by AUSRIA-lI-screening of all blood 
donors could not be reproduced in the FRG, where a similarly significant reduction 
occurred much later and independently of any special donor selecting procedure.
Production period o f  the Total HBsAG Positive
blood units involved positive %
Immediately before
RIA-screening 33 27 82
Immediately after
RIA-screening 54 46 85
Five years later 27 7 26
Source: Red Cross Blood Centre, Muenster, FRG
Consequently, it remains an open question whether the dramatic reduction 
of PTH-B in the USA following introduction of the new donor screening was 
really due to this screening or if it would have occurred anyway.
The observation of hepatitis incidences as such is obviously not an appro­
priate tool for assessing the efficacy of preventive measures.
In the USA, the assumption of a significant contribution to the prevention 
of PTH-B by HBsAg donor screening was additionally supported by some pre­
vious comparative studies investigating the outcome of HBsAg positive or negative 
blood transfusions [7, 8]. The conclusiveness of such studies is, however, im­
paired by the possibility of volatile pseudoassociations, e.g. accidental clustering 
of HBsAg positive and infective donors.
In the FRG, such comparative studies had already been precluded for 
ethical reasons when the non-compliance of PTH-B with the HBsAg donor
H aem ato lo g ia  16, 1983
Table 1
Notified cases of PTH/100 000 blood transfusions
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screening became evident. Therefore we have to envisage the fact that the possible 
efficacy of this donor screening procedure will remain a mystery forever.
In fact this is the second time that we had encumbered our blood procure­
ment system by an irreversible burden without previous assessment of its clinical 
efficacy. The first step along this way was the compulsory ALT-screening of all 
blood donations introduced in 1968.
Undoubtedly, every additional donor screening procedure impaires the 
general performance of a blood procurement system, which is not completely 
meaningless because the fear is irrefutable that nowadays ‘most bleeding patients 
who die, die of the blood they did not receive, not from the blood they were 
given’ [9].
Therefore, the experience wilth ALT- and HBsAg-screening, both of them 
irreversibly established without previous assessment of their clinical efficacy and 
both without any visible success, should lead to more caution before declaring 
compulsory all further screening procedures.
What Can be Achieved by Donor Screening Procedures in General ?
Basically even the best donor selecting procedure will not prevent hepatitis 
cases that are not transmitted by transfusion blood. Therefore, we tried to elucidate 
the maximum transfusion-transmitted part of PTH as a whole. For this purpose 
four comparative prospective studies were evaluated, two by our European Work­
ing Group on PTH [3, 10] and two by independent West German authors [2, 4].
All four studies had in common that blood recipients and control patients 
of each study were highly comparable and exposed to the same environmental 
risks of infection at the same theatres within the same periods of time, and were 
followed for 6 months for biochemical symptoms of hepatitis as well as for 
HBsAg seroconversion.
Control patients were those, who could be operated upon without blood 
transfusion or with exclusive administration of autologous blood.
Procedure
Surgery employing donor 
blood (>  1000 units) 
Surgery without 
donor blood
No. of 
patients
Hepatitis
or
A g’emia
Per cent
465 30 6 .4
2 0 0 14 7 .0
Sources: Copenhagen, Amts Sygehus, 10; Erlangen, University Clinic, 2; Essen, 
University Clinic, 3; West Berlin, University Clinic 4
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Patients who had HB markers or hepatitis symptoms before surgery were 
not considered eligible for the studies.
As it appears from Table 2, these studies gave no evidence of a nigher spe­
cific risk of the blood recipients. This general result applies to each respective 
study so that they could be summarized without biasing one of them. No other 
study known to me appearing to demonstrate a hepatitis risk of blood recipients 
exceeding that of control patients, does disclose how the adequacy of the control 
patients was established.
But if omission of donor blood transfusion does not visibly reduce the 
incidence of postoperative hepatitis, neither will any imaginable panel of donor 
screening procedures do so.
What Can be Achieved by Anti-HBc Donor Screening in Particular ?
Nevertheless, a new candidate for further additional donor screening regula­
tions is already advocated, the HB marker anti-HBc. It is said to be the most 
stable [11] and the most reliable [12] marker of HB infection. Moreover, it is 
expected to indicate not only HB but also HNANB infectivity [13].
If it is true that HB infection is regularly accompanied by development of 
anti-HBc, any blood donor who transmits HB to a recipient will carry anti-HBc 
at least when the hepatitis of the recipient becomes apparent, even if the antibody 
was not yet demonstrable at the time of the blood donation in question.
And if it is also true that PTH-B is regularly transmitted by the transfused 
blood, one should regularly find at least one anti-HBc carrying donor per case 
of PTH-B.
We have tested all implicated donors of 21 notified cases of PTH-B for 
anti-HBc by CORABrM (Table 3). The donors of 8 additional cases were tested 
by the University Transfusion Centre, Tuebingen [14]. In 24 of 29 cases (83 per 
cent) no donor testing positive for anti-HBc was detected. The frequency of anti-
Table 3
Implication of donors with anti-HBc in cases PTH-B
Cases with Cases without
Country anti-HBc positive anti-HBc positive Total
donor(s) donor
F R G 5 (1 7 % ) 24 29
U S A 11 (7 3 % ) 4 15
CH2 =13.44 1 D. F. P <  0.0005
Sources: Red Cross Blood Centre, Muenster, FRG; Tuebingen, University Clinic 14; 
USA, TTV Study, 16
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HBc-carriers among all implicated donors tested was 6 of 132 or 4.5 per cent, 
thus it did not exceed the rate of anti-HBc carriers in the average West German 
donor population.
According to recent findings of a French research group, 11 of 13 patients 
with anti-HBc had no detectable HBV DNA in their liver cells while 3 of 8 chronic 
HBV carriers had no serologic HB markers [15].
Our retrospective studies do not encourage anti-HBc donor-screening be­
cause the PTH-B patients did not receive more anti-HBc containing blood units 
than recipients in general, and the results of the French group do not even suggest 
that there exists a statistical correlation between anti-HBc and HBV carriership. 
Furthermore the correlation between carriership and infectivity may be still 
another question.
Conclusions
The non-compliance of PTH-B with HBsAg donor screening in the FRG, 
the identical postoperative hepatitis incidence of recipients and adequately selected 
controls and the apparent non-correlation of anti-HBc carriership and HBV in­
fectivity neither refute nor corroborate that a certain minority of PTH-B or PTH- 
NANB might indeed be transmitted by infected donor blood.
The possibly transfusion-transmitted hepatitis cases are, however, regularly 
concealed by a preponderant number of not transfusion-transmitted hepatitis 
cases of blood recipients. This makes a conclusive efficacy control of donor select­
ing procedures practically impossible.
Once the regulation is compulsory, every supposedly preventive measure 
becomes definitely inaccessible to efficacy control.
This was the case with ALT and HBsAg donor screening in the FRG.
Since the avoidance of donor blood transfusion did not significantly reduce 
the incidence of postoperative hepatitis, no such reduction by further donor 
selecting procedures can realistically be expected.
Thus, the introduction at random of one Screeningtest after the other may 
well prolong the way of blood from the donor to the recipient and perhaps ac­
centuate blood shortages as well as expenses. Whether these drawbacks will be 
compensated by visible gains in hepatitis prevention can be doubted with good 
reason.
As far as the third generation donor screening for HBsAg is concerned, we 
have absolutely no evidence beyond theoretical considerations that it contributed 
to the obvious reduction of PTH-B in the FRG.
These experiences remind us again that a theory is nothing more than a 
subjective picture of reality, not reality in itself, and that the strength of our 
subjective belief in the correctness of a theory is not always a reliable indicator 
of this correctness.
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New Antisickling Agents
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Sickle cell anemia has variable clinical expression, ranging from benign cases 
to very severe ones. This situation suggest that, unless a perfect drug is identified, 
the therapeutic approaches may also vary. Great progress has been made in this last 
decade in the understanding of the Hb S polymer structure, the kinetics of polymeriza­
tion and some of the cellular contributions to the disease. This progress has suggested 
that we could alter the course of the disease by impairing the polymerization of Hb S 
through three mechanisms: a) interfering in the areas of contacts involved in polymer 
formation by covalent and non-covalent agents, b) changing the oxygen affinity of 
Hb S to decrease the changes induced by deoxygenation, c) diluting the Hb S by increas­
ing the MCV of the cells and consequently decreasing its MCHC. This last result 
is achieved by a modification of the permeability of the red cell membrane.
Keywords: sickle cell anemia, new antisickling agents, Hb S
*
At present, the therapy of sickle cell disease remains a non-specific one. it in­
cludes on the one hand a symptomatic treatment of the anemia and the thrombo­
embolic crises, on the other hand a development of hygiene and prophylaxis which 
by itself may explain the differences of the disease in underdeveloped and industri­
alized countries. Together with this physiological approach, since more than twenty 
years the progressive understanding of the molecular pathology of the disease has 
been an incentive to research of any agent which could specifically inhibit the poly­
merization of hemoglobin S and the subsequent sickling of the red cell. Most, if not 
all, of the drugs which have been and still are studied are in fact models of a possible 
pharmacological action, and the obtained results may be milestones to direct fur­
ther research.
Among the investigated compounds, some have indeed to be used in vitro 
at concentrations never reached in vivo. Some are highly toxic, some others do not 
enter the cell or are active only when not metabolised. They obviously cannot be 
used clinically as such. In limited cases, as for example cyanate or nitrogen mus­
tards, they have been used for extracorporeal treatment of the red ceils which are 
then reinjected in the patient’s circulation. This can even be a temporary treatment 
when applied to a few selected cases in rich countries. It is clear that it has no prac­
tical value for mass therapy, especially in Subsaharan Africa. Nevertheless in these
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areas a treatment is badly needed, since the demographic and economic conditions 
of the major cities increase dramatically the number of homozygotes.
The pathophysiology of sickle cell disease is now well understood, and an ef­
ficient therapy could theoretically act at various levels of the vicious circle respon­
sible for the sickling of cells and vasoocclusive crises.
The final goal of any drug remains to inhibit the polymerization of hemo­
globin S, acting either on this polymerization itself or on one of the factors respon­
sible for it, namely the concentration of hemoglobin and the degree of deoxygena­
tion. Figure 1 recalls the various natural causes acting on one of these points. It is 
well known that the contacts of the hemoglobin S polymer are modified by the 
presence of other hemoglobins, normal hemoglobin F and hemoglobin A2 or ab­
normal hemoglobins. The oxygen affinity curve may be shifted by variations in the 
pH, the temperature, or the anion concentration. And finally, the intraerythrocytic 
concentration of hemoglobin is partially under the control of the membrane status 
and the osmolality. The three arrows indicate in a simplified way where the poten­
tial therapeutic drugs could act. (For more details see refs [1 ] and [2]).
1. The drugs disrupting the polymer contacts are all chaotropic agents. They 
include urea, which was first proposed, and alkylureas which cannot reach in vivo 
the required concentrations. Aromatic aminoacids and short peptides act well on 
hemoglobin solutions, but their entrance into the cell is limited. Solvents, deter­
gents, gases are of no therapeutic use.
2. Another large group would involve different products modifying the oxy­
gen affinity of hemoglobin S, and therefore decreasing the proportion of deoxy­
hemoglobin S. The most thoroughly studied among these drugs was cyanate which 
has been tried also in vivo. Its toxicity is due to that, despite a preferential binding 
to hemoglobin, it binds unspecifically to all the proteins.
Fig. 1. Possible impact of drugs delaying Hb S polymerization
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Among the other compounds, a particular interest is devoted to those which 
bind to cystein 93, the first model having been cystamine. One has also to mention 
nitrogen mustards which cross-link with histidine 2 and other bifunctional reagents. 
The modifying action of the latter compounds is in fact more complex. All the 
products listed in this second group nevertheless raise the question how much one 
can increase the oxygen affinity of blood without impairing oxygen delivery to the 
tissues.
3. Finally, the third group acts only in an indirect way on hemoglobin S poly­
merization, the primary action being at the membrane level. This group is highly 
heterogeneous, including drugs as different as zinc, local anesthetics, antiarrhyth- 
mic agents, antibiotics, tranquillizers, platelet antiaggregants, etc. Their proposed 
mechanism of action is by membrane expansion, which has been proved experimen­
tally [3]. Among this wide spectrum of agents, some have pharmacological prop­
erties which do not allow any in vivo long-term treatment, or present major side- 
effects. In contrast, some of them have already been used for other disturbances, 
and are not obviously contra-indicated in sickle-cell disease. This explains the wide 
research in this field in the last years.
The fact itself that the proposed drugs are so numerous and have such varying 
secondary effects proves already that none is outstanding. A practical improvement 
could perhaps be the combined use of several drugs acting by various pharmaco­
logical mechanisms.
A supplementary problem is raised by the difficulty in interpreting the ob­
served results in vivo, this being due to the high clinical polymorphism of the dis­
ease, and to the fact that most of the criteria used are not objective such as how to 
evaluate pain or what is to be called a crisis, etc.
It is also known that the clinical course of the disease may be influenced by 
a number of factors. Some of these are external to the disease itself, namely those 
which are related to climatic or ecological conditions, or to the socio-economic sta­
tus of the patients. The disease is not the same in African Sahelian countries and 
in the industrialized Western world. Гп a survey performed recently in villages of 
Upper Volta, we found 15 per cent heterozygotes, but among more than 1000 
subjects there was only one homozygote, and he was less than 5 years old. Due to 
malnutrition, the lack of medical care, or the very hot and dry climate, the homo­
zygotes do not survive. In African larger cities, where some drugs could be assayed, 
some improvement of the clinical status may be observed simply by more attention 
and a better nursing, this being often observed when the efficacy of a new com­
pound is assayed.
It has also been shown that the association of other genetical defects may be 
beneficial to sickle cell disease. This is now well established for the minor form of 
a-thalassemia, namely only one a gene expressed per chromosome 16 [4]. It could 
be true also for the heterocellular form of HPFH. And there are surely other still 
unknown causes.
This only emphasizes the urgent need for antisickling drugs and the major 
difficulty in interpreting their potential results.
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Demand for factor VIII varies greatly and exceeds supply in many places. 
Logical analysis of this difficult situation has been undertaken by observing actual 
usage, calculating potential need, and analysing factors which limit or influence pro­
duction and distribution. Usage exceeds production potential in some places. It is 
concluded that factor VIII production/usage in the range of 20 000-60 000 IU per 
hemophilia A patient per year is both feasible and adequate. Production/use below 
10 000 IU is not adequate. Production above 60 000 IU is not practicable using cur­
rent technology.
Keywords: albumin, blood transfusion, factor VIII, hemophilia, plasma 
fractionation, supply
Introduction
Hemophilia treatment has made great advances in the last decade. The prin­
cipal reason for the progress was the increasing availability of the concentrated 
clotting factor preparations required by hemophiliacs for the control of bleeding.
Clinical advances have created a demand for antihemophilic products which 
exceeds the supply in many countries. This situation presents interesting challenges 
to the organizations responsible for the provision of the plasma products required 
by hemophilic patients. This statement applies equally to those national, regional 
and local blood transfusion agencies responsible for the preparation of cryoprecip- 
itate and the provision of recovered plasma for fractionation, and to the various 
organizations who prepare plasma fractions on an industrial scale. The recognition 
that there are problems in this area has led the International Society of Blood 
Transfusion (ISBT) [I ], League of Red Cross Societies (LoRCS) [2], World Health 
Organization (WHO) [3], Council of Europe [4], International Federation of 
Pharmaceutical Manufacturers Associations (IFPMA) [5] and the World Federa­
tion of Hemophilia (WFH) [6] to pay special attention to the issues involved in as­
suring the availability of factor VIII preparations. At the national level, studies of 
this problem are known to be active in England, Scotland, Sweden, Denmark, 
the Netherlands, Germany (Federal Republic), France and Canada.
WFH has appointed a Task Force, comprising the five authors of this paper, 
to attend to the question of worldwide availability of plasma products for hemo­
philia treatment. Some preliminary thinking was presented in 1981 [7].
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Table 1
Factor VIII problems
Users
Inadequate supplies in many countries
Disagreement about dosage need
High prices in Europe and many developing countries
Providers
National blood transfusion services 
difficulty meeting demand 
Industry
factor VIII need overtaking albumin demand 
low prices in USA
Haemophilia is a generic term encompassing two biochemically different but 
clinically similar disorders (Factor Vili and Factor IX deficiency). Factor VIII 
deficiency (hemophilia A) accounts for about 80 per cent of the affected patients 
and is responsible for all the significant product supply difficulties (Table 1). Factor 
VIII alone is the focus of this analysis, designed to reduce a conflict, which has 
become politicized, to a level of scientific logic which will permit rational decision­
making.
Methods
The authors have considered available information on production, usage and 
need of factor VIII and have analysed it in order to identify problems and potential 
solutions. Issues are considered from the standpoint of both the clinician and the 
producer of transfusible products. These issues are complex technically, logistically, 
ethically and geographically; oversimplification has, of necessity, been utilized to 
aid understanding. Some definitions are offered (Appendix I) to explain the intend­
ed meaning of certain key words that might otherwise be ambiguous.
Observations and Discussion
The size of the clinical problem is definable by the number of patients and 
the amount of factor VIII needed to treat each one. This calculation has been at­
tempted in detail by Cash [8] in his projection of Scottish factor VIII needs.
The number of patients with hemophilia A is remarkably constant around the 
world, approximately 50 cases per million population. If mildly affected patients 
are included, the number will be higher; this observation is not consequential when 
considering product usage since mild cases require little treatment. The assumption 
of 50 cases per million population is utilized throughout this discussion.
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Table 2
Factor VII1 usage by country (units/patient/year)
High dosage
Germany (Fed. Rep.)** 80 000
USA (Treatment centers) [10] 55 000
Belgium* 51 000
the Netherlands* 50 000
USA* 36 000
Moderate dosage
UK* 22 000
Spain* 19 000
Sweden* 18 000
Austria* 16 000
Finland* 15 000
* See Ref. [5]
** There are no realiable published data for the Federal Republic of Germany. The 
authors’ best estimate, based upon multiple fragments of data, puts total annual factor VIII 
usage at 200 million units, equivalent to 80 000 units/patient. Henning (personal communica­
tion, April, 1981 ) believes that total usage is 300 million units (Table 12)
The amount of factor VIII needed to treat each hemophilic patient is not 
constant. There are some remarkable differences from country to country, illus­
trated in Table 2 and also in the report of the WFH Home Care Committee [9]. 
Comparable differences have been reported by Levine within the UnitedStates [10].
Table 3
Philosophies of hemophilia treatment
F actor VIII need* 
units/year/patient
1. Prevent bleeding at all costs 547 500
2. Prevent all severe bleeding 91 250
3. Reduce bleeding by conservative maintenance 51000
4. Control all bleeding episodes 36 750
5. Treat all bleeding with conservative doses 16 250
6. Control all severe bleeding 13 500
7. Treat all severe bleeding, conserving supplies 7 000
8. Treat only life-threatening bleeding 5 000
9. Minimize treatment, because of risks 2 000
10. No treatment —
* These numbers differ somewhat from those originally published [7]. The basis for 
these calculations is lengthy and complex; it is available from Dr. Britten upon request
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Analysis of this phenomenon leads to the conclusion that usage is influenced 
strongly by the philosophy (therapeutic intent) of the clinician (Table 3). Some 
arithmetical relationships, helpful in interpreting Table 3 and other data, are set 
out in Appendix II.
Ten different philosophies are considered in Table 3. Each one has a logic 
which may seem reasonable. Yet the amounts of plasma products required to im­
plement these philosophies vary enormously. Analysis of likely outcomes reveals 
that philosophies 7-10 will not achieve effective treatment; they will lead to the 
well-known and severe physical and social disabilities so predictable when treat­
ment is unavailable. These options are therefore not acceptable and must be elimi­
nated from consideration.
Superficial evaluation of philosophies 1-6 could lead to the conclusion that 
the best clinical results can be expected with philosophy 1. There is, however, a need 
to consider the factors which limit supplies of factor VIII.
The economic realities of plasma fractionation require producers to make 
more than one marketable product from each batch of plasma. Production of factor 
VIII concentrates is limited by the demand/need for albumin. Table 4 illustrates 
this linear relationship, assuming the production of 25 g albumin and 200 units 
factor VIII from each liter of fresh frozen plasma fractionated. Factor VIII pro­
duction is favorably influenced by higher production yields (i.e. > 200 units/liter 
plasma) and adversely affected by fractionation of source materials depleted of 
factor VIII.
The critical nature of this factor VIII : albumin ratio becomes clear when con­
sidering albumin usage by country (Table 5). Only those few countries which ex­
perience a high demand for albumin products are able to cause much factor VIII 
concentrate to be produced+ (e.g. Switzerland, Japan, USA, Belgium, Germany
Table 4
Relationship of albumin to factor VIII production*
Liters plasm a
Albumin
production,
kg
Factor
VIII production, 
units X 10e
4 000 100 0.8
8 000 200 1.6
12 000 300 2.4
16 000 400 3.2
* Assumption: 1 liter fresh frozen plasma generates 25 g albumin and 200 units factor
VIII
+ It is noteworthy that production does not need to be in the same country. Indirectly, 
high albumin usage in Japan may help sustain enormous factor VIII usage in the FRG, 
through American production of both products.
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Table 5
Albumin usage by country*
Country
Albumin usage 
(kg/million pop.)
FRG 555
Switzerland 485
USA 296
Sweden 117
UK 45
Brazil 14
* These data were developed from those of 1FPMA [5]; this list is incomplete, being 
selected to demonstrate the wide difference between countries
(Federal Republic)). The difficulty faced by other countries in meeting factor VIII 
demands becomes apparent.
Factor VIII, in the form of cryoprecipitate, is limited by whole blood needed 
for transfusion. In most medically developed communities this limitation is based 
on a need of around 50 000 whole blood donations per million population per year. 
A further constraint arises in that logistic realities and conflicting service demands 
decree that cryoprecipitate cannot be prepared from every donated unit (Tables 6 
and 7). *6
Table 6
Factor VIII production limits
Source
of
product
Factor VIII prod, (u X 10я/ 10я population/year)
Equivalent
u/patient/year
Fractionation* Cryoprecipitate Total
Realistic
maximum
Fractionation 0 .8 0 .8 0 .8 16 000
Cryoprecipitate — 5.0 5.0 3.0 60 000
Combination 0 .8 5.0 5.8 3.8 76 000
Realistic Comb. 0 .8 2 .0 2 .8 2.8 56 000
* Assuming albumin use 100 kg/million population/year
Analysis of production potential reveals that a combination of fractionation 
and cryoprecipitate production leads to optimal factor VIII production only if 
albumin usage is high; otherwise almost total reliance upon cryoprecipitate (Table
6) must be weighed against dependence upon imported concentrates.
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Table 7
Factor VIII production limits
Source
of
product
Factor VIII Prod, (u x 106/ 10e population/year)
Fractionation* Cryoprecipitate Total
Realistic
maximum
Equivalent
u/patient/year
Fractionation 3.2 — 3.2 3.2 64 000
Cryoprecipitate — 5.0 5.0 3.0 60 000
Combination 3.2 5.0 8.2 6.2 124 000
Realistic Comb. 3.2 1.0 4.2 4.2 84 000
* Assuming albumin use 400 kg/million population/year
Plasma that is not fresh frozen is a suitable source of albumin but cannot be 
effectively utilized for factor VIII production. This relationship is particularly im­
portant when the plasma for fractionation is derived from whole blood donation 
(Table 8); every unit that is not useful for factor VIII reduces the overall production 
of factor VIII and thus reduces the treatment of hemophilia. Examples of how un­
suitable practices may depress factor VIII production are
1. Use of plasma, not fresh frozen, for fractionation
2. Use of placentas as a source of albumin
3. Fractionation for albumin in facilities not producing factor VIII
4. Use of low-yield technology for factor VIII production.
Review of the limitations to factor VIII production demonstrates clearly that 
philosophies 1, 2 (Table 3) are impractical. There is no way to provide the amounts 
of plasma products required for general implementation of these philosophies. 
Reasonable discussion must be limited to philosophies 3-6. Within this range, some 
countries are clustered in the higher dosage range while others are more conserva-
Table 8
Effect of fractionating ‘not fresh’ plasma
Factor VIII production (u x 10e/year)
Fraction of
‘not fresh’ plasma 
(units/million population)
Albumin 
production 
100 kg/106
Album in 
production 
400 k g /10«
0 0 .8 3.2
10 000 0.4 2 .8
2 0  0 0 0 — 2.4
30 000 — 2 .0
40 000 — 1.6
50 000 — 1.2
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tive (Table 2). The explanation of this difference is that annual production of 
10 000-30 000 units per patient is relatively easy in countries with fully developed 
blood transfusion services. Production in the higher range (>30 000 units/patient, 
equivalent to philosophies 3, 4) is possible but difficult, and is being attempted in 
a few countries only.
Allain [11] approaches the factor VIII usage question from the standpoint of 
dosage used in the treatment of individual bleeding episodes. His data were used 
in developing Table 9. Clinical benefit results from higher doses but the gains di-
Table 9
Effect of dosage upon therapeutic success rate in treatment of hemophilia A
Therapeutic Factor Approximate
success VIII dosage, factor VIII usage,
rate, % u/kg u/patient/year
90 15 36 750
95 20 49 000
99 31 75 950
minish as dosage is increased, particularly above 15 units/kg. These data can be ap­
proximately related to annual usage per patient. Allain’s recommendation of at 
least 26 units per kg, a high-dosage variant of philosophy 4, would imply usage at 
the rate of more than 60 000 units per patient. With the solitary exception of the 
commercial fractionation industry in the United States, no country has been able 
to achieve production at such a level.
One must strive for clinically normal patients so a case can be made for using 
the highest dose possible. The logical conclusion from this discussion is that, while 
philosophies 5, 6 may be acceptable if supplies are necessarily limited, philosophies 
3 or 4 are desirable (Table 10).
If one assumes a worldwide need of 20 000 units per patient, the supply of 
factor VIII concentrates is inadequate (Table 11). The actual usage pattern is
Table 10
Applicability of different philosophies
Philosophy 
(from Table 3) Applicability
1 -  2 Impossible
3- 4 Desirable
5- 6 Acceptable
7-10 Not acceptable
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uneven, being heavily concentrated in North America and parts of Western Europe 
(Table 12). Clearly much progress is needed in the development of more general 
availability. It is necessary to consider ways to increase production and reduce 
wastage.
There is a growing demand for high purity concentrates because they are con­
venient and reliable. Unfortunately, as purification increases, the yield is reduced; 
some factor VIII is lost at each purification step. There is a need to emphasize more 
economical products, even though their purity is less.
The transfusion of fresh frozen plasma introduces another problem. Plasma 
transfusion in the United States has increased threefold in 5 years. If this plasma,
Table 11
World supply/need for factor VIII
Population 
Hemophilia A cases 
Need/case
Total factor VIII need 
Supply* 
4 500 000 000 
225 000 
20 000 u/year 
4 500 000 000 u/year 
+  900 000 000 u/year
Supply is +20%  of need
* Calculated from multiple sources of soft data; the assumptions are that 5 million 
litres of fresh frozen or source plasma were fractionated in 1980 at an average yield of 180 
units/litre. These figures do not include single-donor or small pool cryoprecipitate; only frac­
tionation products are considered (Table 12)
Table 12
Factor ѴІП concentrate usage, 1980 (in millions of units)
USA 400"
FRG 200*
Canada [12] 30
Japan [13] 30
UK [14] 20
Rest of world 220*
Total 900“
(much from USA)
(mostly from USA) 
(mostly from USA) 
(mostly from outside UK)
“ There are no reliable data. Industry spokesmen estimate usage at 400 million units. 
The authors’s best estimate, based on projections of regional data, is close to that figure. 
Projection of usage at major treatment centers [10] would put usage at +720 million units
* See Table 2
“Calculation is based on subtracting usage for major consuming countries [12-14] 
from the estimated total production worldwide 
d See Table 11
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now representing nearly 20 per cent of the blood resource, is transfused in the fresh 
frozen state, factor VIII that could be available for hemophilia treatment is given 
to patients who do not need it. This wastage is now equivalent, in cryoprecipitate, 
to 200 million factor VIII units annually in the United States alone.
Table 13 can serve as a basis for considering plasma management in a blood 
transfusion service. These data are hypothetical, based upon a population of one 
million from which 50 000 blood donations are collected each year. Table 13 illus­
trates an undesirable production pattern which is commonly encountered. Each
Table 13
Plasma usage per million population (hypothetical)
Blood donations 50 000
Plasma available 50 000
Plasma usage
Whole blood transfused 
Plasma transfused 
Plasma fractionated
20 000* 
10 000*
F. VIII, u Albumin, kg
Fresh frozen 5 000 200 000 25
Not fresh frozen 5 000 — 25
Cryoprecipitate
depleted 10 000 50
Cryoprecipitate 10 000 I 000 000 —
Total I 200 000 100
* Additional cryoprecipitate may be derived (maximum 3 million units)
Table 14
Plasma production scheme in Groningen-Drenme Region
Blood donations 50 000
Plasma available 50 000
Resulting products
Modifiedwhole blood 15 000
Plasma for transfusion 10 000
Plasma for fractionation F VIII, u Albumin, kg
Fresh frozen 25 000 1 000 000 125
Not fresh frozen — — —
Cryoprecipitate
depleted — — —
Cryoprecipitate 15 000 1 500 000 —
Total 2 500 000 125
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blood donation contains a unit of plasma; each represents one plasma decision. 
Accounting for this plasma will determine how much hemophilia treatment is pos­
sible. The maximum factor VIII yield will result from maximizing cryoprecipitate 
production and fractionation of fresh frozen plasma. Transfusion of whole blood 
or plasma, and fractionation of plasma not containing factor VIII, all serve to 
reduce factor VIII production. Table 14 shows Smit Sibinga’s actual production 
capability in the Groningen-Drenthe region in the Netherlands, much more effec­
tive production.
These various observations serve to expose a difficult situation. There is a 
growing demand and a definable need for factor VIII. Yet there are absolute limita­
tions to the amount that can be produced with current technology. Compromises 
are necessary in developing a practical policy.
Conclusions
A few specific suggestions are offered to help rationalize the demand for 
factor VIII and its production. Clinicians must be willing to use frozen cryoprecipi­
tate, particularly in a hospital setting. Conserving supplies must always be an im­
portant consideration. Blood transfusion services must accept the need to maximize 
factor VIII production including at least some high purity concentrates for home 
treatment and for patients prone to allergic reactions to cryoprecipitate. Fresh 
frozen plasma must never be transfused without specific indication, since this wastes 
factor VIII; factor VIII-depleted plasma is generally a satisfactory substitute. All 
plasma for fractionation should be fresh frozen since other plasma generates al­
bumin only, thus inhibiting factor VIII production. Clinicians, hemophilia organiza­
tions, blood transfusion services and fractionators need to work together to coordi­
nate their planning. Only in this way can demand and production potential be 
rationally linked.
Appendix I
Cryoprecipitate 
Concentrates 
Plasma fractions
Hemophilia A
Definitions
Factor VIII prepared by cryoprecipitation, frozen or 
lyophilized, single-donor, small-pool, or large-pool.
Lyophilized factor VIII preparations resulting from cryo­
precipitation plus further purification steps.
Plasma derivatives prepared from large-volume multidonor 
plasma pools. Examples are albumin, immunoglobulins, 
factor VIII concentrates, factor IX complex, etc.
Congenital deficiency of factor VIII coagulant activity 
(VIII :C)
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Source plasma
Recovered plasma
Supply
Demand
Need
Use (usage)
Plasma, obtained by plasmapheresis and intended for 
further manufacturing purposes (e.g. fractionation).
Plasma, obtained from whole blood donation and intended 
for further manufacturing purposes (e.g. fractionation).
Equivalent to effective production plus imports minus 
exports.
The amount that is wanted.
The amount that is needed to achieve a stated clinical 
objective.
The amount that is actually used (equal to ‘effective 
demand’)
Appendix II
1. I blood donation
= 450 ml (+  10%) whole blood 
= + 225 ml plasma
= 100 units factor VIII as cryoprecipitate (yield 40-50 per cent)
2. 1 liter plasma
= 25 g albumin
s  200 (±  100) units factor VIII as concentrate (yield 10-30 per cent)
3. Whole blood collectionlmillion populationlyear
= 50 000 donations/year
=  11 250 liters plasma for fractionation (maximum)
= 8000 liters plasma —a realistic goal 
= 200 kg albumin
s  1.6 (+  0.8) million units factor VIII as concentrate 
=  32 000 units factor VIII/patient
4. Albumin
Albumin needs up to 200 kg/million population/year can be met from ‘normal’ 
whole blood donations
Additional albumin can be obtained only by one or more of the following
1. Plasmapheresis
2. Overcollection of whole blood
3. Importation
5. Albumin and factor VIII
4000 liters fresh frozen plasma 
=  100 kg albumin, and 0.8 million units factor VIII 
= 16 000 units factor VIII/patient 
16 000 liters fresh frozen plasma 
= 400 kg albumin, and 3.2 million units factor VIII 
= 64 000 units factor VIII/patient
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6. Hemophilia treatment needs 
35 hemorrhages/year 
10 severe hemorrhages/year 
15 units factor Vni/kg body weight
= factor VIII increase of 30 per cent (0.3 u/ml), (controls bleeding + 90 per 
cent of the time (Table 9)
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Up to present times, transfusional matters had been viewed under clinical, 
and still more recently, legislative aspects.
Legislation or sets of rules have been designed in numerous countries. 
The WHO, the League of Red Cross Societies, the European Council and the 
ISBT have supported that some principles be the basis for this legislation in order 
to assure transfusions with the greatest possible security, both for the donor and 
for the receiver.
According to general opinion, everything about transfusion must be kept 
under the responsibility of Public Health Services. These are responsible for the 
correct therapeutical use of blood and blood derivatives among the population 
on both the national and the international scene.
We must not forget, however, that this ethical and clinical responsibility 
goes along with liability. According to present day life conditions and considering 
the possibility to process blood derivatives in some countries whereas the raw 
material comes from another country, we should not consider the liability of 
Public Health Departments in the restricted frame of one single country, be it 
producer or user.
This means mutual exchanges between different countries which implies 
enlarged clinical, technical and juridical controls.
The processing and the use of high quantities of stable derivatives make 
them a kind of industrial product. Therefore the liability of Public Health Services 
is great and must take into account not only the criteria previously defined but 
also economical ones.
There is a kind of supranational responsibility that must aim at distribut­
ing among countries with poor productive levels the surplus from other parts 
of the world.
The responsibility of Public Health Services is assumed in the fields of
research
promotion of routine care
quality control
respect of basic ethical and juridical principles
greatest possible security both for the donor and for the receiver.
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This concerns any therapeutical product of human origin in general, and 
blood in particular: fresh derivatives, on the one hand, and stable derivatives 
on the other.
Fresh derivatives: the impossible storage except at very high expense and 
transport difficulties make it hard to process them on a large scale. Obviously 
all recommendations and ethical rules designed deal particularly with these fresh 
products that are going to be distributed within a short time. These recommenda­
tions must also apply to stable blood derivatives. This requires an industry-like 
organization with specific controls.
These controls should not overshadow well-known basic ethical principles 
like volunteering and goodwill.
Experience shows that only under the control of Public Flealth Services can 
these ethical principles be taken into account. That is why if private initiative 
can give good results, it must remain under government control. Governments 
should therefore choose the most useful way but should also keep it under ad­
equate control.
International relationships are developing considerably and they prompt 
us to uniform sets of controls and legislation. They are still more necessary, since 
numerous illnesses are blood transmitted. Moreover, some of them spread in 
certain countries more than in others. So we have to define an international 
standard of control.
It is also impossible to equate blood, its fresh and stable derivatives, with 
drugs, even though their conditioning makes them similar. The supervision must 
be of a different type. Responsibility rests with Public Health Departments, not 
only for derivatives produced in their own country but also for those imported 
from foreign countries.
The responsibility of Public Health Services also covers the choice of anal­
yses to be done in these controls. For economical and practical reasons, we can­
not run all the analyses available nowadays. Unfrequent illnesses do not require 
systematic control of all donors, but liability arises if we do not do so.
A choice must be made in order not to increase too much the expenses of 
Public Health Departments, which would make it impossible to collect and 
distribute blood.
All these considerations have led us therefore to reanalyze the responsibility 
of the Public Health Departments with the following guidelines:
1. Necessity to provide people in each and every country with the fresh and 
stable blood derivatives they need.
2. Necessity to organize exchanges to distribute surplus production and to 
organize more efficiently the collection of raw material.
3. Necessity to make it clear that blood and blood derivatives are therape­
utical products different from those meant under ‘drugs’.
4. To control and encourage industrial processing without rejecting the 
help provided by non-profit industries.
5. To determine for all countries, respecting their local customs, a uniform
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set of criteria with a minimum and maximum, but with the highest possible 
security for transfusion.
6. These considerations make it clear that Public Health Services must 
accept the moral responsibility connected with blood and blood derivative delivery.
The need for maximum security in transfusional matters both for the donor 
and for the receiver, implies juridical liability that will have to be defined in 
detail and that Public Health Services must be aware of.
This Round Table was conceived in order to give a maximum of informa­
tion in relation to the evolution in transfusion as it must be conceived on a national 
and international level, keeping in mind the socio-economical, clinical, juridical 
and ethical factors.
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The Council of Europe has been active in the blood and immunohaema- 
tology fields for many years. Since 1962, in fact, the Council of Europe’s Com­
mittee of Experts on Blood Transfusion and Immunohaematology has con­
tributed much both to the free movement of blood supplies between the Council’s 
member states and to the standardization of blood products [I, 2]. Four im­
portant aspects of blood transfusion have received full attention: the organization 
of blood collection, storage, distribution and transfusion services, staff training, 
recruitment of donors, and laboratory techniques including quality control. It 
would be inappropriate to go into great detail concerning over 20 years of work 
which has resulted in over 15 sets of recommendations to member states and 
some three agreements (ratifiable instruments). I should prefer on this occasion 
to describe in some detail our present concern as they affect blood transfusion 
services in Europe.
Guidelines on the Organization of Blood Transfusion and 
the Protection of Donors and Recipients
We hope to begin in 1984 the preparation of an innovatory legal instrument 
to define the responsibilities of national public administrations in the field of 
blood transfusion. Initially it would be appropriate to set out these guidelines 
within a Recommendation to be addressed by the Council of Europe’s Com­
mittee of Ministers to its member states. It is, however, envisaged that this way 
of suggesting future solutions to current problems could lead to a greater com­
mitment on the part of some at least of the member states, that is, to a ratifiable 
instrument (an agreement or convention) which would be binding to the Con­
tracting Parties.
The reason for this initiative lies in the existence of developments of which 
you are all aware in the field of blood transfusion. There are now many new 
techniques which can expose donors and recipients to greater hazards than has 
previously been the case. The trend is also towards greater responsibility being 
taken by the State itself or by the public health administrations. It has sometimes
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been observed that where the organization of blood transfusion services has been 
left to private bodies, there appears to be less efficient supervision of donors and 
greater incidence of diseases communicable by blood or blood products, diseases 
which are only detectable by using exceptionally costly techniques. We in the 
Council of Europe have sought to rationalize the tendency for public health 
administrations to take greater responsibility for the health of all those within 
the state’s jurisdiction and, to this end, we look very closely at the implications 
for legislation bound up in new developments in the field of blood transfusion.
To give you an idea of how this general approach is working in practice, 
I should mention a report drawn up by Professor André in collaboration with 
Professor Hässig, Dr. Gullbring, Dr. Gunson and Dr. Hantchef for the Com­
mittee of Experts’ meeting in Ottawa in May of this year, which lists the follow­
ing recent developments as needing the Committee’s close attention:
1. new methods for taking blood, which impose greater constraints and in 
which the donors are increasingly involved, notably apheresis, plasmapheresis, 
etc., safety standards for the donor need to be drawn up and enforced;
2. infectious diseases: there may be changes as a result of frequent travel 
not only by donors but also by recipients;
3. the increasingly frequent exchanges of blood products, particularly 
stable derivatives;
4. the involvement of the private pharmaceutical industry in the production 
of stable derivatives and the tendency to consider them medicinal products and 
forget their human origin;
5. the need for the health authorities to monitor the manufacture of blood 
derivatives and for controls if they are imported or exported;
6. the need to forecast overall national requirements in blood and its deriva­
tives in order to ensure that optimum use is made of them; this entails stepping 
up exchanges between countries;
7. the need to involve the doctor who takes the blood and its derivatives 
and prepares and distributes it in the diagnosis and in the choice of the appropriate 
blood product;
8. the need to use new or improved diagnostic techniques;
9. the need to monitor laboratory techniques used for taking and prepar­
ing blood and its derivatives;
10. the importance of socio-economic factors which necessitate rationaliza­
tion of monitoring, collection, storage and distribution techniques;
11. the training of specialist staff.
The Council of Europe is an organization whose ethical stance —especially 
enshrined in the European Human Rights Convention — promotes the dignity 
of man and gives a special value to everyone’s autonomy. It is therefore com­
monly felt within our member states that the commercialization of blood col­
lection and the subsequent sale of blood and blood products are not compatible 
with the principle that the human body should not be, whether as a whole or 
in part, the subject of trade or barter. We therefore are extremely reluctant to
H aem ato log ia  16, 1983
F. Marziale : international juridical aspects o f transfusion 129
accept that legislations should allow blood or its derivatives collected from 
voluntary donors to be used for commercial or private gain.
In this context it is especially important to evolve a legal distinction be­
tween profits made for private gain and profits (perhaps made by a body set up 
in the public interest) used to promote blood transfusion.
A second important question has arisen over the basic principle on which 
blood transfusion systems usually work: we ask for volunteers to give blood and 
their benevolence is reflected in benefits accruing on a national and international 
scale. But is it acceptable that the health of the population at large should depend 
on such a small minority of the population?
Both these questions were dealt with through the efforts of the Committee 
of Experts on Blood Transfusion and Immunohaematology and the Reykjavik 
Rules were drawn up in 1975. These Rules have served as a basis for legislation 
in several European countries. I suspect, too, that they have also inspired the 
ISBT’s own Code of Ethics and that of the Red Cross, and they have been pub­
lished by the WHO. The Council of Europe’s own agreements and protocols in this 
field concerning the exchange of therapeutic substances of human origin, and the 
Recommendation on the harmonization of member states on legislations relating 
to the removal, grafting and transplantation of human substances (No. 29 of 
1978) [1] should facilitate positive solutions of these problems. A specific effort 
in the field of European solidarity is represented by the Council of Europe’s 
continuing support for the European Bank of Frozen Blood of Rare Groups 
which is based in Amsterdam.
Blood Products and Legal Liability
1 should now like to move to the consideration of two other matters which 
are of interest to us in the Council of Europe. The first issue arises from the fact 
that some industrialized blood products are being given the status of drugs. This 
is happening even though such products are of human origin, may have involved 
a risk for the donor when collected, and may subsequently involve a risk for the 
recipient, just as ordinary chemical drugs can do. The Council of Europe is con­
vinced that in such a context as this we need to look very closely at the question 
of liability, whether that of manufacturers or of public health services. The Council 
of Europe has already drawn up a convention on product liability which has been 
discussed in relation to the use of products within medical services, but further 
work on this problem is surely needed. National legislation not only needs to 
define product liability but also to determine what body should be responsible 
for the quality control of products and of equipment. In Europe at present govern­
ments do not have a uniform approach to these problems. Many of them avoid 
taking a standpoint on them, and perhaps deliberately maintain a certain degree 
of indeterminacy in their approach. A few European governments with highly 
developed public health services to which public accountability is intrinsic have,
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however, successfully resolved these problems. Yet others, for the moment, are 
considering the products as drugs and applying the relevant legislation. One of 
the Council of Europe’s contributions to cooperation in the health field is the 
European Pharmacopoeia whose specifications are mandatory on Contracting 
Parties. This organ of the Council of Europe has already noted that certain blood 
derivatives are included in national monographs as drugs, but clearly govern­
ments urgently need to be given precise general guidelines in this field. There can, 
however, be no intention to impose complete harmonization on European govern­
ments in this matter.
The Duties of Health Service Staff
The second general question is that of the duties in law which devolve upon 
health service staff in their work, especially, of course, doctors. The Council of 
Europe’s Committee of Experts on Legal Problems in the Medical Field (which 
is at the moment composed of 21 experts from the medical field and 21 legal 
experts) has already carried out a certain number of studies. These have included 
the removal, grafting and transplantation of human substances, artificial insemi­
nation in human beings and the protection of involuntary patients in mental 
institutions. Since June of this year, the Committee has begun to prepare an 
international instrument on the doctor’s duties and liabilities. (This notion implies 
certain rights for the patient, but it is preferred to begin with the traditional notion 
of the doctor’s duties and responsibilities.) This proposed instrument would have 
an important impact on legal aspects of blood transfusion. For instance, discus­
sions have already taken place on the general definition of the medical inter­
vention: ‘All kinds of treatment, intervention or examination having diagnostic, 
prophylactic, therapeutic or rehabilitative aims, which are administered by a 
doctor or under his responsibility.’
The instrument would probably contain a clause to the effect that no medical 
intervention may be administered without the free and informed consent of the 
patient. This provision would invite us to consider the classification of medical 
interventions into two groups: routine and second-order. The routine intervention 
will be one for which the patient’s consent may be presumed from the very fact 
that he has sought the professional services of the doctor. Whilst in this situation 
the doctor is under no obligation subsequently and expressly to obtain the pa­
tient’s consent on the basis of information he provides, he would not thereby be 
excused the general obligation of giving full information to the patient on the 
latter’s state of health unless this is against the patient’s interest.
As regards second-order medical interventions these are those which present 
a certain risk for the patient or affect or are likely to affect the patient’s personal 
privacy. For these second-order interventions the patient’s express and specific 
consent should invariably be required. There would be provisions dealing with 
the absence of consent where the patient is unable, because of his state of health,
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to express his consent and where the patient lacks full legal capacity. These pro­
visions would mean that a patient’s legal representative will often be involved 
in the process of obtaining consent, where relatives are not in existence. Clearly, 
into this second category, come many diagnostic acts such as X-rays, patho­
logical tests, etc., since these involve the risk of accidental lesion or of patient 
discomfort. In discussion, the Committee included as a preliminary step blood 
transfusion in this second category. It must also be noted that conflicts of choice 
may exist between parents or legal representatives and the patient where the latter 
is capable of judgment. The patient may, after all desire to benefit from a trans­
fusion refused by other patients. A well-known case of this sort has arisen in­
volving Cooley’s anaemia.
It was also recognized by the Committee during these preliminary discus­
sions that the obligation of giving full information to the patient about his health 
generally lies with the doctor in charge of the case. Any other health staff work­
ing, e.g., in a haematological laboratory, a blood bank or in a blood transfusion 
service, would only have the obligation to inform the patient on the technical 
aspects of the intervention being carried out, including information on any risks 
involved. Test results and general prognosis would remain the responsibility of 
the doctor in charge.
As to the advantages conferred by this international work, the aim of the 
proposed instrument is not to increase the controls under which doctors work 
and thereby to obstruct the efficient execution of their duties. Rather it is intended 
to give doctors the opportunity to carry out their work without the fear that the 
patient or the patient’s relatives will subsequently bring against him a law claim­
ing the doctor’s liability. Any contact needs a clear and workable basis which 
cannot reside solely in the traditional but somewhat nebulous notions of ‘trust’ 
and ‘entente’.
The field of blood transfusion is traditionally one where international co­
operation shows that the principle of solidarity, of sharing the most needed 
resources between all people, transcends many of the more mundane obstacles 
to international understanding. I must therefore conclude by expressing the hope 
that states who wish to enter into cooperation with the Council of Europe in this 
field should consider doing so for they would be most heartily welcome.
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Initially, transfusion of blood from a donor to a recipient was a medical 
act performed at the bedside. The modern possibilities for the preparation of 
cellular components and plasma derivatives from donor blood have led to the 
development of out-of-hospital blood services with mass production of biologicals 
of human origin. These products must fulfil quality requirements which are just 
as strict as those applied to pharmaceuticals. In-hospital donations and trans­
fusions of blood remain medical acts performed under the responsibility of the 
staff of the institution. The preparation of blood products by regional or national 
blood services should induce public health services to supplement their phar­
maceutical control institutions with a unit supervising good manufacturing and 
laboratory practices related to these products. Another important task of the 
unit would be the surveillance of imported biologicals of human origin.
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The prevention of transfusion reactions calls for stringent selection of blood 
donors and sufficiently sensible cross matches. In most countries these pre­
requisites have been laid down in guidelines.
Despite of proper precautions, infectious agents happen to be transmitted 
by blood and blood products. That is why I confine myself to discuss only in­
fectious diseases.
A very large number of infective agents pathogenic to man are potentially 
transmissible by parenteral exposure to blood or blood products. The require­
ments for such transfer of infection include three major points:
1. Presence of infectious agents for a certain period in individuals not 
severely ill, not limited to narrow age groups and not confined to small geo­
graphical areas.
2. Stability of these agents in blood or blood products.
3. Susceptibility to infection in a significant proportion of the recipient 
population.
Blood transmitted infectious diseases are caused by
I. Virus diseases of
major importance (e.g. hepatitis types B and non-A, non-B; 
occasional importance (e.g. EB and CMV) and 
suspected importance (e.g. slow viruses).
II. Parasitic and bacterial diseases.
I. Virus Diseases
Hepatitis
Transmission of hepatitis by blood or blood products is one of the most 
serious complications of blood transfusion, constituting a hazard to the life and 
health of blood recipients as well as a legal hazard to physicians and blood bank 
services. Blood transmissible virus hepatitis occurs in two major types:
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hepatitis type B and
hepatitis type non-A, non-B.
Hepatitis type B
The introduction of HBsAg screening in the early seventies has reduced 
the proportion of infectious donors, so that more recent surveys of the occurrence 
of post-transfusion HBY infection cover missed cases of new or recent infections 
so that much lower rates of viraemia will now be encountered. Instead of post­
transfusion hepatitis the new term ‘transfusion associated hepatitis’ becomes more 
and more popular.
Socio-economic background is the most important determinant, but also 
sex and ethnic origin are relevant factors as well as environmental factors such 
as illicit drug addiction or male homosexuality.
In combination, risk figures will range from 0.1 per 1000 for Scandinavian 
volunteer donors to perhaps 50 per 1000 in paid donors or in Southern Europe.
In principle, the methods for prevention HBV transmission with blood and 
blood products contain three strategies:
1. Blood donor selection
2. Treatment of the products
3. Immunisation of the recipients.
ad 1. The screening of blood donors for HBsAg has been most successful, 
especially in areas with high prevalence of carrier donors.
After general application of third-generation tests for HBsAg in all blood 
donations, the occurrence of hepatitis B in recipients decreased to less than 0.2 per 
1000 units in most areas.
However, in some studies the prevalence of HBsAg carriers is too low 
and/or the occurrence of non-A, non-B hepatitis too high to yield impressive 
results.
In many situations, another form of donor selection has been performed 
simultaneously: avoidance of paid donors who carry an increased risk of B as 
well as non-A, non-B hepatitis. The impact of this selection alone is probably 
as effective as donor screening for HBsAg although few exact figures are available.
Much debated is the possible benefit from anti-HBc testing. It should be 
realized that the presence of anti-HBc alone in a donor serum might be obtained 
in approximately 10 per cent of all HBV infected individuals, and in most cases 
it will reflect past infection with no infectivity left. However, a few cases of HBV 
transmission from such blood have been reported, but no figures exist to establish 
the value of this additional testing.
ad 2. The fractionation of pooled plasma, by one of several methods yields 
therapeutically useful material, which has some risk of transmitting viral hepatitis. 
Terminal inactivation of albumin and plasma protein fraction (PPF) has been 
mentioned and is generally used in all areas. Immunoglobulin preparation is also 
a safe procedure.
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Among the high risk products are fibrinogen, antihaemophilic factor VIII 
and factor IX concentrate.
In the last two years special techniques have been developed to produce 
a safe factor VIII and IX concentrate without a significant loss of activity.
Attempts to dilute viruses by erythrocyte washing have not proved suffi­
ciently effective.
ad 3. Addition of hyperimmune serum globulin with a high titre of anti- 
HBs seems to be a possible solution, but the costs of this immuno globulin severely 
limit its application.
A final approach to the control of HBV infection in recipients of blood 
products is active immunization of susceptible recipients. This is now a practical 
possibility after the development of a safe and effective HBsAg vaccine. The 
efficiency of the vaccine in relation to the large dose of virus that may be provided 
by blood transfusion has not yet been established, nor has the possibility of 
protection by vaccination after the time of transfusion. Such cost/benefit studies 
have to be carried out before reasonable benefits can be expected from the selec­
tion of recipients.
Immunoglobulin post-exposure prophylaxis with standard immunoglobulin 
has failed to be of any value in preventing blood transfusion infection, while the 
role of anti-HBs-hyperimmunoglobulin has not yet been fully evaluated.
Hepatitis type non-A, non-B
Non-А, non-B hepatitis is a diagnosis of exclusion. Acute viral hepatitis due 
to the hepatitis A or B virus can usually be diagnosed by serologic tests. Hepatitis 
occurring in the absence of these serologic markers is, however, not necessarily 
non-A, non-B viral hepatitis. Other infectious diseases such as mononucleoses, 
CMV infection or syphilis as well as other diseases of the liver, viz. drug-induced 
liver disease, cholecystitis, etc. must also be excluded. The diagnosis of non-A, 
non-B hepatitis should be made with caution and it must rest on the combination 
of typical epidemiological features, history, clinical findings, and serum bio­
chemical laboratory tests. No serological tests are so far known to detect past 
or present infection with non-A, non-B virus.
Circumstantial evidence suggests the existence of two or three types or 
strains of non-A, non-B virus. In clinical trials some patients had several bouts 
of acute hepatitis not associated with hepatitis A virus or hepatitis B virus infec­
tions. In PTH, differences in the incubation period ranging from 7 to 150 days 
have been observed. Also, different patterns are seen in the course of diseases. 
Some cases are of short duration, others are biphasic or present prolonged liver 
enzyme, eg ALT, elevation. Finally, the histological appearance of changes in 
the liver cells suggests two separate types of non-A, non-B hepatitis. These find­
ings, however, have not been sufficiently reproduced in the chimpanzee model.
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Virus distribution in the course of infection and the duration of viraemia 
are only sporadically known. Viraemia may be present for 1-2 weeks prior to 
the onset of symptoms in acute infections, and may last for some weeks after 
the onset. Prolonged viraemia, a virus carrier state lasting more than one year 
has been documented with and without signs of liver damage. As regards the 
distribution or excretion of non-A, non-B virus transmission, studies have dem­
onstrated the presence of the agent in whole blood, plasma, serum and frac­
tionated factor VIII and IX products as well as in liver homogenate. The presence 
of virus in other body fluids or excretions has not been observed.
As regards the potential routes of infection, the above mentioned inocula 
have successfully been administered subcutaneously, i.m. and i.v. No oral infec­
tion has been reported. The infectious dose used in experimental infections has 
been higher than that used in hepatitis B studies. Needle-stick exposures have 
also resulted in infection. In cases not related to blood transfusion, a parenteral 
exposure is not regularly found but, as stated, other viruses may be responsible 
for these cases.
No systematic studies have been published on the stability of the virus(es) 
or methods for its inactivation. There are no reports on the transmission of non- 
A, non-B virus by albumin or some other heated material, or by immunoglobulin 
products.
Epidemiological studies of implicated blood donors revealed a series of 
potentially useful associations all of which, however, await serological confir­
mation:
1. The risk of non-A, non-B post-transfusion hepatitis increases with the 
number of units transfused and the number of donors involved.
2. HBV markers (anti-HBs, anti-HBc) are more prevalent in implicated 
donors than in controls. These markers are, however, found in less than half 
of the cases.
3. Liver enzyme elevation in some implicated donors is estimated at 20 per
cent.
4. Race, sex, age or history of jaundice have no correlation with the risk 
of non-A, non-B infection; however, paid donors carry a 2-4 fold higher risk 
than do volunteers.
II. Parasitic and Bacterial Diseases
Malaria
At present, malaria is the second major cause of non-immunological trans­
fusion accidents after viral hepatitis.
The parasite develops and multiplies in the parasitized red cells, and, by an 
asexual (erythrocytic) cycle, it produces either merozoites or gametocytes (sexual 
cycle).
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Today there is no easily administered serological routine test for malaria. 
Therefore the failure of detection of malaria in blood donors seems to be due to 
insufficient questioning of the donors, lack of knowledge about endemic zones, 
and to the existence of asymptomatic forms.
Serology may solve many of these problems in the near future. Its cost 
should not be excessive in non-endemic zones and the supply of specific antigens 
should be ensured through international cooperation.
At this time the following suggestion would be acceptable:
A potential donor from a malaria area, whatever his malaria case history 
and whatever the length of his stay, should not be accepted within six months 
after having left the endemic zone. Immigrants from a malaria area should not 
be accepted from six months up to three years after having left this area. This 
quarantine period can be shortened, if suitable immunological tests for malaria 
are performed and found to be negative.
There are many other human parasitoses which are transmissible by blood 
transfusion, e.g. Chagas’ disease in the north of South America, ffiariasis or 
leishmaniasis. Recently, a case of babesiosis, transmitted by blood has also been 
described.
Syphilis
The frequency of this disease has declined significantly in the great majority 
of countries (~ 1/10 000), although there are signs of an increase at present.
While the serodiagnosis of syphilis is simple and many of these tests can 
easily be automated, tests should be performed with all donated blood.
It should not be forgotten that there is a long serological negative phase 
and also that blood storage at 4 C inactivates the treponema in about 72 h.
A blood product containing syphilitic antibodies may induce positive sero­
conversion in the recipient; this condition disappears in approximately three 
weeks.
In conclusion, blood services and commercial companies should be obliged 
to declare the quality of the original material, the size of the pool, the source 
of the plasma, the geographical origin of the donors and the number and quality 
of the screening tests used for prevention of transmission of infectious diseases.
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Since many years, the World Health Organization (WHO), the League of 
Red Cross Societies (LRCS) and the International Society of Blood Transfusion 
(1SBT) have tried to contribute to the development of national blood transfusion 
services in developing countries by several approaches.
Briefly summarized, the following activities were undertaken:
1. Engagement of consultants or temporary advisers who are sent to devel­
oping countries, mainly under the auspices of the WHO or other international 
organizations.
2. Organization of courses for fellows from developing countries, either in 
the industrialized countries or in the developing countries themselves.
3. Training of fellows in blood transfusion laboratories in various parts 
of the world.
Another way of developmental cooperation is the sending of a surplus of 
blood components, as has, e.g., been done in the past by the Netherlands Red 
Cross which has distributed large amounts of dried plasma before outdating. 
In later years, red cell concentrates and some protein components, such as gamma­
globulin, have been provided by other countries. However, the transport of red 
cell concentrates is a very expensive procedure, which needs an organization 
enabling quick distribution from the airport to blood banks and hospitals under 
optimal conditions, particularly in tropical and subtropical areas. In countries 
with a poor organizational infrastructure this has encountered great difficulties 
and the result is that the surplus of red cell concentrates are sent to communities 
that in principle should not need them, since the willingness to spend blood is 
not sufficient. As far as protein components are concerned, most non-profit blood 
transfusion organizations are unable to help developing countries to cover their 
needs of albumin, PPS and fraction VIII concentrates. The surplus available is 
mainly pooled i.m. gammaglobulin, a product which so far has had limited 
applications.
It is quite clear that the only way to solve the problem of blood cell and 
protein components in developing countries is the organization of national blood 
transfusion services able to cover their own needs. The difficulties encountered 
in setting up such self-supporting national organizations have been so far:
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a) A poor socio-economic situation which hampers the willingness to donate 
blood on a non-remunerated basis.
b) Poor health of the population caused by malnutrition and endemic 
(tropical) diseases.
c) Religious principles which sometimes are an obstacle against blood 
donation.
d) Large-scale collection of plasma by pharmaceutical companies, against 
payment, which of course is a welcome source of income for the poorest people 
of the world.
Fortunately in many countries precautions are taken nowadays by the 
government to protect the population against these harmful procedures, referred 
to by Dr. David-West, regarding the situation in Africa.
In spite of the above mentioned difficulties it is clear that national organiza­
tions with a non-remunerated donor population should be created in the develop­
ing countries and the initiatives taken in the past and the present should be further 
expanded in the future.
A prerequisite for such a set up, however, is that the governments of the 
countries involved are willing to stimulate the principle of self-support, based 
on a non-profit system, and this should be ratified by law or other official rules.
The organizational structure should preferably consist of a central institute 
for blood transfusion with a network of regional blood banks.
The main tasks of the central institute should be:
1. The recruitment of voluntary, non-remunerated blood donors, in close 
collaboration with the regional blood banks.
2. The training of laboratory, technical and administrative staff.
3. The preparation of the necessary protein components from plasma, pref­
erably by cheap methods (chromatography).
4. Quality control of blood cell and protein components, including the 
prevention of transmissible diseases.
5. Furthermore, the central institute should have the disposal of a blood 
group reference laboratory and a department for the preparation of blood group­
ing reagents.
In the first stage of development such a country needs support for setting 
up an adequate organization, which implies financial, scientific and technical 
aid from one or more industrialized countries. In general the financial support 
will be the largest problem. However, all industrial countries have funds for 
developmental cooperation, and multi- or bilateral agreements with developing 
countries. It would therefore be of great importance if definite commitments could 
be made under the auspices of WHO and in collaboration with the LRCS and 
ISBT, in such a way that each industrial country should earmark a certain per­
centage of its funds for developmental cooperation, to assist in the building up 
a national blood transfusion organization in one or more countries in need of it.
I realize that such assistance exists already, but only incidentally and on 
a limited scale, without the framework of an international body which should
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promote the collaboration in this field. If WHO would be able to set up an inter­
national cooperation, the subsequent activities are not so difficult to realize. 
Transmission of knowledge and experience can be achieved by courses and fellow­
ships in donor countries, with a follow-up in the receiving country itself. The 
highest priority should be given to the recruitment of voluntary, non-remunerated 
donors in the countries involved, and this can be achieved with the aid of the 
public health authorities, assisted by well-trained public relation officers who 
should explain to the population why their blood is needed. All other items, such 
as laboratory equipment, training of laboratory, technical and administrative 
staff, and transport facilities, can be procured without too many difficulties.
As I mentioned before, a lot of activities have already been developed, but 
this is still insufficient, and it is therefore highly desirable that WHO, in collabora­
tion with the LRCS and the ISBT, and in close consultation with the govern­
ments of the donor and of the recipient countries, creates a constructive project 
for financing the development of national blood transfusion organizations wher­
ever they are needed.
H aem ato lo s ia  16, 1983

ANNOUNCEMENT ISBT
Jean Julliard Prize
The 9th Jean Julliard Prize, which was established by the Internation Society of 
Blood Transfusion in memory of its first Secretary General, will be awarded 
during the XVIII International Congress of Blood Transfusion, to be held in 
Munich (FRG) from 22 to 28 July 1984.
This prize is reserved forscientists under 40 years of age in recognition of recently 
completed scientific work on Blood Transfusion and related subjects.
In order to qualify, candidates must forward six (6) copies of an unpublished 
manuscript or recently published papers including a curriculum vitae to the 
Secretary General, Professor Ch. Salmon, 53 boulevard Diderot, 75571 PARIS 
CEDEX 12, France
before the 15th January 1984
This prize will be awarded during the Congress. The value of the prize is 3.000 
Swiss francs.
Further information may be obtained from the Secretary General. The regulations 
for the Jean Julliard Prize are included in the Statutes of the Society.
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ABSTRACTS
Relative reducibilities o f complexes o f Fe( III), 
Co(Ill), M n(III) and Cu(II) with apotrans- 
ferrin using efg and COf .  J. H. Sommer, 
P. B. O’Hara, C. D. Jonah, R. Bersohn (De­
partment of Chemistry, Columbia Univer­
sity, New York, N.Y. and Argonne National 
Labs, Argonne, IL, USA). Biochim. Biophys. 
Acta 703, 62 (1982).
Metal complexes of transferrin with iron 
(III), cobalt(lll), manganese(III) and cop- 
per(II) were exposed to the short-lived, 
extremely powerful reductants e^ and COf. 
The amount of reduction of the metal ions 
was measured by the bleaching of the visible 
charge-transfer absorbance. All of the com­
plexes show less than 7 per cent metal reduc­
tion. A kinetic model was formulated and 
reductive rate constants derived for each 
complex. The rate constants were of the order 
10я M-1 s_l for eaa and 10° M~' s_1 for 
COj. Although these rate constants are 
almost 10 orders of magnitude faster than 
those determined for transferrin with con­
ventional chemical reductants, they are 2-4 
orders of magnitude slower than those for 
aquo- and other protein complexes of the 
same metal ions. Iron transferrin, the bio­
logically important species, is 2-3 times less 
reducible than any of the other complexes, 
which is explained by a small structural 
difference. Direct reduction as a mechanism 
for iron release in the reticulocyte seems un­
likely in view of the results mentioned above.
A. Egyed
The exchange o f Fe'l+ between acetohydrox- 
amic acid and transferrin. Spectrophotometric 
evidence for a mixed ligand complex. R. E. 
Cowart, N. Kojima, G. W. Bates (Depart­
ment of Biochemistry and Biophysics and 
the Texas Agricultural Experiment Station, 
Texas A. M. University, College Station, 
Texas, USA). J. Biol. Chem. 257, 7560 (1982).
Transferrin, the serum iron transport 
protein, provides an excellent model for 
studying biological metal ion exchange re­
actions. A curious problem is that while a 
mixed ligand species of chelate-Fe3+-protein 
is anticipated from theoretical considera­
tions and supported by kinetic results, no 
clear spectrophotometric evidence for such 
an intermediate has heretofore been ob­
tained. In this study of the exchange of Fe3+ 
between acetohydroxamic acid and trans­
ferrin such evidence has been found. The 
reaction of Fe:!+-acetohydroxamic acid with 
apotransferrin-СОз^ is distinctly biphasic 
when examined by stopped flow spectro­
photometry. The first phase is complete 
within ~  4 s and results in the formation 
of a transient species with a distinct spectral 
maximum at 432 nm. The second phase 
requires ~  2 min and results in the forma­
tion of Fe3+-transferrin-COj~. It is sug­
gested that the transient species is a mixed 
ligand complex. The reaction rate-con­
centration relationship for the formation of 
the intermediate is linear for Fe:i+-aceto- 
hydroxamic acid and hyperbolic for apo- 
transferrin-COj- . This suggests a rate-limit­
ing labilization of Fe3+-(acetohydroxamic 
acid)3 preceding attack by the apotransferrin- 
C 03_. The reverse reaction, the removal of
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Fe3+ from the Fe3+-transferrin-C03~ by 
acetohydroxamic acid, does not provide 
spectral evidence for the intermediate. The 
velocity-concentration relationship shows a 
hyperbolic dependence on acetohydroxamic 
concentration and a linear dependence on 
Fe3 + of Fe3+-transferrin-C02- resulting 
from a conformational change.
A. Egyed
Failure o f metallothionein to bind iron or act 
as an iron mobilizing agent. N. Kojima, C. R. 
Young, G. W. Bates (Department of 
Biochemistry and Biophysics, Texas Agri­
cultural Experiment Station, Texas A. M. 
University, College Station, TX, USA). Bio- 
chim. Biophys. Acta 716, 273 (1982).
There are reasons to suggest metallo- 
thionein might act as a transient intra­
cellular iron transport agent. Rabbit kidney 
metallothionein was isolated from animals 
treated with Cd in order to induce metallo­
thionein synthesis. Attempts were made to 
form the iron-protein complex via several 
reaction routes. There was no evidence for 
complex formation. Metallothionein also 
failed to mobilize iron from ghosts of rab­
bit reticulocytes specifically labelled with 
30 Fe.
A. Egyed
Isolation from haemoiysate o f a protein­
aceous inhibitor o f the red ceil Ca'-+-pump 
ATPase. Its action on the kinetics o f the 
enzyme. A. Wüthrich (Department of Veter­
inary Pharmacology, University of Bern, 
Bern, Switzerland). Cell Calcium 3, 201 
(1982).
The purification to apparent homogeneity 
of a small protein from the cytosol of human 
red cells is described. The procedure con­
sists of a combination of anion-exchange- 
chromatography, ultrafiltration, (NH4)2S04- 
and heat-precipitation. The resulting protein 
is a potent inhibitor of (Ca2 + +  Mg2+)- 
ATPase of erythrocyte membranes and of 
Ca2+-uptake into inside-out vesicles. Mem­
brane (Na+ +  K+)-ATPase is not affected 
by the inhibitor. The peptide migrates as a 
single band in SDS gels. Its apparent mo­
lecular weight is 19 000. It causes inhibition 
of the Ca2+-pump by decreasing Ca2+- 
affinity at all calmodulin concentrations.
G. Gárdos
The reconstitution o f the human erythrocyte 
sugar transporter in planar bilayer mem­
branes. I. K. Nickson, M. N. Jones (De­
partment of Biochemistry, University of 
Manchester, Manchester, UK). Biochim. 
Biophys. Acta 690, 31 (1982;.
The degradation of human erythrocyte 
membrane proteins in relation to the identi­
fication of the monosaccharide transporter 
has been investigated in whole membrane 
preparations and membrane protein extracts 
by polyacrylamide gel electrophoresis in 
sodium n-dodecyl sulphate and iodine-125 
labelling. Evidence is presented for the 
degradation of band 3 polypeptide to lower 
molecular weight material some of which 
appears in region 4.5 of the polyacrylamide 
gel electrophoresis profile. It is found that 
the degradation process is inhibited by 
phenylmethylsulphonyl fluoride and is only 
significant in membrane extracts in the 
absence of detergent (Triton X-100) and 
on prolonged incubation at 37 °C, condi­
tions which do not prevail during the isola­
tion of membrane protein extracts for re­
constitution studies. Extracts of band 3 and 
band 4.5 have been prepared and reconstitut­
ed in bilayer lipid membranes. The perme­
abilities of the reconstituted systems to d- 
glucose have been investigated and it is 
found that only bilayers incorporating band 
4.5 exhibited enhanced monosaccharide 
transport. A linear relationship between d- 
glucose transport and the concentration 
of protein in the aqueous phase bathing the 
bilayers suggests a partitioning of the pro­
tein into the bilayer. Reconstitution is stereo­
specific and inhibited by cytochalasin B.
G. Gárdos
Modulation o f ATPase activities o f human 
erythrocyte membranes by free fatty acids or 
phospholipase A . G. Schmalzing, P. Kut­
schern (Department of Toxicology, Uni-
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versify of Tübingen, FRG). J. Membrane 
Biol. 79, 65 (1982).
The artificial insertion of increasing 
amounts of unsaturated fatty acids into 
human erythrocyte membranes modulated 
ATPase activities in a biphasic manner, 
depending on the number and position of 
double bonds, their configuration, and the 
chain length. Uncharged long-chain fatty 
acid derivatives with double bonds and short- 
chain fatty acids were ineffective. Stearic acid 
stimulated Na+K +-ATPase only. Anionic 
and con-ionic detergents and -lysophospha- 
tidylcholine failed to stimulate ATPase 
activities at low, and inhibited them at 
high concentrations. Mg2+-ATPase activ­
ity was maximally enhanced by a factor of 
2 in the presence of monoenoic fatty acids; 
half-maximal stimulation was achieved at a 
molar ratio of cis(trans)-configurated C18 
acids/membrane phospholipid of 0.16 (0.26). 
Na+K +-ATPase activity was maximally 
augmented by 20% in the presence of mono­
enoic C18 fatty acids at 37 °C. Half-maximal 
effects were attained at a molar ratio oleic 
(elaidic) acid/phospholipid of 0.032 (0.075). 
Concentrations of free fatty acids which 
inhibited ATPase activities at 37 °C were 
most stimulatory at reduced temperatures. 
At 10 °C oleic acid increased Na+K+- 
ATPase activity fivefold (molar ratio 0.22). 
Unsaturated fatty acids stimulated the effect 
of calmodulin on Ca2+-ATPase of native 
erythrocyte membranes (i.e. increase of 
Vm!,x from 1.6 to 5 pmol PO|~- phospho­
lipid-1 h -1, decrease of KCa from 6 pM 
to 1.4-1.8 P-М). Stearic acid decreased K^a 
(2 pM) only, probably due to an increase 
of negative surface charges. A stimulation of 
Mg2+-ATPase, Na+K +-ATPase, and Ca2+- 
ATPase could be achieved by incubation 
of the membranes with phospholipase A2. 
An electrostatic segregation of free fatty 
acids by ATPases with ensuing alterations 
of surface charge densities and disordering 
of the hydrophobic environment of the 
enzymes provides an explanation of the 
results.
G. G ár do s
The stoichiometry o f the Ca'- + pump in human 
erythrocyte vesicles: modulation by Ca-+,
Mg'i+ and calmodulin. С. K. Akyempon, 
B. D. Roufogalis (Laboratory of Molecular 
Pharmacology, Faculty of Pharmaceutical 
Sciences, University of British Columbia, 
Vancouver, B.C., Canada). Cell Calcium 
3, 1 (1982).
Active Ca2+ uptake and the associated 
(Ca2+ +  Mg2+)-ATPase activity were stud­
ied under the same conditions in an inside- 
out vesicle preparation of human red blood 
cells made essentially by the procedure of 
Quist and Roufogalis ( J. Supramolec. Struc­
ture 6, 375-381, 1977). Some preparations 
were treated with I mM EDTA at 30 °C 
to further deplete them of endogenous levels 
of calmodulin. As the Ca2+ taken up by 
the EDTA-treated inside-out vesicles, as 
well as the non-EDTA treated vesicles, was 
maintained after addition of 4.1 mM EDTA, 
the vesicles were shown to be impermeable 
to the passive leak of Ca2+ over the time 
course of the experiments. In the absence 
of added calmodulin, both active Ca2 + 
uptake and (Ca2+ +  Mg2+)-ATPase were 
sensitive to free Ca2+ over a four log unit 
concentration range (0.7 pM to 300 pM 
Ca2+) at 6.4 mM MgCI2. Below 24 ,«M Ca2 + 
the stoichiometry of calcium transported 
per phosphate liberated was close to 2 : 1 ,  
both in EDTA and non-EDTA-treated 
vesicles. Above 50 pM Ca2+ the stoichio­
metry approached 1: 1.  When MgCl2 was 
reduced from 6.4 mM to 1.0 mM, the stoichio­
metry remained close to 2 : 1 over the whole 
range of Ca2+ concentrations examined. In 
contrast to the results at 6.4 mM MgCl2, 
the Ca2+ pump was maximally activated at 
about 2 pM free Ca2+ and significantly in­
hibited above this concentration at 1 mM 
MgCl2. Calmodulin (0.5-2.0 pg/ml) had 
little effect on the stoichiometry in any of 
the conditions examined. The possible sig­
nificance of a variable stoichiometry of the 
Ca2+ pump in the red blood cell is dis­
cussed.
Agnes Enyedi
Effects o f trifluoperazine and mitogenic lec­
tins on calcium ATPase activity and calcium 
transport by human lymphocyte plasma mem­
brane vesicles. A. H. Lichtman, G. B. Segel, 
M. A. Lichtman (Departments of Radia-
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tion Biology and Biophysics, Medicine and 
Pediatrics at the University of Rochester 
School of Medicine, Rochester, N.Y., USA). 
J. Cell. Physiol. H I ,  213 (1982).
The phenothiazine, trifluoperazine, and 
the mitogenic lectins, phytohemagglutinin 
(PHA) and Concanavalin A (Con A), were 
tested for their effects on human lympho­
cyte plasma membrane Ca-activated Mg- 
ATPase and ATP-dependent calcium up­
take. Trifluoperazine completely inhibited 
Ca-uptake when present from the start of 
the assay at concentrations of 100 p-M or 
more. When added during measurement of 
calcium uptake, trifluoperazine reduced the 
rate of vesicular calcium accumulation but 
was unlike the calcium ionophore, A 23 187, 
which caused a rapid release of accumulated 
calcium from the vesicles. Trifluoperazine 
also inhibited membrane vesicle Ca-ATPase 
activity, but this inhibition was non-specific 
since the Mg-ATPase and Na, K-ATPase 
activities were inhibited to similar extents at 
the same concentration of the phenothiazine. 
In contrast, concentrations of PHA and 
Con A, which are mitogenic for lymphocytes, 
did not cause any change in Ca-uptake 
when added to suspensions of membrane 
vesicles. Con A had no effect and PHA had 
a weak inhibitory effect on Ca-ATPase 
activity.
Agnes Enyedi
The effect o f  insulin on glucose transport in 
rabbit erythrocytes and reticulocytes. S. G. 
Albert (Division of Endocrinology, Depart­
ment of Internal Medicine, Saint Louis 
University School of Medicine, Saint Louis, 
Missouri, USA). Life Sei. 31, 265 (1982).
Insulin binding and 3-0-Methylglucose 
transport have been studied in erythrocyte- 
and reticulocyte-enriched fractions of blood 
cells is order to determine if the increased 
number of insulin binding sites in reticulo­
cytes is associated with a glucose transport 
response to insulin. In these experiments 
rabbit reticulocytes demonstrate an eight­
fold increase in total insulin receptors when 
compared to erythrocytes. Glucose transport 
activity in the erythrocyte hasaK m of 3.2 mM. 
Reticulocytes demonstrate a saturable glucose 
transport activity of lower affinity, Km 
18.9 mM. Neither the erythrocyte, nor the 
reticulocyte glucose transport activity was 
capable of an increased response to insulin. 
The low affinity glucose transport activity 
in reticulocytes could allow a fourfold in­
crease in facilitated glucose transport at 
supraphysiological glucose concentrations 
that might occur in poorly controlled dia­
betes mellitus.
Agnes Enyedi
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OBITUARY
Distinguished French Professor and long-time member of our Editorial 
Board, Robert A r n a u d  had died on the 22nd December, 1982.
Born in Abilly, France, he had graduated from Tours Medical University. His 
first tutor was professor Antoine Vialle. It was in his laboratory that the young 
doctor took a liking to bacteriology, haematology and pathology. Then came 
Paris and the Pasteur Institute. Later he headed a haematological and clinical 
laboratory established by him. Subsequently he has developed the Tours Labora­
toire de Recherches Biologiques into an internationally renown scientific centre.
Holder and knight of the French Order of Merit, Professor Arnaud had 
been a highly respected member of both the French medical society and the 
International Society of Blood Transfusion (ISBT). An amiable and captivating 
personality, a good organizer and a fine researcher — he was the classical physician.
Our friendship began with a chance acquaintance. During on ISBT meeting 
someone had suggested the grounding of “coordinating faculties” in each of the 
member countries to facilitate international cooperation between nations. This 
is how the Tours Blood Transfusion Centre and the NIHBT from Budapest 
became twins. The collaboration had among others also resulted in numerous 
exchange visits of and friendships between workers of the two institutes.
Professor Robert Arnaud. An eminent figure in both the theory and practice 
of blood transfusion. A true friend whose memory will be enshrined by us.
Susan R. Holtán
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IN STR U C TIO N S TO C O N T R IB U T O R S
HAEMATOLOGIA is designed for the publication of original papers, preliminary 
reports, and reviews which contribute to the advancement in all fields related to haematology 
and blood transfusion. Manuscripts should be submitted in correct English and are accepted on 
the condition that they have not been published or accepted for publication elsewhere. Case 
reports, technical notes, and Letters to the Editor are also welcomed and will be published if 
appropriate.
Manuscripts should be sent to the Editor-in-Chief :
Prof. Susan R. Hollán
National Institute of Haematology and Blood Transfusion
Daróczi út 24
H-1113 Budapest, Hungary
Three copies of the manuscript should be submitted. They should be typed double­
spaced on one side of a good quality paper with proper margins. The first page of the 
manuscript should contain the following information: (1) title of the paper; (2) authors’ 
names; (3) name of institution in which the work has been carried out; (4) name and full 
postal address of the author to whom communications regarding the manuscript should be 
directed ; (5) a short title not to exceed 40 characters (including space) to be used as a run­
ning head. The second page should contain an abstract of 50—100 words, summarizing the 
reasons for the study, the methods used, the results, and the major conclusions. This page 
should also contain 4— 8 keywords placed in alphabetical order. Original papers should not 
exceed 15 printed pages including tables, figures, and references. Case reports should not be 
more than four, technical notes and Letters to the Editor not more than two printed pages in 
length. In the manuscripts the approximate location of tables and figures should be indicated 
in the margin. The manuscript of original papers should be divided into summary, introduc­
tion, materials and methods, results, discussion, acknowledgements and references. Review 
articles should also be appropriately divided. SI units should be used in the manuscript, except 
that, for the time being, litre (1) may be used as a unit of volume.
References : Only papers closely related to the author’s work should be referred to. In 
the text citations should include the name of the authors and/or the reference number in 
parentheses. A list of references, numbered according to the order of their occurrence in the 
text, should be compiled at the end of the paper. It should be typewritten, double-spaced, 
on a separate sheet.
References to periodicals should be typed double-spaced and mention: (1) name(s) 
and initials of all the authors; (2) title of the paper; (3) international abbreviation of the 
periodical; (4) volume; (5) first page number; (6) year of publication in parentheses. Thus: 
4. Liebermann, J. E., Gordon-Smith, E. C. : Red cell pyrimidine 5’-nucleotidase and gluta­
thione in myeloproliferative and lymphoproliférative disorders. Brit. J. Haemat. 44, 425 
(1980).
References to books should include: (1) author(s)’ name(s); (2) title; (3) editor(s); (4) 
publisher; (5) place and year of publication. Thus: 5. Guyton A. C., Taylor, A. E., Granger, 
H. J.: Circulatory Physiology. II. Dynamics and Control o f  Body Fluids. Saunders, Phila­
delphia 1975. Or: 6. Rappaport, J. M.: Granulocyte transfusion. In: Haematology o f Infancy 
and Childhood. D. G. Nathan, F. A. Oski (eds). Saunders, Philadelphia 1974, p. 875.
Illustrations must be cited and numbered in the order they appear in the text. All line 
drawings should be submitted as clear, glossy, black and white originals or good quality 
photographs The author’s name and the title of the paper togetherwith the serialnumber of the 
figure should be written on the back of each print. Legends for illustrations should be type­
written, double-spaced, on a separate sheet, and included at the end of the manuscript. Tables, 
each bearing a title, should be self-explanatory and numbered consecutively.
Authors will receive one set of proofs which must be corrected and returned to the 
Editor-in-Chief within three days o f receipt. Major alterations of the text cannot be accepted.
Authors are entitled to 50 reprints free of charge.
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